<SUBMISSION>
<ACCESSION-NUMBER>0001047469-03-031533
<TYPE>PRE 14A
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20031030
<FILING-DATE>20030924
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>AEROGEN INC
<CIK>0001039160
<ASSIGNED-SIC>3841
<IRS-NUMBER>330488580
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>PRE 14A
<ACT>34
<FILE-NUMBER>000-31913
<FILM-NUMBER>03908652
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>1310 CORONADO DR
<CITY>SANTA CLARA
<STATE>CA
<ZIP>95054
<PHONE>4085432400
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>1310 ORLEANS DRIVE
<CITY>SUNNYVALE
<STATE>CA
<ZIP>94089
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>a2119226zpre14a.htm
<DESCRIPTION>PRE 14A
<TEXT>
<HTML>
<HEAD>

</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#03PAL1722_1">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<P ALIGN="CENTER"><FONT SIZE=2><B>SCHEDULE 14A INFORMATION</B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934<BR>
(Amendment No.&nbsp;&nbsp;&nbsp;) </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2><BR>
Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="95%"><FONT SIZE=2><BR>
Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="95%"><FONT SIZE=2><BR>
Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="95%"><FONT SIZE=2><BR>
Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="95%"><FONT SIZE=2><BR>
Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="95%"><FONT SIZE=2><BR>
Soliciting Material under Rule&nbsp;14a-12<BR></FONT>
</TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER"><BR><FONT SIZE=2><B>AEROGEN, INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER"><HR NOSHADE><FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER"><HR NOSHADE><FONT SIZE=2> (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><FONT SIZE=2>Payment of Filing Fee (Check the appropriate box)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>(1)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>(2)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>(3)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>(4)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>(5)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or
Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
(6)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2><BR>
Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>(7)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>(8)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>(9)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=609225,FOLIO='blank',FILE='DISK032:[03PAL2.03PAL1722]BA1722A.;4',USER='ATOBAK',CD='24-SEP-2003;15:18' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><B>Aerogen,&nbsp;Inc.<BR>
2071 Stierlin Court<BR>
Mountain View, CA 94043  </B></FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="be1722_notice_of_special_meeting_of_s__not02547"> </A>
<A NAME="toc_be1722_1"> </A></FONT> <FONT SIZE=2><B>NOTICE OF SPECIAL MEETING OF STOCKHOLDERS<BR>  TO BE HELD OCTOBER 30, 2003 AT 2:00&nbsp;P.M.    <BR>    </B></FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">


<P><FONT SIZE=2>To
the Stockholders of Aerogen,&nbsp;Inc.: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOTICE
IS HEREBY GIVEN that a Special Meeting of Stockholders of Aerogen,&nbsp;Inc. (the "Company") will be held at the Company's offices at 2071 Stierlin Court, Mountain View,
California 94043, on Thursday, October&nbsp;30, 2003, at 2:00&nbsp;p.m., local time, for the following purposes: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD><FONT SIZE=2>To
approve the second closing of a convertible debt financing with SF Capital Partners,&nbsp;Ltd., including the issuance of a convertible debenture and warrant to purchase Common
Stock;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD><FONT SIZE=2>To
amend the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock pursuant to which any whole number of outstanding shares
between and including four and eight would be combined into one share of our common stock and to authorize our Board of Directors to select and file one such amendment;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD><FONT SIZE=2>To
conduct the annual election of directors prescribed by the Company's Amended and Restated Certificate of Incorporation by electing three Class&nbsp;III directors to hold office
for a term ending in 2006 and until their successors are elected and have qualified;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD><FONT SIZE=2>To
ratify the selection of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December&nbsp;31, 2003; and
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>5.</FONT></DT><DD><FONT SIZE=2>To
transact such other business as may properly come before the meeting and any adjournments or postponements thereof. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board of Directors of the Company has fixed the close of business on October&nbsp;6, 2003 as the record date for the determination of stockholders entitled to notice of and to vote
at the Special Meeting and at any adjournment or postponement thereof. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="49%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%"><FONT SIZE=2>By Order of the Board of Directors,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="49%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="49%"><FONT SIZE=2><BR>
Robert S. Breuil<BR></FONT> <FONT SIZE=2><I>Secretary</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>Mountain
View, California<BR>
October&nbsp;9, 2003 </FONT></P>

<P><FONT SIZE=2><B>All stockholders are cordially invited to attend the meeting in person. Whether or not you expect to attend the meeting, please complete, date, sign and return the enclosed
proxy as promptly as possible in order to ensure your representation at the meeting. A return envelope (which is postage prepaid if mailed in the United States) is enclosed for that purpose. Even if
you have given your proxy, you may still vote in person if you attend the meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote
at the meeting, you must obtain from the record holder a proxy issued in your name.</B></FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=2,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=109914,FOLIO='blank',FILE='DISK032:[03PAL2.03PAL1722]BE1722A.;8',USER='ATOBAK',CD='24-SEP-2003;15:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_de1722_1_1"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><B>Aerogen,&nbsp;Inc.<BR>
2071 Stierlin Court<BR>
Mountain View, CA 94043  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="de1722_proxy_statement_for_a_special___pro02469"> </A>
<A NAME="toc_de1722_1"> </A>
<BR></FONT><FONT SIZE=2><B>PROXY STATEMENT<BR>  FOR A SPECIAL MEETING OF STOCKHOLDERS<BR>  <BR>    </B></FONT><FONT SIZE=2>October&nbsp;30, 2003    <BR></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="de1722_questions_and_answers_a__de102490"> </A>
<A NAME="toc_de1722_2"> </A>
<BR></FONT><FONT SIZE=2><B>QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING    <BR>    </B></FONT></P>


<P><FONT SIZE=2><B>Why am I receiving these materials?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We sent you this proxy statement and the enclosed proxy card because the Board of Directors of Aerogen,&nbsp;Inc. (sometimes referred to as the "Company" or
"Aerogen") is soliciting your proxy to vote at a Special Meeting of Stockholders. You are invited to attend the special meeting and we request that you vote on the proposals described in this proxy
statement. However, you do not need to attend the meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company intends to mail this proxy statement and accompanying proxy card on or about October&nbsp;9, 2003 to all stockholders of record entitled to vote at the special meeting. </FONT></P>

<P><FONT SIZE=2><B>Who can vote at the special meeting?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only stockholders of record at the close of business on October&nbsp;6, 2003 will be entitled to vote at the special meeting. On this record date, there were
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares of common stock outstanding and entitled to vote. </FONT></P>

<UL>

<P><FONT SIZE=2><I> Stockholder of Record: Shares Registered in Your Name  </I></FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If on October&nbsp;6, 2003 your shares were registered directly in your name with Aerogen's transfer agent, Mellon Investor Services, LLC, then you are a
stockholder of record. As a stockholder of record, you may vote in person at the meeting or vote by proxy. Whether or not you plan to attend the meeting, we urge you to fill out and return the
enclosed proxy card to ensure your vote is counted. </FONT></P>

<UL>

<P><FONT SIZE=2><I> Beneficial Owner: Shares Registered in the Name of a Broker or Bank  </I></FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If on October&nbsp;6, 2003 your shares were held in an account at a brokerage firm, bank, dealer, or other similar organization, then you are the beneficial
owner of shares held in "street name" and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered the stockholder of record for
purposes of voting at the special meeting. As a beneficial owner, you have the right to direct your broker or other agent on how to vote the shares in your account. You are also invited to attend the
special meeting. However, since you are not the stockholder of record, you may not vote your shares in person at the meeting unless you request and obtain a valid proxy from your broker or other
agent. </FONT></P>

<P><FONT SIZE=2><B>What am I voting on?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are four matters scheduled for a vote: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>Approve
the second closing of a convertible debt financing with SF Capital Partners,&nbsp;Ltd., including the issuance of a convertible debenture and warrant to purchase
Common Stock; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=3,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=636959,FOLIO='1',FILE='DISK032:[03PAL2.03PAL1722]DE1722A.;5',USER='ATOBAK',CD='24-SEP-2003;15:03' -->
<A NAME="page_de1722_1_2"> </A>
<UL>
<UL>
</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>Approval
of amendments to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock pursuant to which any whole
number of outstanding shares between and including four and eight would be combined into one share of our common stock and to authorize our Board of Directors to select and file one such amendment;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>To
conduct the annual election of directors by electing three Class&nbsp;III directors to hold office until 2006; and
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>Ratification
of PricewaterhouseCoopers LLP as independent auditors of the Company for its fiscal year ending December&nbsp;31, 2003. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2><B>How do I vote?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may either vote "For" all the nominees to the Board of Directors or you may abstain from voting for any nominee you specify. For each of the other matters to
be voted on, you may vote "For" or "Against" or "Abstain" from voting. Abstaining will have the same effect as a "No" vote. The procedures for voting are fairly simple: </FONT></P>

<UL>

<P><FONT SIZE=2><I> Stockholder of Record: Shares Registered in Your Name  </I></FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a stockholder of record, you may vote in person at the special meeting or vote by proxy using the enclosed proxy card. Whether or not you plan to
attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote in person if you have already voted by proxy. </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>To
vote in person, come to the special meeting and we will give you a ballot when you arrive.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>To
vote using the proxy card, simply complete, sign and date the enclosed proxy card and return it promptly in the envelope provided. If you return your signed proxy card to
us before the special meeting, we will vote your shares as you direct. </FONT></DD></DL>
</UL>
<UL>

<P><FONT SIZE=2><I> Beneficial Owner: Shares Registered in the Name of Broker or Bank  </I></FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received a proxy card and voting instructions
with these proxy materials from that organization rather than from Aerogen. Simply complete and mail the proxy card to ensure that your vote is counted. Alternatively, you may vote by telephone or
over the Internet as instructed by your broker or bank. To vote in person at the special meeting, you must obtain a valid proxy from your broker, bank, or other agent. Follow the instructions from
your broker or bank included with these proxy materials, or contact your broker or bank to request a proxy form. </FONT></P>

<P><FONT SIZE=2><B>How many votes do I have?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On each matter to be voted upon, you have one vote for each share of common stock you own as of October&nbsp;6, 2003. </FONT></P>


<P><FONT SIZE=2><B>What if I return a proxy card but do not make specific choices?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you return a signed and dated proxy card without marking any voting selections, your shares will be voted: (i)&nbsp;"For" the approval of the second closing
of the convertible debt financing with SF Capital Partners,&nbsp;Ltd., including the sale of a convertible debenture and warrant; (ii)&nbsp;"For" the amendment of the Company's Amended and
Restated Certificate of Incorporation; (iii)&nbsp;"For" the election of all three nominees for director; and (iv)&nbsp;"For" the ratification of PricewaterhouseCoopers LLP as independent auditors
of the Company for its fiscal year ending December&nbsp;31, 2003. If any other matter is properly </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=4,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=1047211,FOLIO='2',FILE='DISK032:[03PAL2.03PAL1722]DE1722A.;5',USER='ATOBAK',CD='24-SEP-2003;15:03' -->
<A NAME="page_de1722_1_3"> </A>
<BR>

<P><FONT SIZE=2>presented
at the meeting, your proxy (one of the individuals named on your proxy card) will vote your shares using his or her best judgment. </FONT></P>

<P><FONT SIZE=2><B>Who is paying for this proxy solicitation?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will pay for the entire cost of soliciting proxies. In addition to these mailed proxy materials, our directors and employees and Mellon Investor Services, LLC
may also solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting
proxies</FONT><FONT SIZE=2><B>,</B></FONT><FONT SIZE=2> but Mellon Investor Services, LLC will be paid its customary fee of approximately $9,500 plus out-of-pocket expenses if
it solicits proxies. We will also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners. </FONT></P>

<P><FONT SIZE=2><B>What does it mean if I receive more than one proxy card?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you receive more than one proxy card, your shares are registered in more than one name or are registered in different accounts. Please complete, sign and
return </FONT><FONT SIZE=2><B>each</B></FONT><FONT SIZE=2> proxy card to ensure that all of your shares are voted. </FONT></P>

<P><FONT SIZE=2><B>Can I change my vote after submitting my proxy?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes. You can revoke your proxy at any time before the final vote at the meeting. You may revoke your proxy in any one of three ways: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>You
may submit another properly completed proxy card with a later date.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>You
may send a written notice that you are revoking your proxy to the Company's Secretary at 2071 Stierlin Court, Mountain View, CA 94043.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>You
may attend the special meeting and vote in person. Simply attending the meeting will not, by itself, revoke your proxy. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2><B>When are stockholder proposals due for next year's annual meeting?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To be considered for inclusion in next year's proxy materials, your proposal must be submitted in writing by December&nbsp;27, 2003, to the Secretary of the
Company, 2071 Stierlin Court, Mountain View, CA 94043. If you wish to bring a matter before the stockholders at next year's annual meeting and you do not notify Aerogen,&nbsp;Inc. before
February&nbsp;4, 2004</FONT><FONT SIZE=2><B>,</B></FONT><FONT SIZE=2> the Company's management will have discretionary authority to vote all shares for which it has proxies in opposition to the
matter. Stockholders are also advised to review the Company's Bylaws, which contain additional requirements with respect to advance notice of stockholder proposals and director nominations. </FONT></P>

<P><FONT SIZE=2><B>How are votes counted?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Votes will be counted by the inspector of election appointed for the meeting, who will separately count "For" and (with respect to proposals other than the
election of directors) "Against" votes, abstentions and broker non-votes. ("Broker non-vote" occurs when a nominee holding shares for a beneficial owner does not vote on a
particular proposal because the nominee does not have discretionary voting power with respect to that proposal and has not received instructions with respect to that proposal from the beneficial owner
(despite voting on at least one other proposal for which the nominee does have discretionary authority or for which the nominee has received instructions). Abstentions will be counted towards the vote
total for each proposal, and will have the same effect as "Against" votes. Broker non-votes are counted towards a quorum, but are not counted for any purpose in determining whether a
matter has been approved. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=5,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=917280,FOLIO='3',FILE='DISK032:[03PAL2.03PAL1722]DE1722A.;5',USER='ATOBAK',CD='24-SEP-2003;15:03' -->
<A NAME="page_de1722_1_4"> </A>
<BR>


<P><FONT SIZE=2><B>How many votes are needed to approve each proposal?  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>To
be approved, Proposal No.&nbsp;1, the proposed second closing of the convertible debt transaction with SF Capital Partners,&nbsp;Ltd., must receive a "For" vote from
the majority of shares present and entitled to vote either in person or by proxy. If you "Abstain" from voting, it will have the same effect as an "Against" vote. Broker non-votes will
have no effect.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>To
be approved, Proposal No.&nbsp;2, the amendment of our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our Common Stock pursuant to
which any whole number of outstanding shares between and including four and eight would be combined into one share of our common stock, must receive a "For" vote from the majority of the outstanding
shares. If you "Abstain" from voting, it will have the same effect as an "Against" vote. Broker non-votes will have the same effect as an "Against" vote.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>For
the election of directors, the three nominees receiving the most "For" votes (among votes properly cast in person or by proxy) will be elected. Broker
non-votes will have no effect.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>To
be approved, Proposal No.&nbsp;4, the ratification of PricewaterhouseCoopers LLP as independent auditors of the Company for its fiscal year ending December&nbsp;31,
2003, must receive a "For" vote from the majority of shares present and entitled to vote either in person or by proxy. If you "Abstain" from voting, it will have the same effect as an "Against" vote.
Broker non-votes will have no effect. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2><B>What is the quorum requirement?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if at least a majority of the outstanding shares are represented by votes
at the meeting or by proxy. On the record date, there were [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares outstanding and entitled to vote.
Thus [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares must
be represented by votes at the meeting or by proxy to have a quorum. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
shares will be counted towards the quorum only if you submit a valid proxy vote or vote at the meeting. Abstentions and broker non-votes will be counted towards the
quorum requirement. If there is no quorum, a majority of the votes present at the meeting may adjourn the meeting to another date. </FONT></P>

<P><FONT SIZE=2><B>How can I find out the results of the voting at the special meeting?  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preliminary voting results will be announced at the special meeting. Final voting results will be published in the Company's annual report on
Form&nbsp;10-K for the year ending December&nbsp;31, 2003. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=6,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=329217,FOLIO='4',FILE='DISK032:[03PAL2.03PAL1722]DE1722A.;5',USER='ATOBAK',CD='24-SEP-2003;15:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_dg1722_1_5"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="dg1722_proposal_1_approval_of_the_sec__pro04133"> </A>
<A NAME="toc_dg1722_1"> </A>
<BR></FONT><FONT SIZE=2><B>PROPOSAL 1<BR>  APPROVAL OF THE SECOND CLOSING OF A CONVERTIBLE DEBT<BR>  TRANSACTION WITH SF CAPITAL PARTNERS,&nbsp;LTD.    <BR>    </B></FONT></P>

<P><FONT SIZE=2><B>INTRODUCTION  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The following description of the principal</I></FONT><FONT SIZE=2> terms </FONT><FONT SIZE=2><I>of the transaction and the securities
already issued and to be issued, is a summary only. The complete text of each of the agreements relating to this transaction are filed as exhibits to the Company's Current Report on
Form&nbsp;8-K filed with the SEC on September&nbsp;&nbsp;&nbsp;&nbsp;, 2003.</I></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
September&nbsp;10, 2003, the Company completed the first part of a planned two-part convertible debt financing (the "Financing") with SF Capital Partners,&nbsp;Ltd.
("SF Capital"). The closing of the first part of the Financing (the "First Closing") resulted in gross proceeds to the Company of approximately $950,000. The second part of the Financing is subject to
approval by the Company's stockholders, and is expected to close in November&nbsp;2003 (the "Second Closing"). If and when the Second Closing is completed, it will result in aggregate gross proceeds
to the Company of between $500,000 and $2,000,000. The Company intends to use the proceeds of the Second Closing to fund general working capital requirements. </FONT></P>

<P><FONT SIZE=2><B>DESCRIPTION OF THE SECURITIES  </B></FONT></P>

<P><FONT SIZE=2><B><I>Debenture Issued at the First Closing  </I></B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the First Closing, the Company issued to SF Capital a secured convertible debenture with a face amount of $950,000.10 (the "First Debenture"). The First
Debenture bears interest at a rate of 10% per annum and matures on December&nbsp;31, 2003. In addition, the First Debenture is convertible into
Common Stock at any time prior to December&nbsp;31, 2003 at the option of SF Capital at an initial conversion price of $0.35 per share. If converted in full at such price, the First Debenture would
result in the issuance of 2,714,286 shares of Common Stock. The conversion price and the number of shares of Common Stock issuable upon conversion of the First Debenture and, if issued, the Second
Debenture (defined below), are subject to proportional adjustments for stock dividends, splits, combinations and the like. The First Debenture is secured by a first priority security interest in
substantially all of the Company's personal property assets, including its intellectual property assets. At any time prior to the maturity date of the First Debenture, after delivery of a written
notice to SF Capital (a "Prepayment Notice"), the Company may prepay all or a portion of the principal amount of the First Debenture (including accrued and unpaid interest thereunder), for an amount
in cash equal to (i)&nbsp;110% of the principal amount to be prepaid, and (ii)&nbsp;all accrued and unpaid interest on the principal amount to be prepaid. SF Capital will have the right to convert
the First Debenture within 10&nbsp;days of receipt of a Prepayment Notice. The conversion price of the First Debenture is subject to proportional adjustments for stock dividends, splits,
combinations and the like. In addition, subject to certain exceptions, if the Company issues securities at less than $0.35 per share (as adjusted for stock, dividends, splits, combinations or the
like) while the First Debenture is outstanding, then the conversion price of the First Debenture will be adjusted to equal the price at which the securities are issued. In no case, however, prior to
stockholder approval of this Proposal&nbsp;1, will the First Debenture result in the issuance of more than 2,714,286 shares. If there is any reduction in the conversion price, any remaining
principal after issuance of such number of shares on conversion would be subject to repayment by the Company to SF&nbsp;Capital. </FONT></P>

<P><FONT SIZE=2><B><I>Warrant Issued at the First Closing  </I></B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the First Debenture, the Company issued to SF Capital at the First Closing a four-year warrant to purchase up to 1,357,143 shares of
Common Stock at an exercise price of $0.35 per share (the "First Warrant"). The exercise price and number of shares issuable upon exercise of the First Warrant and, if issued, the Second Warrant
(described below), are subject to proportional </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=7,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=293722,FOLIO='5',FILE='DISK032:[03PAL2.03PAL1722]DG1722A.;11',USER='DNICHOL',CD='24-SEP-2003;16:02' -->
<A NAME="page_dg1722_1_6"> </A>
<BR>

<P><FONT SIZE=2>adjustments
for stock dividends, splits, combinations and the like. In addition, subject to certain exceptions, if the Company issues securities at less than $0.35 per share (as adjusted for stock,
dividends, splits, combinations or the like) while the Warrants are outstanding, then the exercise price of the First Warrant and Second Warrant will be adjusted to equal the price at which the
securities are issued. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SF
Capital may exercise the First Warrant and the Second Warrant, if issued, without paying the exercise price to the Company, if the market price of the Company's Common Stock exceeds
the then-current exercise price requiring the Company to issue to SF Capital that number of shares of Common Stock with an aggregate market value on the date of exercise equal to
(i)&nbsp;the amount by which the market price on the date of exercise exceeds the exercise price, multiplied by (ii)&nbsp;the number of shares for which the warrant is exercisable. </FONT></P>


<P><FONT SIZE=2><B><I>Debenture and Warrant to Be Issued at the Second Closing  </I></B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the stockholders approve the Second Closing of the convertible debt transaction with SF Capital, the Company will issue SF Capital a secured convertible
debenture with a face amount of between $500,000 and $2,000,000, with the actual investment amount to be determined at SF Capital's sole discretion (the "Second Debenture" and collectively with the
First Debenture, the "Debentures"). The Second Debenture would bear interest at a rate of 10% per annum and would mature on March&nbsp;1, 2004. In addition to the Second Debenture, the Company
expects to issue SF Capital a four-year warrant to purchase a number of shares of common stock equal to 50% of the number of shares initially issuable upon full conversion of the debenture
issued at the Second Closing (the "Second Warrant" and, collectively with the First Warrant, the "Warrants"). The initial conversion price of the Second Debenture and the initial exercise price of the
Second Warrant would each be equal to the lesser of the 10 or 30 trading-day average daily volume-weighted average price ("VWAP") per share of Aerogen's common stock measured during the 10
or 30 trading-days prior to the Second Closing. The terms of the Second Debenture and the Second Warrant otherwise would be substantially the same as the terms of the First Debenture and
the First Warrant described above, including similar provisions for adjustment of the exercise price of the Second Warrant and the conversion price of the Second Debenture under certain conditions.
The Second Closing, including the issuance of the Second Debenture and Second Warrant, is subject to the approval of this Proposal 1 by the stockholders of the Company. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the terms above, the parties have agreed that under no circumstances will SF Capital purchase a Second Debenture that is convertible into more than 10,800,000 shares of
Common Stock, or a Second Warrant that is exercisable for more than 5,400,000 shares of Common Stock, for an aggregate maximum of 16,200,000 shares. The actual number of shares into which the Second
Debenture is convertible and the Second Warrant exercisable will depend on the VWAP and the amount invested by SF Capital, as discussed above. The following table provides examples of the </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=8,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=692642,FOLIO='6',FILE='DISK032:[03PAL2.03PAL1722]DG1722A.;11',USER='DNICHOL',CD='24-SEP-2003;16:02' -->
<A NAME="page_dg1722_1_7"> </A>
<BR>

<P><FONT SIZE=2>numbers
of shares issuable upon conversion and exercise of the Second Debenture and Second Warrant at various VWAP's and investment amounts: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE WIDTH="50%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Amount Invested</B></FONT><HR NOSHADE></TH>
<TH WIDTH="8%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Applicable VWAP</B></FONT><HR NOSHADE></TH>
<TH WIDTH="8%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="40%" ALIGN="CENTER"><FONT SIZE=1><B>Aggregate Number of Shares<BR>
Issuable Under Second Debenture<BR>
and Second Warrant</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="20%" ALIGN="RIGHT"><FONT SIZE=2>500,000</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>0.75</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="40%" ALIGN="RIGHT"><FONT SIZE=2>1,000,000 shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="20%" ALIGN="RIGHT"><FONT SIZE=2>500,000</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>0.50</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="40%" ALIGN="RIGHT"><FONT SIZE=2>1,500,000 shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="20%" ALIGN="RIGHT"><FONT SIZE=2>500,000</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>0.25</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="40%" ALIGN="RIGHT"><FONT SIZE=2>3,000,000 shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=7 ALIGN="RIGHT"><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="20%" ALIGN="RIGHT"><FONT SIZE=2>1,000,000</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>0.75</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="40%" ALIGN="RIGHT"><FONT SIZE=2>2,000,000 shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="20%" ALIGN="RIGHT"><FONT SIZE=2>1,000,000</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>0.50</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="40%" ALIGN="RIGHT"><FONT SIZE=2>3,000,000 shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="20%" ALIGN="RIGHT"><FONT SIZE=2>1,000,000</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>0.25</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="40%" ALIGN="RIGHT"><FONT SIZE=2>6,000,000 shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=7 ALIGN="RIGHT"><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="20%" ALIGN="RIGHT"><FONT SIZE=2>2,000,000</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>0.75</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="40%" ALIGN="RIGHT"><FONT SIZE=2>4,000,000 shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="20%" ALIGN="RIGHT"><FONT SIZE=2>2,000,000</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>0.50</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="40%" ALIGN="RIGHT"><FONT SIZE=2>6,000,000 shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="20%" ALIGN="RIGHT"><FONT SIZE=2>2,000,000</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>0.25</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="40%" ALIGN="RIGHT"><FONT SIZE=2>12,000,000 shares</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2><B><I>Participation in Future Financing Transactions  </I></B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SF Capital has a limited three-year right to participate in future financings of the Company. If, prior to September&nbsp;9, 2006, the Company
issues Common Stock or securities convertible into Common Stock, other than in certain excluded transactions (a "Subsequent Financing"), the Company must first notify SF Capital of the terms of the
Subsequent Financing and allow SF Capital to participate up to the lesser of: (i)&nbsp;SF Capital's beneficial ownership (expressed as a percentage) of the Company's Common Stock and securities
convertible into Common Stock and (ii)&nbsp;$2,000,000. </FONT></P>

<P><FONT SIZE=2><B><I>Limitations on Stock Ownership  </I></B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SF Capital has agreed to limit its ownership of the Company's Common Stock. So long as SF Capital holds any of the Debentures or Warrants, it has agreed that it
will not own or control at any one time more than 19.999% of the Company's outstanding Common Stock. </FONT></P>


<P><FONT SIZE=2><B><I>Restrictions on Sale of Assets and Future Indebtedness  </I></B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company may sell all or a portion of the collateral used to secure the Debentures for a net purchase price which is equal to or greater than the fair market
value of such collateral if such purchaser delivers the purchase price (or portion thereof, if applicable) to SF Capital in payment of the Company's prepayment price for the prepayment in full of the
all outstanding Debentures. Notwithstanding the foregoing, the Company may not sell, convey, assign, lease, abandon or otherwise transfer or dispose of, voluntarily or involuntarily, any of its
properties or assets, tangible or intangible, subject to certain permitted exceptions. In addition, so long as there remains any outstanding principal amount under the First or Second Debenture, if
issued, the Company may not, without the prior written consent of SF Capital, incur, create, assume, guarantee or become or remain liable for any indebtedness, subject to certain permitted exceptions. </FONT></P>

<P><FONT SIZE=2><B><I>Registration Rights  </I></B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has agreed to register for resale the shares underlying the Debentures and Warrants. The Company will prepare and file registration statements on
Form&nbsp;S-3 (the "Registration Statements") for the resale of the shares of Common Stock issuable upon conversion of the respective Debentures and exercise of the respective Warrants
(the "Registrable Securities") within 45&nbsp;days of the First and Second Closings, respectively. The Company has agreed to use its best efforts to cause the Registration Statements to become
effective as promptly as possible, but in no event later than 120&nbsp;days after each respective Closing. The Company has agreed to make such filings as are necessary </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=9,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=23597,FOLIO='7',FILE='DISK032:[03PAL2.03PAL1722]DG1722A.;11',USER='DNICHOL',CD='24-SEP-2003;16:02' -->
<A NAME="page_dg1722_1_8"> </A>
<BR>

<P><FONT SIZE=2>to
keep the Registration Statements effective until the date which is two years after the date that such Registration Statement is declared effective by the SEC or such earlier date when all
Registrable Securities covered by a Registration Statement have been sold or may be sold without volume restrictions pursuant to Rule&nbsp;144(k) as determined by the counsel to the Company. The
Company is entitled to suspend the effectiveness of each Registration Statement for no more than 20 trading days without the consent of SF Capital. The Company will bear the expenses associated with
the Registration Statements. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that the Company fails to cause a Registration Statement to be timely filed or to be kept effective (other than pursuant to the permissible suspension periods), it has
agreed to pay as liquidated damages the amount of 1% of the aggregate purchase price ("Purchase Price") paid by SF Capital for the Debentures and Warrants for the first 30-day delay (or a
pro rata portion for any delay less than 30&nbsp;days) and an additional 2% of the Purchase Price for each month anniversary thereafter (or a pro rata portion for any partial month). </FONT></P>

<P><FONT SIZE=2><B><I>Ownership Percentages  </I></B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table indicates the (1)&nbsp;beneficial ownership of the Company's voting securities held by SF Capital upon the First Closing and (2)&nbsp;the
maximum beneficial ownership of the Company's voting securities that could be held by SF Capital upon the Second Closing, assuming no additional Common Stock issuances prior to the Second Closing: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="44%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="12%" ALIGN="CENTER"><FONT SIZE=1><B>Debentures</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="11%" ALIGN="CENTER"><FONT SIZE=1><B>Warrants</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="12%" ALIGN="CENTER"><FONT SIZE=1><B>Maximum<BR>
Total<BR>
Shares<BR>
Beneficially<BR>
Owned</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="11%" ALIGN="CENTER"><FONT SIZE=1><B>Maximum<BR>
% Voting<BR>
Securities<BR>
Beneficially<BR>
Owned</B></FONT><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2><B>First Closing (September 10, 2003)</B></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2>2,714,286</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="CENTER"><FONT SIZE=2>1,357,143</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2>4,071,429</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="CENTER"><FONT SIZE=2>16.55%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="44%"><BR><FONT SIZE=2><B>Second Closing (Anticipated in November, 2003)</B></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
10,800,000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="CENTER"><FONT SIZE=2><BR>
5,400,000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
16,200,000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="CENTER"><FONT SIZE=2><BR>
44.11%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="CENTER"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="CENTER"><HR NOSHADE></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="44%"><BR><FONT SIZE=2><B>Total (both Closings)</B></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
13,514,286</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="CENTER"><FONT SIZE=2><BR>
6,757,143</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
20,271,429</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="CENTER"><FONT SIZE=2><BR>
49.68%</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>Percentage
ownership is determined by including shares exercisable currently or within 60&nbsp;days following the date of this proxy statement upon exercise of warrants and conversion of debentures,
and excludes shares underlying warrants held by any person other than SF Capital. The calculation used above is for purposes of calculating ownership to determine whether a "change of control" has
occurred under the rules of The Nasdaq Stock Market. "Beneficial ownership" for purposes of SEC filings is set forth in the footnote under the caption "Security Ownership of Certain Beneficial Owners
and Management" in this Proxy Statement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming
stockholder approval of this Proposal 1, the Company may issue an aggregate amount of up to approximately 13,514,286 shares of Common Stock upon conversion of the Debentures,
and up to 6,757,143 shares of Common Stock upon exercise of the Warrants, depending upon the amount invested in the Second Closing and the conversion price of the Debentures, as described above. </FONT></P>

<P><FONT SIZE=2><B>REQUIREMENTS FOR STOCKHOLDER APPROVAL  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's Common Stock is listed on The Nasdaq SmallCap Market, and, as a result, we are subject to Nasdaq's rules. We are required to seek stockholder
approval for the Second Closing with SF Capital in order to ensure compliance with Rule&nbsp;4350 of the Nasdaq rules ("Nasdaq Rule&nbsp;4350"). Nasdaq Marketplace Rule&nbsp;4350(i)(1)(B)
requires stockholder approval in connection with the issuance of securities that could result in a "change of control" of an issuer, as such term is defined by Nasdaq. In addition, Nasdaq
Rule&nbsp;4350(i)(1)(D) requires stockholder approval prior to the issuance of securities under certain circumstances, including a transaction involving the sale and issuance of common stock at </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=10,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=771877,FOLIO='8',FILE='DISK032:[03PAL2.03PAL1722]DG1722A.;11',USER='DNICHOL',CD='24-SEP-2003;16:02' -->
<A NAME="page_dg1722_1_9"> </A>
<BR>

<P><FONT SIZE=2>a
price below the book value or market value, where the amount of stock being issued is equal to 20% or more of the issuer's common stock outstanding before such issuance. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
stockholders are being asked to approve the issuance and sale by Aerogen of up to 10,800,000 shares of Common Stock upon conversion of the Debentures, and up to 5,400,000 shares of
Common Stock upon exercise of the Warrants of our common stock, depending upon the amount invested at the Second Closing and the conversion price of the Debentures. Such approval is required under
Nasdaq rules because the financing would be considered a "change of control" of the Company, as defined under Nasdaq Marketplace Rule&nbsp;4350(i)(1)(B) and guidance provided by Nasdaq, and because
the financing will result in the issuance of more than 20% of our outstanding common stock at a price that may be below the market value of our Common Stock at the time of issuance, which would
trigger Nasdaq Marketplace Rule&nbsp;4350(i)(1)(D). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;First,
because the financing described in this Proposal 1 involves the potential issuance by the Company of securities convertible into, and exercisable for, shares of Common Stock that
would cause SF Capital to own more than 20% of the Company's currently outstanding Common Stock, the Company issued only the First Debenture convertible into 2,714,286 shares of Common Stock and
Warrant exercisable to purchase 1,357,143 shares of Common Stock at the First Closing, and will only sell an additional debenture convertible to purchase 10,800,000 shares of Common Stock and a
Warrant exercisable to purchase 5,400,000 shares of common stock if approved by the stockholders pursuant to this Proposal 1. The issuance of the First Debenture and First Warrant in the First Closing
was not sufficient to cause SF Capital to own in excess of 20% of the Company's outstanding Common Stock, calculated as set forth in "Ownership Percentages" above, and, therefore, did not constitute a
"change of control" of the Company as defined in Nasdaq Marketplace Rule&nbsp;4350(i)(1)(B). Although the Company does not necessarily believe that the issuance of the Debentures and Warrants in the
Second Closing will constitute a change in control of the Company, the Company is now seeking approval by the stockholders of the Company of the issuance of Second Debenture and Second Warrant at the
Second Closing that would cause SF Capital to cumulatively own in excess of 20% of the Company's outstanding Common Stock, calculated as set forth in "Ownership Percentages" above, which could
potentially constitute a "change of control" of the Company for purposes of Nasdaq Marketplace Rule&nbsp;4350(i)(1)(B). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Second,
the Company will have issued at the First and Second Closing, debentures and warrants to SF Capital that are, in the aggregate, equal to greater than 20% of the Common Stock
outstanding prior to the First Closing. While the conversion price of the Second Debenture and exercise price of the Second Warrant have not been determined, such amounts may be less than the market
value. As a result, the Company is seeking stockholder approval of the Second Closing for purposes of Nasdaq Marketplace Rule&nbsp;4350(i)(1)(D). </FONT></P>

<P><FONT SIZE=2><B>RATIONALE FOR THE SECOND CLOSING OF THE SF CAPITAL TRANSACTION  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is in need of additional funds in order to continue as a going concern. The additional funds to be received by the Company at the Second Closing will
allow the Company to continue operations while we continue to pursue funding through other sources. Without the Second Closing, the Company may not be able to conclude the activities necessary to
raise such additional funds. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Second Closing described in this Proposal 1 will provide the Company additional capital, which is critical to its ability to maintain its business and to sustain the confidence of
its customers, business partners and employees. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=11,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=315581,FOLIO='9',FILE='DISK032:[03PAL2.03PAL1722]DG1722A.;11',USER='DNICHOL',CD='24-SEP-2003;16:02' -->
<A NAME="page_dg1722_1_10"> </A>
<BR>

<P><FONT SIZE=2><B>DESCRIPTION OF COMMON STOCK  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's authorized capital stock consists of 95,000,000 shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of Preferred Stock, par
value $0.001 per share. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of September&nbsp;15, 2003, there were 20,529,231 shares of Common Stock outstanding, held of record by 184 stockholders. In addition, as of September&nbsp;15, 2003, there were
2,467,187 shares of Common Stock subject to outstanding options, 1,378,809 shares of Common Stock subject to outstanding warrants and 2,714,286 shares issuable upon conversion of the First Debenture
to SF Capital. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
share of Common Stock entitles its holder to one vote on all matters to be voted upon by stockholders. Holders of Common Stock may receive ratably any dividends that the Board of
Directors may declare out of funds legally available for that purpose. In the event of the liquidation, dissolution or winding up of the Company, the holders of Common Stock are entitled to share
ratably in all assets remaining after payment of liabilities and any liquidation preference of any preferred stock that may be issued in the future. The Common Stock has no preemptive rights,
conversion rights, subscription rights or redemption or sinking fund provisions. All outstanding shares of Common Stock are fully paid and non-assessable. </FONT></P>

<P><FONT SIZE=2><B>Warrants  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of September&nbsp;15, 2003, in addition to the First Warrant, which is currently exercisable for 1,357,143 shares, two warrants to purchase a combined
aggregate of 21,666 shares of Common Stock were outstanding at a weighted average exercise price of $3.00 per share. Such warrants will expire on October&nbsp;14, 2004. </FONT></P>

<P><FONT SIZE=2><B>Anti-Takeover Provisions  </B></FONT></P>

<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delaware Law.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company is subject to Section&nbsp;203 of the Delaware General Corporation Law, which regulates
acquisitions of some Delaware corporations. In general, Section&nbsp;203 prohibits, with some exceptions, a publicly held Delaware corporation from engaging in a business combination with an
interested stockholder for a period of three years following the date the person becomes an interested stockholder, unless: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>the
Board of Directors approved the business combination or the transaction in which the person became an interested stockholder prior to the date the person attained this
status;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>upon
consummation of the transaction that resulted in the person becoming an interested stockholder, the person owned at least 85% of the Company's voting stock outstanding
at the time the transaction commenced, excluding shares owned by persons who are directors and also officers and by employee stock plans in which employee participants do not have the right to
determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>on
or subsequent to the date the person became an interested stockholder, the Board of Directors approved the business combination and the stockholders other than the
interested stockholder authorized the transaction at an Special or special meeting of stockholders by the affirmative vote of at least 66.67% of the outstanding stock not owned by the interested
stockholder. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;203
defines a "business combination" to include: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>any
merger or consolidation involving the Company and the interested stockholder; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=12,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=638111,FOLIO='10',FILE='DISK032:[03PAL2.03PAL1722]DG1722A.;11',USER='DNICHOL',CD='24-SEP-2003;16:02' -->
<A NAME="page_dg1722_1_11"> </A>
<UL>
<UL>
</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>any
sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the Company's assets;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>in
general, any transaction that results in the issuance or transfer by the Company of any of the Company's stock to the interested stockholder;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>any
transaction involving the corporation that has the effect of increasing the proportionate share of the Company's stock owned by the interested stock holders; or
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>the
receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the Company. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
general, Section&nbsp;203 defines an "interested stockholder" as any person who, together with the person's affiliates and associates, owns, or within three years prior to the
determination of interested stockholder status did own, 15% or more of a corporation's voting stock. </FONT></P>

<P><FONT SIZE=2><B>Certificate of Incorporation and Bylaw Provisions.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's certificate of incorporation and bylaws include a number of provisions that may have the effect of deterring hostile takeovers or delaying or
preventing changes in control or management of the Company. First, the certificate of incorporation provides that all stockholder actions must be effected at a duly called meeting of holders and not
by a consent in writing. Second, the bylaws provide that special meetings of the stockholders may be called only by the Company's chairman of the Board of Directors, the Company's chief executive
officer, the Company's Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors, or holders of 50% or more of the Common Stock. Third, the
certificate of incorporation provides that the Company's Board of Directors can issue shares of preferred stock. Fourth, the certificate of incorporation and the bylaws provide for a classified Board
of Directors, in which approximately one-third of the directors would be elected each year. Consequently, any potential acquiror would need to successfully complete two proxy contests in
order to take control of the Board of Directors. Finally, the bylaws establish procedures, including advance notice procedures with regard to the nomination of candidates for election as directors and
stockholder proposals. These provisions of the Company's certificate of incorporation and bylaws could discourage potential acquisition proposals and could delay or prevent a change in control or
management of the Company. </FONT></P>

<P><FONT SIZE=2><B>Rights Plan  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On June&nbsp;5, 2001, the Board approved the adoption of a Stockholder Rights Plan (the "Plan"). Terms of the Plan provide for a dividend distribution of one
preferred share purchase right (a "Right") for each outstanding share of common stock, par value $0.001 per share (the "Common Shares"), of the Company. The dividend was paid on June&nbsp;26, 2001
to the stockholders of record on that date. Each Right entitles the registered holder to purchase from the Company one one-hundredth of a share of Series&nbsp;A Junior Participating
Preferred Stock, par value $0.001 per share (the "Preferred Shares"), at a price of $60.00 per one one-hundredth of a Preferred Share, subject to adjustment. Each one
one-hundredth of a Preferred Share has designations and powers, preferences and rights, and the qualifications, limitations and restrictions which make its value approximately equal to the
value of a Common Share. The description and terms of the Rights are set forth in a Rights Agreement, dated as of June&nbsp;5, 2001, and as amended on February&nbsp;24, 2003, between the Company
and MELLON INVESTOR SERVICES LLC, as rights agent. </FONT></P>


<P><FONT SIZE=2><B>CONSEQUENCE OF NON-APPROVAL  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Company fails to obtain the required stockholder approval by the required approval date, such failure will prevent the Second Closing of the SF Capital
transaction and the sale of the Second </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=7,SEQ=13,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=152764,FOLIO='11',FILE='DISK032:[03PAL2.03PAL1722]DG1722A.;11',USER='DNICHOL',CD='24-SEP-2003;16:02' -->
<A NAME="page_dg1722_1_12"> </A>
<BR>

<P><FONT SIZE=2>Debenture
and Second Warrant and the receipt by the Company of between $500,000 and $2,000,000 in connection therewith. Our Company's Board of Directors has determined that the sale of the Second
Debenture and Second Warrant will further the best interests of the Company. </FONT></P>

<P><FONT SIZE=2><B>INCORPORATION BY REFERENCE OF ANNUAL REPORT ON FORM 10-K  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concurrently with this proxy statement, the Company is sending a copy of its Annual Report on Form&nbsp;10-K for the fiscal year ended
December&nbsp;31, 2002 (the "Form&nbsp;10-K") to its stockholders. This proxy statement incorporates by reference Items 7, 7A, 8 and 9 of the Form&nbsp;10-K, which
contains important information about the Company and its financial condition that is not included in this proxy statement. A copy of the Form&nbsp;10-K has also been filed with the SEC
and may be accessed from the SEC's homepage (www.sec.gov). </FONT></P>


<P><FONT SIZE=2><B>REQUIRED VOTE  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The affirmative vote of a majority of all of the votes present or represented and entitled to vote at the Special Meeting, excluding for this purpose any shares
of common stock held by SF Capital, is required to ratify and approve the Second Closing and the issuance of the Second Debenture and Second Warrant pursuant thereto, which would cause SF Capital to
beneficially own in excess of 20% of the Company's outstanding Common Stock as defined by Nasdaq rules. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS<BR>
A VOTE IN FAVOR OF PROPOSAL&nbsp;1.  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=8,SEQ=14,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=375967,FOLIO='12',FILE='DISK032:[03PAL2.03PAL1722]DG1722A.;11',USER='DNICHOL',CD='24-SEP-2003;16:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_di1722_1_13"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="di1722_proposal_2_approval_of_amendme__pro04887"> </A>
<A NAME="toc_di1722_1"> </A>
<BR></FONT><FONT SIZE=2><B>PROPOSAL 2<BR>  APPROVAL OF AMENDMENT TO OUR CERTIFICATE<BR>  OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT<BR>  OF OUR COMMON STOCK    <BR>    </B></FONT></P>

<P><FONT SIZE=2><B>OVERVIEW  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board has approved a proposal to amend our certificate of incorporation to effect a reverse stock split of all outstanding shares of our common stock at an
exchange ratio ranging from one-to-four to one-to-eight. The Board has recommended that this proposal be presented to our stockholders for approval. You
are now being asked to vote upon amendments to our certificate of incorporation to effect this reverse stock split whereby a number of outstanding shares of our common stock between and including four
and eight, such number consisting only of whole shares, will be combined into one share of our common stock. Pending stockholder approval, the Board will have the sole discretion pursuant to
Section&nbsp;242(c) of the Delaware General Corporation Law to elect, as it determines to be in the best interests of Aerogen and its stockholders, whether or not to effect a reverse stock split,
and if so, the number of shares of our common stock between and including four and eight that will be combined into one share of our common stock, at any time before the first anniversary of this
special meeting of stockholders. The Board believes that stockholder approval of amendments granting the Board this discretion, rather than approval of a specified exchange ratio, provides the Board
with maximum flexibility to react to then-current market conditions and, therefore, is in the best interests of Aerogen and its stockholders. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
text of the forms of proposed amendments to our certificate of incorporation is attached to this proxy statement as Appendix&nbsp;A. By approving these amendments, stockholders
will approve a series of amendments to our certificate of incorporation pursuant to which any whole number of outstanding shares between and including four and eight would be combined into one share
of our common stock, and authorize the Board to file only one such amendment, as determined by the Board in the manner described herein, and to abandon each amendment not selected by the Board. The
Board may also elect not to do any reverse split. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
approved by the stockholders, and following such approval, the Board determines that effecting a reverse stock split is in the best interests of Aerogen and its stockholders, the
reverse stock split will
become effective upon filing one such amendment with the Secretary of State of the State of Delaware. The amendment filed thereby will contain the number of shares selected by the Board within the
limits set forth in this proposal to be combined into one share of our common stock. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Board elects to effect a reverse stock split following stockholder approval, the number of issued and outstanding shares of common stock would be reduced in accordance with an
exchange ratio determined by the Board within the limits set forth in this proposal. Except for adjustments that may result from the treatment of fractional shares as described below, each stockholder
will hold the same percentage of our outstanding common stock immediately following the reverse stock split as such stockholder held immediately prior to the reverse stock split. Currently, Aerogen is
authorized to issue up to a total of 100,000,000 shares of capital stock, consisting of 5,000,000 shares of preferred stock and 95,000,000 shares of common stock. The amendment would not change the
number of total authorized shares of our capital stock. Thus, immediately following the reverse stock split, the total number of authorized shares of capital stock would remain at 100,000,000,
consisting of 5,000,000 shares of preferred stock and 95,000,000 shares of common stock. The par value of our common stock and preferred stock would remain unchanged at $0.001 per share, as well.
Based on the number of issued and outstanding shares of common stock as of September&nbsp;15, 2003, a total of approximately 74,470,769 shares of common stock would be authorized but unissued
immediately prior to the reverse stock split. Currently, the Board does not have any definite plans with regard to the authorized but unissued shares of common stock of the Company following the
reverse stock split. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=15,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=912740,FOLIO='13',FILE='DISK032:[03PAL2.03PAL1722]DI1722A.;5',USER='ATOBAK',CD='24-SEP-2003;15:19' -->
<A NAME="page_di1722_1_14"> </A>
<BR>

<P><FONT SIZE=2><B>REASONS FOR THE REVERSE STOCK SPLIT  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board believes that a reverse stock split may be desirable for a number of reasons. First, the Board believes that a reverse stock split may allow us to avoid
having our common stock delisted from the Nasdaq SmallCap Market. Second, the Board believes that a reverse stock split could improve the marketability and liquidity of our common stock. Third, the
Board believes that a reverse stock split is desirable in order to increase our common stock price in the near term while the Company continues to progress towards achieving its business objectives. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock is quoted on the Nasdaq SmallCap Market. In order for our common stock to continue to be quoted on the Nasdaq SmallCap Market, we must satisfy certain listing
maintenance standards established by Nasdaq. Among other things, if the closing bid price of our common stock does not reach $1.00 per share or higher for a minimum of ten consecutive trading days by
November&nbsp;3, 2003, or such later date as Nasdaq may subsequently allow, Nasdaq may delist our common stock from trading on the Nasdaq SmallCap Market. If our common stock were to be delisted,
our common stock would trade on the OTC Bulletin Board or in the "pink sheets" maintained by the National Quotation Bureau,&nbsp;Inc. Such alternative markets are generally considered to be less
efficient than, and not as broad as, the Nasdaq SmallCap Market. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November&nbsp;2002, we received notice from Nasdaq Stock Market&nbsp;Inc., that our common stock would be delisted from the Nasdaq National Market on November&nbsp;19, 2002
because the stock had not closed with a bid price of above $1.00 per share for at least 10 consecutive trading days during the preceding 90 calendar days. In December&nbsp;2002, the listing of our
common stock was transferred to the Nasdaq SmallCap Market. Notwithstanding the transfer, we are still subject to the requirement of a share minimum bid price of $1.00. Nasdaq has granted us two
consecutive additional grace periods ending on November&nbsp;3, 2003 within which to regain compliance. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board expects that a reverse stock split of our common stock will increase the market price of our common stock so that we are able to regain compliance with the Nasdaq minimum bid
price listing standard. However, the effect of a reverse split upon the market price of our common stock cannot be predicted with any certainty, and the history of similar stock split combinations for
companies in like circumstances is varied. It is possible that the per share price of our common stock after the reverse split will not rise in proportion to the reduction in the number of shares of
our common stock outstanding resulting from the reverse stock split, and there can be no assurance that the market price per post-reverse split share will either exceed or remain in excess
of the $1.00 minimum bid price for a sustained period of time. The market price of our common stock may be based also on other factors that may be unrelated to the number of shares outstanding,
including our future performance. In addition, there can be no assurance that we will not be delisted due to a failure to meet other continued listing requirements even if the market price per
post-reverse split share of our common stock remains in excess of $1.00. Notwithstanding the foregoing, the Board believes that the proposed reverse stock split, when implemented within
the proposed exchange ratio range, will result in the market price of our common stock rising to the level necessary to satisfy the $1.00 minimum bid price requirement. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board also believes that the increased market price of our common stock expected as a result of implementing a reverse stock split will improve the marketability and liquidity of our
common stock and will encourage interest and trading in our common stock. Because of the trading volatility often associated with low-priced stocks, many brokerage houses and institutional
investors have internal policies and practices that either prohibit them from investing in low-priced stocks or tend to discourage individual brokers from recommending
low-priced stocks to their customers. Some of those policies and practices may function to make the processing of trades in low-priced stocks economically unattractive to
brokers. Additionally, because brokers' commissions on low-priced stocks generally represent a higher percentage of the stock price than commissions on higher-priced stocks, the current </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=16,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=193631,FOLIO='14',FILE='DISK032:[03PAL2.03PAL1722]DI1722A.;5',USER='ATOBAK',CD='24-SEP-2003;15:19' -->
<A NAME="page_di1722_1_15"> </A>
<BR>

<P><FONT SIZE=2>average
price per share of our common stock can result in individual stockholders paying transaction costs representing a higher percentage of their total share value than would be the case if the
share price were substantially higher. It should be noted that the liquidity of our common stock may be adversely affected by the proposed reverse stock split given the reduced number of shares that
would be outstanding after the reverse stock split. The Board is hopeful, however, that the anticipated higher market price will reduce, to some extent, the negative effects on the liquidity and
marketability of the common stock inherent in some of the policies and practices of institutional investors and brokerage houses described above. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board is hopeful that the price of our common stock will increase as a result of improvements in the Company's business. The Board believes that the market price of our common stock
will increase to the extent the Company is able to achieve commercial success over time. Nevertheless, the Board believes that a reverse stock split is desirable because of the anticipated higher
market price of our common stock resulting from such action. </FONT></P>


<P><FONT SIZE=2><B>BOARD DISCRETION TO IMPLEMENT THE REVERSE STOCK SPLIT  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the reverse stock split is approved by our stockholders, it will be effected, if at all, only upon a determination by the Board that a reverse stock split
(with an exchange ratio determined by the Board as described above) is in the best interests of Aerogen and its stockholders. The determination by the Board as to whether the reverse split will be
effected, if at all, will be based upon certain factors, including meeting the listing requirements for the Nasdaq SmallCap Market, existing and expected marketability and liquidity of our common
stock, prevailing market conditions and the likely effect on the market price of our common stock. If the Board determines to effect the reverse stock split, the Board will consider certain factors in
selecting the specific exchange ratio, including the overall market conditions at the time and the recent trading history of our common stock. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
approval of the reverse stock split by the stockholders, the Board may, in its sole discretion, abandon all of the proposed amendments and determine prior to the
effectiveness of any filing with the Secretary of State of the State of Delaware not to effect the reverse stock split prior to the one-year anniversary of this special meeting of
stockholders, as permitted under Section&nbsp;242(c) of the Delaware General Corporation Law. If the Board fails to implement any of the reverse stock splits prior to the one-year
anniversary of this special meeting of stockholders, stockholder approval again would be required prior to implementing any reverse stock split. </FONT></P>

<P><FONT SIZE=2><B>EFFECTS OF THE REVERSE STOCK SPLIT  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After the effective date of the proposed reverse stock split, each stockholder will own a reduced number of shares of our common stock. However, the proposed
reverse stock split will affect all of our stockholders uniformly and will not affect any stockholder's percentage ownership interest in us, except to the extent that the reverse stock split results
in any of our stockholders owning a fractional share as described below. Proportionate voting rights and other rights and preferences of the holders of our common stock will not be affected by the
proposed reverse stock split (other than as a result of the payment of cash in lieu of fractional shares). For example, a holder of 2% of the voting power of the outstanding shares of common stock
immediately prior to the reverse stock split would continue to hold 2% of the voting power of the outstanding shares of common stock immediately after the reverse stock split. The number of
stockholders of record will not be affected by the proposed reverse stock split (except to the extent that any stockholder holds only a fractional share interest and receives cash for such interest
after the proposed reverse stock split). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
the proposed reverse stock split will not affect the rights of stockholders or any stockholder's proportionate equity interest in Aerogen, subject to the treatment of fractional
shares, the number of authorized shares of common stock will not be reduced. This will increase significantly the </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=17,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=905908,FOLIO='15',FILE='DISK032:[03PAL2.03PAL1722]DI1722A.;5',USER='ATOBAK',CD='24-SEP-2003;15:19' -->
<A NAME="page_di1722_1_16"> </A>

<P><FONT SIZE=2>ability
of the Board to issue authorized and unissued shares without further stockholder action. The issuance in the future of such additional authorized shares may have the effect of diluting the
earnings per share and book value per share, as well as the stock ownership and voting rights, of the currently outstanding shares of common stock. The effective increase in the number of authorized
but unissued shares of common stock may be construed as having an anti-takeover effect by permitting the issuance of shares to purchasers who might oppose a hostile takeover bid or oppose
any efforts to amend or repeal certain provisions of our certificate of incorporation or bylaws. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
proposed reverse stock split will reduce the number of shares of common stock available for issuance under our Amended and Restated 1994 Stock Option Plan, 2000 Equity Incentive
Plan, 2000 Non-Employee Directors' Stock Option Plan and the 2000 Employee Stock Purchase Plan in proportion to the exchange ratio selected by the Board within the limits set forth in this
proposal. We also have certain outstanding stock options and warrants to purchase shares of our common stock. Under the terms of the outstanding stock options and warrants, the proposed reverse stock
split will effect a reduction in the number of shares of common stock issuable upon exercise of such stock options and warrants in proportion to the exchange ratio of the reverse stock split and will
effect a proportionate increase in the exercise price of such outstanding stock options and warrants. In connection with the proposed reverse stock split, the number of shares of common stock issuable
upon exercise or conversion of outstanding stock options and warrants will be rounded to the nearest whole share and no cash payment will be made in respect of such rounding. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the proposed reverse stock split is implemented, it will increase the number of stockholders of Aerogen who own "odd lots" of less than 100 shares of our common stock. Brokerage
commission and other costs of transactions in odd lots are generally higher than the costs of transactions of more than 100 shares of common stock. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock is currently registered under Section&nbsp;12(g) of the Securities Exchange Act of 1934, as amended, and we are subject to the periodic reporting and other
requirements of the Exchange Act. The proposed reverse stock split will not affect the registration of the common stock under the Exchange Act. Subject to Nasdaq's consent, if the proposed reverse
stock split is implemented, our common stock will continue to be reported on the Nasdaq SmallCap Market under the symbol "AEGN" (although Nasdaq would likely add the letter "D" to the end of the
trading symbol for a period of 20 trading days to indicate that the reverse stock split has occurred). </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
proposed reverse stock split will not affect the par value of our common stock. As a result, on the effective date of the reverse stock split, the stated capital on our balance sheet
attributable to the common stock will be reduced in proportion to the exchange ratio selected by the Board in the manner
described above, and the additional paid-in capital account shall be credited with the amount by which the stated capital is reduced. The per share net income or loss and net book value of
our common stock will be increased because there will be fewer shares of our common stock outstanding. </FONT></P>


<P><FONT SIZE=2><B>EFFECTIVE DATE  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The proposed reverse stock split would become effective as of 5:00&nbsp;p.m. Eastern Time on the date of filing of a certificate of amendment to our certificate
of incorporation with the office of the Secretary of State of the State of Delaware. Except as explained below with respect to fractional shares, on the effective date, shares of common stock issued
and outstanding immediately prior thereto will be combined and converted, automatically and without any action on the part of the stockholders, into new shares of common stock in accordance with
reverse stock split ratio determined by the Board within the limits set forth in this proposal. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=18,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=335806,FOLIO='16',FILE='DISK032:[03PAL2.03PAL1722]DI1722A.;5',USER='ATOBAK',CD='24-SEP-2003;15:19' -->
<A NAME="page_di1722_1_17"> </A>
<BR>

<P><FONT SIZE=2><B>PAYMENT FOR FRACTIONAL SHARES  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No fractional shares of common stock will be issued as a result of the proposed reverse stock split. Instead, stockholders who otherwise would be entitled to
receive fractional shares, upon surrender to the exchange agent of such certificates representing such fractional shares, will be entitled to receive cash in an amount equal to the product obtained by
multiplying (i)&nbsp;the closing sales price of our common stock on the effective date as reported on the Nasdaq SmallCap Market by (ii)&nbsp;the number of shares of our common stock held by such
stockholder that would otherwise have been exchanged for such fractional share interest. </FONT></P>

<P><FONT SIZE=2><B>EXCHANGE OF STOCK CERTIFICATES  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As soon as practicable after the effective date, stockholders will be notified that the reverse split has been effected. Our transfer agent will act as exchange
agent for purposes of implementing the exchange of stock certificates. We refer to such person as the "exchange agent." Holders of pre-reverse split shares will be asked to surrender to
the exchange agent certificates representing pre-reverse split shares in exchange for certificates representing post-reverse split shares in accordance with the procedures to
be set forth in a letter of transmittal to be sent by us. No new certificates will be issued to a stockholder until such stockholder has surrendered such stockholder's outstanding certificate(s)
together with the properly completed and executed letter of transmittal to the exchange agent. </FONT><FONT SIZE=2><B>Stockholders should not destroy any stock certificate and should not submit any
certificates until requested to do so.</B></FONT></P>

<P><FONT SIZE=2><B>ACCOUNTING CONSEQUENCES  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The par value per share of our common stock would remain unchanged at $0.001 per share after the reverse stock split. As a result, on the effective date of the
reverse split, the stated capital on our balance sheet attributable to the common stock will be reduced proportionally, based on the exchange ratio of the reverse stock split, from its present amount,
and the additional paid-in capital account shall be credited with the amount by which the stated capital is reduced. The per share common stock net income or loss and net book value will
be increased because there will be fewer shares of our common stock outstanding. We do not anticipate that any other accounting consequences would arise as a result of the reverse stock split. </FONT></P>

<P><FONT SIZE=2><B>NO APPRAISAL RIGHTS  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, our stockholders are not entitled to appraisal rights with respect to our proposed amendments to our charter to effect
the reverse stock split, and we will not independently provide our stockholders with any such rights. </FONT></P>

<P><FONT SIZE=2><B>MATERIAL FEDERAL U.S. INCOME TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of important tax considerations of the proposed reverse stock split. It addresses only stockholders who hold the
pre-reverse split shares and post-reverse split shares as capital assets. It does not purport to be complete and does not address stockholders subject to special rules, such as
financial institutions, tax-exempt organizations, insurance companies, dealers in securities, mutual funds, foreign stockholders, stockholders who hold the pre-reverse split
shares as part of a straddle, hedge or conversion transaction, stockholders who hold the pre-reverse split shares as qualified small business stock within the meaning of
Section&nbsp;1202 of the Internal Revenue Code of 1986, as amended (the "Code"), stockholders who are subject to the alternative minimum tax provisions of the Code and stockholders who acquired
their pre-reverse split shares pursuant to the exercise of employee stock options or otherwise as compensation. This summary is based upon current law, which may change, possibly even
retroactively. It does not address tax considerations under state, </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=19,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=746619,FOLIO='17',FILE='DISK032:[03PAL2.03PAL1722]DI1722A.;5',USER='ATOBAK',CD='24-SEP-2003;15:19' -->
<A NAME="page_di1722_1_18"> </A>
<BR>

<P><FONT SIZE=2>local,
foreign and other laws. Furthermore, we have not obtained a ruling from the Internal Revenue Service or an opinion of legal or tax counsel with respect to the consequences of the reverse stock
split. </FONT><FONT SIZE=2><B>Each stockholder is advised to consult his or her tax advisor as to his or her own situation.</B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
reverse stock split is intended to constitute a reorganization within the meaning of Section&nbsp;368 of the Code. Assuming the reverse split qualifies as a reorganization, a
stockholder generally will not recognize gain or loss on the reverse stock split, except to the extent of cash, if any, received in lieu of a fractional share interest in the post-reverse
split shares. The aggregate tax basis of the post-reverse split shares received will be equal to the aggregate tax basis of the pre-reverse split shares exchanged therefor
(excluding any portion of the holder's basis allocated to fractional shares), and the holding period of the post-reverse split shares received will include the holding period of the
pre-reverse split shares exchanged. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
holder of the pre-reverse split shares who receives cash will generally recognize gain or loss equal to the difference between the portion of the tax basis of the
pre-reverse split shares allocated to the fractional share interest and the cash received. Such gain or loss will be a capital gain or loss and will be short term if the
pre-reverse split shares were held for one year or less and long term if held more than one year. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
gain or loss will be recognized by the Company as a result of the reverse stock split. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS<BR>
A VOTE IN FAVOR OF PROPOSAL 2.  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=20,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=800427,FOLIO='18',FILE='DISK032:[03PAL2.03PAL1722]DI1722A.;5',USER='ATOBAK',CD='24-SEP-2003;15:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_dk1722_1_19"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="dk1722_proposal_3_election_of_directors"> </A>
<A NAME="toc_dk1722_1"> </A>
<BR></FONT><FONT SIZE=2><B>PROPOSAL 3<BR>  ELECTION OF DIRECTORS    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aerogen's Amended and Restated Certificate of Incorporation provides for three classes of directors: Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. Only
one class of directors is elected by the Stockholders at each annual election, each director to serve for a three-year term. In accordance with the Amended and Restated Certificate of
Incorporation, Class&nbsp;III directors are to be elected at the 2003 annual meeting of stockholders, Class&nbsp;I directors are to be elected at the 2004 annual meeting of stockholders, and
Class&nbsp;II directors are to be elected at the 2005 annual meeting. Since the Company did not hold its annual meeting of stockholders in 2003, the required election of directors is being conducted
at the Special Meeting. The Board is currently composed of seven directors, and the term of three of these directors expires in 2003. </FONT></P>

<P><FONT SIZE=2><B>Nominees  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Three Class&nbsp;III directors are to be elected to the Board at the Special Meeting, each to serve until the annual meeting of stockholders to be held in 2006
and until his or her successor has been elected and has qualified, or until his or her earlier death, resignation or removal. The nominees for election at the Special Meeting are
Jean-Jacques Bienaim&eacute;, Yehuda Ivri and Bernard Collins, the current Class&nbsp;III directors. If any nominee is unable or unwilling to serve as a director, proxies may be
voted for a substitute nominee designated by the present Board. The Board has no reason to believe that any nominee will be unable or unwilling to serve as a director if elected. Proxies received will
be voted "</FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" the election of all nominees, unless marked to the contrary. Pursuant to applicable Delaware corporation law and assuming the presence of
a quorum, three directors will be elected, from among those persons duly nominated for such positions, by a plurality of the votes actually cast by stockholders entitled to vote at the Special Meeting
who are present in person or by proxy. Thus, nominees who receive the first and second highest number of votes in favor of their election will be elected, regardless of the number of abstentions or
broker non-votes. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table provides the names and current ages of the nominees for election as directors and of each other director, and indicates the periods during which such persons have
served as directors of Aerogen. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="71%" ALIGN="LEFT"><FONT SIZE=1><B>Name and Positions with Aerogen in Addition to Director<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="4%" ALIGN="CENTER"><FONT SIZE=1><B>Age</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="20%" ALIGN="CENTER"><FONT SIZE=1><B>Director<BR>
Continuously&nbsp;Since</B></FONT><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="71%"><FONT SIZE=2><B>Nominees: Class III Directors</B></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="20%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="71%"><FONT SIZE=2>Jean-Jacques Bienaim&eacute;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="RIGHT"><FONT SIZE=2>50</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="RIGHT"><FONT SIZE=2>1999</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="71%"><FONT SIZE=2>Yehuda Ivri (Chief Technical Officer)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="RIGHT"><FONT SIZE=2>52</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="RIGHT"><FONT SIZE=2>1991</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="71%"><FONT SIZE=2>Bernard Collins(1)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="RIGHT"><FONT SIZE=2>54</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="RIGHT"><FONT SIZE=2>2002</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="71%"><FONT SIZE=2><B>Incumbents: Class I Directors</B></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="20%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="71%"><FONT SIZE=2>Dr. Phyllis I. Gardner</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="RIGHT"><FONT SIZE=2>53</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="RIGHT"><FONT SIZE=2>2000</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="71%"><FONT SIZE=2>Philip M. Young</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="RIGHT"><FONT SIZE=2>63</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="RIGHT"><FONT SIZE=2>1994</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="71%"><FONT SIZE=2><B>Class II Directors</B></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="20%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="71%"><FONT SIZE=2>Thomas R. Baruch</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="RIGHT"><FONT SIZE=2>64</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="RIGHT"><FONT SIZE=2>1994</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="71%"><FONT SIZE=2>Dr. Jane E. Shaw (Chairman and Chief Executive Officer)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="RIGHT"><FONT SIZE=2>64</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="RIGHT"><FONT SIZE=2>1998</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE ALIGN="LEFT" WIDTH="120">
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD><FONT SIZE=2>Mr.&nbsp;Collins
joined the Board on March&nbsp;12, 2002. </FONT></DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=21,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=1000451,FOLIO='19',FILE='DISK032:[03PAL2.03PAL1722]DK1722A.;6',USER='ATOBAK',CD='24-SEP-2003;15:11' -->
<A NAME="page_dk1722_1_20"> </A>

<P><FONT SIZE=2><B>Business Experience of Directors  </B></FONT></P>


<P><FONT SIZE=2><B>Nominees </B></FONT><FONT SIZE=2><B><I>(Class&nbsp;III Directors)  </I></B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Jean-Jacques Bienaim&eacute;</B></FONT><FONT SIZE=2> has served as a director of Aerogen since 1999.
Mr.&nbsp;Bienaim&eacute; has been the President, Chief Executive Officer and a director of Genencor International&nbsp;Inc., a biotechnology company, since November&nbsp;2002.
Mr.&nbsp;Bienaim&eacute; was President, Chief Executive Officer and a director of SangStat Medical Corporation, a biopharmaceutical company, from 1998 to 2002, and Chairman of its Board of
Directors from October&nbsp;2000 to November&nbsp;2002. Mr.&nbsp;Bienaim&eacute; held various positions at Rh&ocirc;ne Poulenc Rorer&nbsp;Inc., a leading pharmaceutical
company, from 1992 to 1998, most recently as Senior Vice President of Corporate Marketing and Business Development. Mr.&nbsp;Bienaim&eacute; received an M.B.A. from the Wharton School at the
University of Pennsylvania and a degree in Economics from Ecole Sup&eacute;rieure de Commerce de Paris in France. Mr.&nbsp;Bienaim&eacute; serves as a director of the Fox Chase
Cancer Center in Philadelphia. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Yehuda Ivri</B></FONT><FONT SIZE=2> founded Aerogen in 1991 and has served as a member of the Board of Directors since its inception. Mr.&nbsp;Ivri has served
as Aerogen's Chief Technical Officer since 1996 and previously was Chief Scientist and Vice President. Mr.&nbsp;Ivri received an M.S. in Mechanical Engineering from the Technion-Israel Institute of
Technology. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Bernard Collins</B></FONT><FONT SIZE=2> joined the Board of Directors on March&nbsp;12, 2002. Mr.&nbsp;Collins currently is an independent consultant in the
areas of business strategy and management. From 1994 to 2000, he was the Vice President, International Operations of Boston Scientific Corporation. Prior to that time he was a management consultant
and held management positions in medical device/healthcare companies. Mr.&nbsp;Collins received a B.A. in Industrial Psychology from the National University of Cork. He serves as a director of
several privately held companies. </FONT></P>

<P><FONT SIZE=2><B><I>Directors Continuing in Office  </I></B></FONT></P>

<P><FONT SIZE=2><B><I>Class&nbsp;I Directors  </I></B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Phyllis I. Gardner, M.D.</B></FONT><FONT SIZE=2> has served as a director of Aerogen since May&nbsp;2000. Dr.&nbsp;Gardner is
currently an Associate Professor of Medicine at Stanford University School of Medicine and has been with the
university since 1984. Dr.&nbsp;Gardner was Vice President of Research and Principal Scientist of ALZA Corporation and head of ALZA Technology Institute from 1996 to 1998. She was Principal
Scientist and a consultant to ALZA from 1994 to 1996. Dr.&nbsp;Gardner received a B.S. in Biology from the University of Illinois and an M.D. from Harvard Medical School. Dr.&nbsp;Gardner serves
as a director of Aronex Pharmaceuticals,&nbsp;Inc., a biopharmaceutical company, and BioMarin Pharmaceutical,&nbsp;Inc., a biotechnology company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Philip M. Young</B></FONT><FONT SIZE=2> has served as a director of Aerogen since 1994. Mr.&nbsp;Young has been a General Partner with U.S. Venture Partners, a
venture capital firm, since 1990. Mr.&nbsp;Young was a Managing Director of Dillon Read&nbsp;&amp; Co., a financial services company, and Concord Partners, a venture capital firm managed by Dillon
Read, from 1986 to 1990. Mr.&nbsp;Young was President and CEO of Oximetrix,&nbsp;Inc., a privately held manufacturer of high technology medical instruments and sterile disposable products, from
1977 to 1985. Mr.&nbsp;Young received a B.M.E. in Mechanical Engineering from Cornell University, an M.S. from George Washington University and an M.B.A. from Harvard Business School, where he was a
Baker Scholar. Mr.&nbsp;Young serves as a director of Zoran Corporation, a digital solutions provider, and several privately-held companies. </FONT></P>

<P><FONT SIZE=2><B><I>Class&nbsp;II Directors  </I></B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Thomas R. Baruch</B></FONT><FONT SIZE=2> has served as a director of Aerogen since 1994. He has been a General Partner at CMEA Ventures, a
venture capital firm (previously an affiliated fund of New Enterprise Associates), since 1988. Mr.&nbsp;Baruch was a special partner of New Enterprise Associates from 1990 to 1996. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=22,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=20840,FOLIO='20',FILE='DISK032:[03PAL2.03PAL1722]DK1722A.;6',USER='ATOBAK',CD='24-SEP-2003;15:11' -->
<A NAME="page_dk1722_1_21"> </A>
<BR>

<P><FONT SIZE=2>Mr.&nbsp;Baruch
received a B.S. in Engineering from Rensselaer Polytechnic Institute and a J.D. from Capital University. Mr.&nbsp;Baruch serves as a director of Netro Corporation, a
telecommunications company, Symyx Technologies, a technology research company, Physiometrix&nbsp;Inc., a medical products company, and Aclara Biosciences,&nbsp;Inc., a life science company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Jane E. Shaw, Ph.D.</B></FONT><FONT SIZE=2> has served as Chairman of the Board of Directors and as the Company's Chief Executive Officer since 1998.
Dr.&nbsp;Shaw was a founder and consultant of The Stable Network, a consulting company focusing on improving the productivity and profitability of biopharmaceutical companies, from 1994 to 1998.
Dr.&nbsp;Shaw held various scientific and management positions with ALZA Corporation, a pharmaceutical company, from 1970 to 1994, most recently as President and Chief Operating Officer from 1987 to
1994. Dr.&nbsp;Shaw received a B.Sc. and Ph.D. in Physiology from Birmingham University in England. Dr.&nbsp;Shaw also serves as a director of Boise Cascade Corporation, an office, wood and paper
products company, Intel Corporation, a semiconductor manufacturer, and McKesson Corporation, a healthcare supply management company. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOR OF EACH OF THE<BR>
NAMED NOMINEES.</B></FONT></P>

<P><FONT SIZE=2><B>Meetings and Committees of the Board  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There were four meetings of the full Board during the fiscal year ended December&nbsp;31, 2002. All of the directors attended at least 75% of the meetings of
the Board and the committees on which he or she served, held during the period in which he or she served. The Board has two standing committees: the Compensation Committee and the Audit Committee. The
current members of the Compensation Committee are Mr.&nbsp;Bienaim&eacute;, Dr.&nbsp;Gardner and Mr.&nbsp;Young. The Compensation Committee, which met five times during 2002, approves
all of the Company's compensation plans, including grants of stock options under Company's stock plans and the compensation arrangements for the Company's executives. The current members of the Audit
Committee are Mr.&nbsp;Baruch, Mr.&nbsp;Collins and Mr.&nbsp;Young. Dr.&nbsp;Desmond-Hellmann was a member of the Audit Committee until her resignation from the Board in March&nbsp;2002. The
Audit Committee, which met seven times during 2002, is responsible for assisting the Board in its responsibilities of overseeing the Company's financial affairs. In this capacity, the Audit Committee
reviews the Company's consolidated financial statements and quarterly earnings with management and with the Company's independent accountants, and consults with the Company's independent accountants
concerning their audit plan, the results of their audit, the appropriateness of accounting principles used by the Company, the adequacy of the Company's internal controls and the independence of the
accountants. The duties of the Audit Committee are set forth in more detail in its report at page 8 of this Proxy Statement. All members of the Audit Committee are independent, as independence is
defined in Rule&nbsp;4200(a)(14) of the NASD listing standards. There are no family relationships among any directors or executive officers of the Company. Directors currently receive no cash
compensation from Aerogen for their services as members of the Board, or for attendance at Board or committee meetings. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="dk1722_audit_committee_report1"> </A>
<A NAME="toc_dk1722_2"> </A>
<BR></FONT><FONT SIZE=2><B>AUDIT COMMITTEE REPORT<SUP>1</SUP>    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of the Audit Committee are Thomas R. Baruch, Bernard Collins and Philip M. Young. Each member of the Audit Committee is independent, as defined under
the National Association of Securities Dealers' listing standards. The Audit Committee, which was first appointed by the Board in August&nbsp;2000, operates under a written charter adopted by the
Board in August&nbsp;2000, which was amended in July&nbsp;2002. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
primary function of the Audit Committee is to assist the Board in fulfilling its oversight responsibility by serving as an independent and objective party to monitor the Company's
financial reporting process and internal control systems; reviewing and appraising the audit efforts of the </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=23,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=842679,FOLIO='21',FILE='DISK032:[03PAL2.03PAL1722]DK1722A.;6',USER='ATOBAK',CD='24-SEP-2003;15:11' -->
<A NAME="page_dk1722_1_22"> </A>
<BR>

<P><FONT SIZE=2>Company's
independent accountants and any internal auditing department; and providing an open avenue of communication among the independent accountants, management, the internal finance department and
the Board. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management
is responsible for the Company's internal controls and financial reporting process. PricewaterhouseCoopers LLP is responsible for performing an independent audit of the
Company's consolidated financial statements in accordance with auditing standards generally accepted in the United States and to issue a report on those financial statements. The Audit Committee is
responsible for monitoring and overseeing these activities. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
this context, the Audit Committee has met and held discussions with management and the independent accountants concerning the audited consolidated financial statements of the Company
for the year ended December&nbsp;31, 2002. The Audit Committee has discussed with PricewaterhouseCoopers LLP the matters required to be discussed by Statement on Auditing Standards No.&nbsp;61
(Communication with Audit Committees) and has discussed the independence of PricewaterhouseCoopers LLP with that firm. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on the Audit Committee's review and discussions described above, the Audit Committee recommended to the Board, and the Board approved, that the Company's audited consolidated
financial statements for the year ended December&nbsp;31, 2002 be included in the Company's Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2002, for filing with
the Securities and Exchange Commission. The Audit Committee and the Board have also selected, subject to stockholder ratification, PricewaterhouseCoopers; LLP as the Company's independent accountants
for the year ending December&nbsp;31, 2003. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>AUDIT COMMITTEE</B></FONT><FONT SIZE=2><BR>
Thomas R. Baruch<BR>
Bernard Collins<BR>
Philip M. Young </FONT></P>

<HR NOSHADE ALIGN="LEFT" WIDTH="120">
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><SUP>1</SUP></FONT></DT><DD><FONT SIZE=2>The
material in this report is not "soliciting material," is not deemed "filed" with the Securities and Exchange Commission and is not to be incorporated by reference into
any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language
contained in such filing. </FONT></DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=24,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=613220,FOLIO='22',FILE='DISK032:[03PAL2.03PAL1722]DK1722A.;6',USER='ATOBAK',CD='24-SEP-2003;15:11' -->
<A NAME="page_dk1722_1_23"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="dk1722_proposal_4_ratification_of_sel__pro02524"> </A>
<A NAME="toc_dk1722_3"> </A>
<BR></FONT><FONT SIZE=2><B>PROPOSAL 4<BR>  RATIFICATION OF SELECTION OF INDEPENDENT ACCOUNTANTS    <BR>    </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board has selected PricewaterhouseCoopers LLP as the Company's independent accountants for the year ending December&nbsp;31, 2003, and has further directed
that management submit the selection of independent accountants for ratification by the stockholders at the Special Meeting. PricewaterhouseCoopers LLP has audited the Company's financial statements
since its inception in 1991. Representatives of PricewaterhouseCoopers LLP are expected to be present at the Special Meeting will have an opportunity to make a statement if they so desire and will be
available to respond to appropriate questions. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder
ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent accountants is not required by the Company's Bylaws or otherwise. However, the Board
is submitting the selection of PricewaterhouseCoopers LLP to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit
Committee and the Board will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee and the Board in their discretion may direct the appointment of
different independent accountants at any time during the year if they determine that such a change would be in the best interests of the Company and its stockholders. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
affirmative vote of the holders of a majority of the shares present in person or represented by proxy and entitled to vote at the Special Meeting will be required to ratify the
selection of PricewaterhouseCoopers LLP. Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as negative votes.
Broker non-votes are counted towards a quorum, but are not counted for any purpose in determining whether this matter has been approved. </FONT></P>

<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit Fees.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;For the year ended December&nbsp;31, 2002, the aggregate fees to be billed by PricewaterhouseCoopers LLP for
the audit of the Company's consolidated financial statements were
approximately $74,200. Audit fees for 2002 included approximately $29,800 for reviews of the Company's quarterly financial statements. </FONT></P>


<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All Other Fees.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;For the year ended December&nbsp;31, 2002, PricewaterhouseCoopers LLP billed the Company approximately
$13,557 for a statutory audit of the Company's subsidiary in Galway, Ireland; $15,125 for domestic accounting and international tax advice; $13,125 for preparation of the Company's tax return; and
$19,923 for preparation of the Irish tax return for the Company's subsidiary. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Information Systems Design and Implementation Fees. No fees were billed for information technology consulting services for the year ended December&nbsp;31, 2002. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee has determined that the rendering of its non-audit services by PricewaterhouseCoopers LLP is compatible with maintaining the accountants' independence. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOR OF PROPOSAL 4</B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=25,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=211121,FOLIO='23',FILE='DISK032:[03PAL2.03PAL1722]DK1722A.;6',USER='ATOBAK',CD='24-SEP-2003;15:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_dm1722_1_24"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="dm1722_security_ownership_of_certain___sec02525"> </A>
<A NAME="toc_dm1722_1"> </A>
<BR></FONT><FONT SIZE=2><B>SECURITY OWNERSHIP OF<BR>  CERTAIN BENEFICIAL OWNERS AND MANAGEMENT    <BR>    </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the beneficial ownership of the Company's Common Stock as of September&nbsp;15, 2003, except as otherwise noted, (i)&nbsp;by
each person, entity or "group" of persons or entities known by the Company to be beneficial owners of more than 5% of the Company's Common Stock, (ii)&nbsp;by each director, and each of the Named
Executive Officers listed in the Summary Compensation Table, and (iii)&nbsp;by all executive officers and directors as a group. Percentage ownership is based on 20,529,231 shares of Common Stock
outstanding on September&nbsp;15, 2003. Except as described below, each person has sole voting and investment power with respect to the Common Stock described in the table. Unless otherwise
indicated, the address of each of the individuals named below is: c/o Aerogen,&nbsp;Inc., 2071 Stierlin Court, Mountain View, California 94043. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="61%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="19%" ALIGN="CENTER"><FONT SIZE=1><B>Amount and Nature<BR>
of Beneficial Ownership of<BR>
Common Stock (1)</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="13%" ALIGN="CENTER"><FONT SIZE=1><B>Percent of<BR>
Outstanding<BR>
Shares</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="61%"><FONT SIZE=2><B>Five Percent Holders:</B></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="61%"><FONT SIZE=2>SF Capital Partners, Ltd. (2)<BR>
c/o Staro Asset Management, LLC<BR>
3600 South Lake Drive<BR>
St. Francis, WI 53235</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT" VALIGN="TOP"><FONT SIZE=2>4,071,429</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT" VALIGN="TOP"><FONT SIZE=2>16.6</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="61%"><FONT SIZE=2><BR>
Entities Affiliated with U.S. Venture Partners (3)<BR>
2735 Sand Hill Road<BR>
Menlo Park, CA 94025</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT" VALIGN="TOP"><FONT SIZE=2><BR>
1,936,142</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT" VALIGN="TOP"><FONT SIZE=2><BR>
9.4</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=2><BR>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="61%"><FONT SIZE=2><BR>
Entities Affiliated with Chemicals and Materials Enterprise Associates, Limited Partnership(4)<BR>
One Embarcadero Center, Suite 3250<BR>
San Francisco, CA 94111-3600</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=2><BR>
<BR>
1,447,292</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2><BR>
<BR>
7.0</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR><BR>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="61%"><FONT SIZE=2><BR>
Entities Affiliated with Interwest Partners(5)<BR>
3000 Sand Hill Road Building 3, Suite 255<BR>
Menlo Park, CA 94025</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT" VALIGN="TOP"><FONT SIZE=2><BR>
1,264,549</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT" VALIGN="TOP"><FONT SIZE=2><BR>
6.2</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=2><BR>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="61%"><BR><FONT SIZE=2><B>Directors and Executive Officers:</B></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="61%"><FONT SIZE=2>Jane E. Shaw, Ph.D. (6)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=2>784,215</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>3.8</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="61%"><FONT SIZE=2>Thomas R. Baruch (7)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=2>1,470,625</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>7.2</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="61%"><FONT SIZE=2>Jean-Jacques Bienaim&eacute; (8)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=2>26,433</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>*</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="61%"><FONT SIZE=2>Robert S. Breuil (9)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=2>130,590</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>*</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="61%"><FONT SIZE=2>Bernard Collins (10)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=2>22,799</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>*</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="61%"><FONT SIZE=2>Robert S. Fishman (11)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=2>135,025</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>*</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="61%"><FONT SIZE=2>Phyllis I. Gardner, M.D. (12)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=2>26,666</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>*</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="61%"><FONT SIZE=2>Nancy Isaac, J.D. (13)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=2>34,583</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>*</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="61%"><FONT SIZE=2>Yehuda lvri (14)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=2>986,666</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>4.8</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="61%"><FONT SIZE=2>John S. Power (15)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=2>450,087</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>2.2</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="61%"><FONT SIZE=2>John E. Ross (16)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=2>122,083</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>*</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="61%"><FONT SIZE=2>Philip M. Young (17)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=2>1,959,475</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>9.5</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="61%"><FONT SIZE=2>All executive officers and directors as a group (12 persons)(18)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT" VALIGN="TOP"><FONT SIZE=2>6,149,247</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT" VALIGN="TOP"><FONT SIZE=2>27.9</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE ALIGN="LEFT" WIDTH="120">
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD><FONT SIZE=2>Percentages
are not shown if holdings total less than 1% of total outstanding shares.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD><FONT SIZE=2>Includes
outstanding stock options that will be vested on or before November&nbsp;14, 2003, to purchase shares of the Company's Common Stock, as described in the footnotes below.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD><FONT SIZE=2>Includes
2,714,286 shares issuable upon conversion of a debenture that is or will be convertible within 60&nbsp;days of September&nbsp;15, 2003 and 1,357,143 shares issuable upon
exercise of a warrant that is or will be exercisable within 60&nbsp;days of September&nbsp;15, 2003. </FONT></DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=26,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=564919,FOLIO='24',FILE='DISK032:[03PAL2.03PAL1722]DM1722A.;7',USER='ATOBAK',CD='24-SEP-2003;15:13' -->
<A NAME="page_dm1722_1_25"> </A>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD><FONT SIZE=2>Information
is as provided by the holder in its Schedule&nbsp;13G filed with the SEC as of February&nbsp;13, 2003 and confirmed by written communication to the Company on
March&nbsp;4, 2003. Includes 1,674,763 shares held by U.S. Venture Partners IV, L.P., 203,295 shares held by Second Ventures II, L.P. and 58,084 shares held by USVP Entrepreneur Partners II, L.P.
(collectively, the "USVP Entities"). Presidio Management Group IV, L.P. is the general partner of the USVP Entities. Philip M. Young, a director of Aerogen, is a general partner of Presidio Management
Group IV, L.P. and shares voting and dispositive power with respect to these shares. Mr.&nbsp;Young disclaims beneficial ownership of the shares held by the USVP Entities within the meaning of
Rule&nbsp;13d-3 under the Securities Exchange Act of 1934.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD><FONT SIZE=2>Information
is as provided by the holder in its Schedule&nbsp;13G/A filed with the SEC on February&nbsp;10, 2003. Includes 1,299,144 shares held by Chemical and Materials
Enterprise Associates, Limited Partnership (CMEA) and 148,148 shares held by CMEA Life Sciences Fund, L.P. NEA Chemicals and Materials Partners, Limited Partnership ("CMEA Partners") is a general
partner of CMEA. The individual general partners of CMEA Partners are Cornelius&nbsp;C. Bond, Jr., Nancy&nbsp;L. Dorman, Richard Kramlich, Thomas C. McConnell and Charles&nbsp;W. Newhall III.
Donald R. Murfin is also a general partner of CMEA. Mr.&nbsp;Baruch, a director of Aerogen, is a general partner of CMEA and also a general partner of CMEA Life Sciences Fund, L.P. In such capacity,
he has shared voting power and shared dispositive power with respect to all of the shares. Mr.&nbsp;Baruch disclaims beneficial ownership of the shares held by Chemical and Materials Enterprise
Associates, Limited Partnership and CMEA Life Sciences Fund, L.P. within the meaning of Rule&nbsp;13d-3 under the Securities Exchange Act of 1934.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD><FONT SIZE=2>Information
is as provided by the holder in its Schedule&nbsp;13G/A filed with the SEC on February&nbsp;13, 2003. Includes 37,486 shares held by Interwest Investors VI, LP and
1,227,063 shares held by Interwest Partners VI, LP. The voting and dispositive power with respect to these shares is shared by the managing directors of Interwest Management Partners VI LLC (Harvey B.
Cash, Alan W. Crites, Philip T. Gianos, W. Scott Hedrick, W. Stephen Holmes, Robert R. Momsen and Arnold L. Oronsky) and the venture member of Interwest Management Partners VI LLC (Gilbert H. Kliman).
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD><FONT SIZE=2>Includes
233,333 shares issuable upon exercise of options that are or will be exercisable within 60&nbsp;days of September&nbsp;15, 2003, 14,814 shares held by the Carpenter
Family Trust, in which Dr.&nbsp;Shaw has an economic interest, and 47,619 shares held by the Carpenter 1983 Irrevocable Trust, in which Dr.&nbsp;Shaw has an economic interest.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD><FONT SIZE=2>See
Note&nbsp;4 above. Also includes 23,333 shares issuable to Mr.&nbsp;Baruch upon the exercise of options that are or will be exercisable within 60&nbsp;days of
September&nbsp;15, 2003.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD><FONT SIZE=2>Includes
23,333 shares issuable upon the exercise of options that are or will be exercisable within 60&nbsp;days of September&nbsp;1, 2003.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD><FONT SIZE=2>Includes
89,583 shares issuable upon the exercise of options that are or will be exercisable within 60&nbsp;days of September&nbsp;15, 2003.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD><FONT SIZE=2>Includes
10,694 shares issuable upon the exercise of options that are or will be exercisable within 60&nbsp;days of September&nbsp;15, 2003.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD><FONT SIZE=2>Includes
105,499 shares issuable upon the exercise of options that are or will be exercisable within 60&nbsp;days of September&nbsp;15, 2003.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD><FONT SIZE=2>Includes
23,333 shares issuable upon the exercise of options that are or will be exercisable within 60&nbsp;days of September&nbsp;15, 2003.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD><FONT SIZE=2>Consists
of 34,583 shares issuable upon the exercise of options that are or will be exercisable within 60&nbsp;days of September&nbsp;15, 2003.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(14)</FONT></DT><DD><FONT SIZE=2>Includes
20,000 shares issuable upon the exercise of options that are or will be exercisable within 60&nbsp;days of September&nbsp;15, 2003. </FONT></DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=27,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=994995,FOLIO='25',FILE='DISK032:[03PAL2.03PAL1722]DM1722A.;7',USER='ATOBAK',CD='24-SEP-2003;15:13' -->
<A NAME="page_dm1722_1_26"> </A>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(15)</FONT></DT><DD><FONT SIZE=2>Includes
56,667 shares issuable upon the exercise of options that are or will be exercisable within 60&nbsp;days of September&nbsp;15, 2003.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(16)</FONT></DT><DD><FONT SIZE=2>Consists
of 122,083 shares issuable upon the exercise of options that are or will be exercisable within 60&nbsp;days of September&nbsp;15, 2003.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(17)</FONT></DT><DD><FONT SIZE=2>See
Note&nbsp;2 above. Also includes 23,333 shares issuable upon the exercise by Mr.&nbsp;Young of options that are or will be exercisable within 60&nbsp;days of
September&nbsp;15, 2003.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(18)</FONT></DT><DD><FONT SIZE=2>Includes
shares described in the notes above as applicable to directors and current executive officers. </FONT></DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="dm1722_section_16(a)_beneficia__dm102045"> </A>
<A NAME="toc_dm1722_2"> </A>
<BR></FONT><FONT SIZE=2><B>SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16(a) of the Securities Exchange Act of 1934 requires Aerogen's directors and executive officers, and persons who own more than 10% of the
Company's Common Stock, to file reports of ownership and changes in ownership of such stock with the Securities and Exchange Commission ("SEC"). Directors, executive officers and greater than 10%
stockholders are required by SEC regulations to furnish the Company with copies of all Section&nbsp;16(a) forms they file. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
our knowledge, based solely on a review of the copies of such forms filed with the SEC and written representations that no other reports were required to be filed during the fiscal
year ended December&nbsp;31, 2002, our directors, executive officers and greater than 10% stockholders complied with all Section&nbsp;16(a) filing requirements except as follows: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Bienaim&eacute;
inadvertently filed one late Form&nbsp;4 concerning one open market purchase in May&nbsp;2002, of 1,000 shares of the company's common stock at a
price per share of $1.36. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Breuil,
Mr.&nbsp;Power, Mr.&nbsp;Ross, Mr.&nbsp;Ivri, Dr.&nbsp;Fishman and Ms.&nbsp;Isaac each inadvertently filed one late Form&nbsp;4 to report one stock option
grant by the Company under the Company's stock plans in December&nbsp;2002. </FONT></P>

<P><FONT SIZE=2><B>Executive Officers  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information concerning our executive officers as of September&nbsp;15, 2003: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="45%" ALIGN="LEFT"><FONT SIZE=1><B>Name<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="5%" ALIGN="CENTER"><FONT SIZE=1><B>Age</B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="45%" ALIGN="CENTER"><FONT SIZE=1><B>Position</B></FONT><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="45%"><FONT SIZE=2>Jane E. Shaw, Ph.D.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>64</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>Chief Executive Officer and Chairman of the Board of Directors</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="45%"><FONT SIZE=2>Yehuda Ivri</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>52</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>Chief Technical Officer, Director and Founder</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="45%"><FONT SIZE=2>John E. Ross</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>58</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>Senior Vice President, Worldwide Operations</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="45%"><FONT SIZE=2>Robert S. Breuil</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>41</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>Chief Financial Officer, Vice President, Corporate Development</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="45%"><FONT SIZE=2>Robert S. Fishman, M.D.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>41</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>Vice President, Scientific Affairs</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="45%"><FONT SIZE=2>Nancy Isaac</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>41</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>Vice President, Regulatory Affairs and Quality</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="45%"><FONT SIZE=2>John S. Power</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>44</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>Managing Director Aerogen (Ireland) Limited and Senior Vice President, Sales</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Jane E. Shaw, Ph.D.</B></FONT><FONT SIZE=2> has served as Chairman of our Board of Directors and as our Chief Executive Officer since 1998. Dr.&nbsp;Shaw was a
founder and consultant of The Stable Network, a consulting company focusing on improving the productivity and profitability of biopharmaceutical companies, from 1994 to 1998. Dr.&nbsp;Shaw held
various scientific and management positions with ALZA Corporation, a pharmaceutical company, from 1970 to 1994, most recently as President and Chief Operating Officer from 1987 to 1994.
Dr.&nbsp;Shaw received a B.Sc. and Ph.D. in Physiology from Birmingham University in England. Dr.&nbsp;Shaw serves as a director of Boise Cascade Corporation, an office, wood and paper </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=28,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=833859,FOLIO='26',FILE='DISK032:[03PAL2.03PAL1722]DM1722A.;7',USER='ATOBAK',CD='24-SEP-2003;15:13' -->
<A NAME="page_dm1722_1_27"> </A>
<BR>

<P><FONT SIZE=2>products
company, Intel Corporation, a semiconductor manufacturer, and McKesson Corporation, a healthcare supply management company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Yehuda Ivri</B></FONT><FONT SIZE=2> founded Aerogen in 1991 and has served as a member of our Board of Directors since its inception. Mr.&nbsp;Ivri has served
as our Chief Technical Officer since 1996 and previously was our Chief Scientist and Vice President. Mr.&nbsp;Ivri received an M.S. in Mechanical Engineering from the Technion-Israel Institute of
Technology. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>John E. Ross,</B></FONT><FONT SIZE=2> Senior Vice President of Worldwide Operations, joined Aerogen in September&nbsp;2001. Prior to joining Aerogen,
Mr.&nbsp;Ross served as Vice President and General Manager for ASTeX product group of MKS Instruments, a component and system supply company serving the semiconductor industry. He served as
President and COO for ASTeX&nbsp;Inc., responsible for worldwide operations, from 2000 to its acquisition by MKS in 2001. Mr.&nbsp;Ross held a number of other senior operations positions including
Senior Vice President of Operations at Topaz Technologies from 1999 to 2000, Vice President and General Manager at Applied Magnetics Corporation from 1993 to 1998, Director of Wafer Fab Operations at
Read Rite Corporation from 1991 to 1993, and Executive Vice President, responsible for operations, at Tegal Corporation, a division of Motorola from 1984 to 1991. Mr.&nbsp;Ross holds a B.Sc. honors
degree in chemistry from the University of Hull, England. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Robert S. Breuil,</B></FONT><FONT SIZE=2> Chief Financial Officer, Vice President Corporate Development, joined Aerogen in April&nbsp;2002 as Vice President,
Corporate Development. In July&nbsp;2002 Mr.&nbsp;Breuil was appointed Chief Financial Officer. Prior to joining Aerogen, Mr.&nbsp;Breuil spent eight years at ALZA Corporation, where he served
in numerous leadership positions including Controller of ALZA Pharmaceuticals and Director of Corporate Planning and Analysis. Prior to joining ALZA, Mr.&nbsp;Breuil served for eight years as a
Naval Officer and Aviator. Mr.&nbsp;Breuil received a B.S. in Electrical Engineering at the United States Naval Academy and an M.B.A. from the Stanford Graduate School of Business. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Robert S. Fishman, M.D. F.C.C.P.,</B></FONT><FONT SIZE=2> Vice President, Scientific Affairs since July&nbsp;2002, joined Aerogen in June&nbsp;1998 as
Director of Clinical Operations and was promoted to Vice President of Clinical Operations in 2001. Prior to joining Aerogen, Dr.&nbsp;Fishman was Director of Clinical Affairs at
Heartport,&nbsp;Inc. from 1995 to 1998, where he led the clinical trials, medical monitoring, and clinical training development functions. Prior to Heartport, he was Assistant Professor of Medicine
at Stanford University and was
Associate Medical Director of the Stanford Lung and Heart-Lung Transplant Program from 1993 to 1995. He received an A.B. in Biology from Harvard University and an M.D. from Stanford
University School of Medicine, and completed his fellowship training in pulmonary and critical care medicine at Massachusetts General Hospital. Dr.&nbsp;Fishman continues to teach respiratory
physiology at Stanford. He is a Fellow of the American College of Chest Physicians and a member of the American Thoracic Society. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Nancy Isaac, J.D., M.P.H.</B></FONT><FONT SIZE=2>, Vice President, Regulatory Affairs and Quality, joined Aerogen in August&nbsp;2002. Prior to joining Aerogen
she was employed by BD Biosciences, a business segment of Becton, Dickinson&nbsp;&amp; Company from 1997 to 2002, most recently as Worldwide Vice President, Regulatory and Quality. Prior to BD,
Ms.&nbsp;Isaac held a senior regulatory position at Genzyme Corporation. Ms.&nbsp;Isaac received a J.D. from Boston University, a Masters in Public Health from Harvard University, and a Bachelor
of Science in Cell and Molecular Biology from San Francisco State University. She is a member of the State Bar of California. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>John Power,</B></FONT><FONT SIZE=2> Managing Director Aerogen (Ireland) Limited and Senior Vice President Sales, has served as Senior Vice President Sales since
January&nbsp;2003 and as Aerogen's Vice President, European Operations and Managing Director, Aerogen (Ireland) Limited since May&nbsp;2000. Mr.&nbsp;Power was the founder and Managing Director
of Cerus Limited (now Aerogen (Ireland) Limited), from 1998 to 2000. Mr.&nbsp;Power was Engineering Manager in Mechanical Development at Nellcor Puritan Bennett from 1993 to 1997, and an engineering
consultant to various companies from 1988 to 1992. Registered with I. Eng. status from UK Engineering Council, Mr.&nbsp;Power holds qualifications in both Computer Mechanical and Production
Engineering and an MBA from Oxford Brookes University, Oxford, England. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=29,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=1033665,FOLIO='27',FILE='DISK032:[03PAL2.03PAL1722]DM1722A.;7',USER='ATOBAK',CD='24-SEP-2003;15:13' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_do1722_1_28"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="do1722_executive_compensation"> </A>
<A NAME="toc_do1722_1"> </A>
<BR></FONT><FONT SIZE=2><B>EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>


<P><FONT SIZE=2><B>COMPENSATION OF DIRECTORS  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directors currently receive no cash compensation from Aerogen for their service as members of the Board, or for their attendance at Board or committee meetings.
The Company has a 2000 Non-Employee Directors' Stock Option Plan, approved by the stockholders in November&nbsp;2000, that provides for the automatic grant of options to purchase shares
of Common Stock to non-employee directors. Any director first elected to the Board after November&nbsp;2000 will receive an initial option to purchase 15,000 shares of Common Stock,
vesting one third on the first anniversary of the date of grant, and the remainder in 24 equal monthly installments thereafter. In addition, on the date of each annual meeting of stockholders, each
non-employee director will receive an annual option to purchase 5,000 shares of Common Stock, vesting in equal monthly installments over 36&nbsp;months. The exercise price of options
granted under this plan will be the fair market value of the Common Stock on the date of the grant. Under this plan, all of the members of the Board on May&nbsp;14, 2002, the date of Aerogen's 2002
annual stockholders' meeting, received an option to purchase 5,000 shares of Common Stock at an exercise price of $1.40 per share under this plan. Mr.&nbsp;Collins also received an initial option to
purchase 15,000 shares of Common Stock at a exercise price of $1.62 per share on March&nbsp;12, 2002, when he joined the Board. </FONT></P>

<P><FONT SIZE=2><B>COMPENSATION OF EXECUTIVE OFFICERS  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>SUMMARY COMPENSATION TABLE  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information relating to compensation paid or accrued for services in all capacities during the fiscal years indicated with
respect to Dr.&nbsp;Jane E. Shaw, the Company's Chairman and Chief Executive Officer, and each of the Company's other four most highly compensated executive officers at December&nbsp;31, 2002 (the
"Named Executive Officers"). </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="39%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%" ROWSPAN=2><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=7 ROWSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Annual Compensation</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="11%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="13%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH WIDTH="39%" ROWSPAN=2 ALIGN="LEFT"><FONT SIZE=1><B>Name and Principal Positions<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%" ROWSPAN=2><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="11%" ROWSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Securities<BR>
Underlying<BR>
Options</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%" ROWSPAN=2><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="13%" ROWSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>All Other<BR>
Compensation</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="6%" ALIGN="CENTER"><FONT SIZE=1><B>Year</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Salary(1)</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Bonus</B></FONT><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="39%"><FONT SIZE=2>Dr. Jane E. Shaw, Ph.D.<BR>
Chairman and<BR>
Chief Executive Officer</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>2002<BR>
2001<BR>
2000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$<BR>$<BR>$</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>271,188<BR>
300,000<BR>
240,000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR><BR>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;<BR>
&#151;<BR>
50,000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>&#151;<BR>
125,000<BR>
233,333</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>&#151;<BR>
&#151;<BR>
&#151;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="39%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="11%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="39%"><FONT SIZE=2>John E. Ross (2)<BR>
Senior Vice President<BR>
Worldwide Operations</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>2002<BR>
2001<BR>
2000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$<BR>$<BR></FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>240,774<BR>
64,080<BR>
&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$<BR>$<BR></FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>25,000<BR>
25,000<BR>
&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>45,000<BR>
157,000<BR>
&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>&#151;<BR>
&#151;<BR>
&#151;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="39%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="11%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="39%"><FONT SIZE=2>Robert S. Fishman, M.D.<BR>
Vice President,<BR>
Scientific Affairs</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>2002<BR>
2001<BR>
2000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$<BR>$<BR>$</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>203,638<BR>
178,161<BR>
163,368</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;<BR>
&#151;<BR>
&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>45,000<BR>
87,000<BR>
8,333</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>&#151;<BR>
&#151;<BR>
&#151;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="39%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="11%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="39%"><FONT SIZE=2>Yehuda Ivri<BR>
Chief Technical Officer<BR></FONT>
</TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>2002<BR>
2001<BR>
2000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$<BR>$<BR>$</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>191,736<BR>
181,159<BR>
160,022</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;<BR>
&#151;<BR>
&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>45,000<BR>
7,500<BR>
&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>&#151;<BR>
&#151;<BR>
&#151;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="39%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="11%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="39%"><FONT SIZE=2>Robert S. Breuil (3)<BR>
Chief Financial Officer<BR>
Vice President Corporate Development</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="6%" ALIGN="RIGHT"><FONT SIZE=2>2002<BR>
2001<BR>
2000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$<BR><BR></FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>136,125<BR>
&#151;<BR>
&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;<BR>
&#151;<BR>
&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>182,500<BR>
&#151;<BR>
&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="RIGHT"><FONT SIZE=2>&#151;<BR>
&#151;<BR>
&#151;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE ALIGN="LEFT" WIDTH="120">
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD><FONT SIZE=2>Amounts
shown include compensation earned and received by the Named Executive Officers as well as amounts deferred at the election of such persons under the Company's Tax Deferral
Investment Plan.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD><FONT SIZE=2>Ms.&nbsp;Ross
joined the Company in September&nbsp;2001.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD><FONT SIZE=2>Mr.&nbsp;Breuil
joined the Company in April&nbsp;2002. </FONT></DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=30,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=178205,FOLIO='28',FILE='DISK032:[03PAL2.03PAL1722]DO1722A.;9',USER='ATOBAK',CD='24-SEP-2003;15:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_dq1722_1_29"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="dq1722_fiscal_year_2002_option_grants"> </A>
<A NAME="toc_dq1722_1"> </A>
<BR></FONT><FONT SIZE=2><B>FISCAL YEAR 2002 OPTION GRANTS    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information relating to options granted in 2002 to the Named Executive Officers. In addition, in accordance with the rules of the
SEC, the table shows hypothetical gains that would exist for such options based on assumed rates of annual compound stock price appreciation of 5% and 10% per year from the date the options were
granted over the full option term. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="34%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH WIDTH="10%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH WIDTH="10%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH WIDTH="9%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%" ROWSPAN=4><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=4 ALIGN="CENTER"><FONT SIZE=1><B>Potential<BR>
Realizable Value<BR>
at Assumed<BR>
Special Rates<BR>
of Stock Price<BR>
Appreciation for<BR>
Option Term(1)(4)</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH WIDTH="34%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER"><FONT SIZE=1><B>Individual Grants</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH WIDTH="34%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="10%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%" ROWSPAN=3><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="10%" ROWSPAN=3 ALIGN="CENTER"><FONT SIZE=1><B>Percent of<BR>
Total<BR>
Options<BR>
Granted to<BR>
Employees<BR>
in Fiscal<BR>
Year(3)</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="9%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH WIDTH="34%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%" ROWSPAN=2><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="10%" ROWSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Options<BR>
Granted(2)</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="9%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH WIDTH="34%" ALIGN="LEFT"><FONT SIZE=1><B>Name<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Exercise<BR>
Price Per<BR>
Share(4)</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="9%" ALIGN="CENTER"><FONT SIZE=1><B>Expiration<BR>
Date</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>5% Per<BR>
Year</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>10% Per<BR>
Year</B></FONT><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="34%"><FONT SIZE=2>Jane E. Shaw, Ph.D.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="34%"><FONT SIZE=2><BR>
John E. Ross</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
45,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
4.76</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>%</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>$</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>
0.37</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>
12/10/12</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2><BR>
10,471</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2><BR>
26,536</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="34%"><FONT SIZE=2><BR>
Robert Fishman, M.D.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
45,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
4.76</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>%</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>$</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>
0.37</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>
12/10/12</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2><BR>
10,471</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2><BR>
26,536</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="34%"><FONT SIZE=2><BR>
Yehuda Ivri</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
45,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
4.76</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>%</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>$</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>
0.37</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>
12/10/12</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2><BR>
10,471</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2><BR>
26,536</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="34%"><FONT SIZE=2><BR>
Robert S. Breuil</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
137,500<BR>
45,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
19.31</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>%</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>$<BR>$</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>
1.62<BR>
0.37</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2><BR>
03/12/12<BR>
12/10/12</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>$<BR>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2><BR>
140,086<BR>
10,471</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>$<BR>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2><BR>
355,006<BR>
26,536</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE ALIGN="LEFT" WIDTH="120">
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD><FONT SIZE=2>The
closing price of the Company's Common Stock as reported on the Nasdaq SmallCap Market was $0.37 on December&nbsp;31, 2002 and $0.28 on March&nbsp;26, 2003. Actual gains, if
any, on stock option exercises are dependent on the future performance of the Company's Common Stock. There can be no assurance that any of the values reflected in the table will be achieved.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD><FONT SIZE=2>All
options were granted for a term of ten years. All unvested options are subject to earlier termination in the event of the termination of the employee's relationship with Aerogen.
For Mr.&nbsp;Ross, Dr.&nbsp;Fishman, Mr.&nbsp;Ivri and Mr.&nbsp;Breuil, the $0.37 options vest in 36 equal monthly installments beginning April&nbsp;8, 2002. For Mr.&nbsp;Breuil, 100,000
of the $1.62 options vest as follows: 25% vested on April&nbsp;8, 2003 and the remaining 75% vest in 36 equal monthly installments beginning April&nbsp;8, 2003. For Mr.&nbsp;Breuil, 37,500 of
the $1.62 options vested as follows: 20% vested on June&nbsp;30, 2002, 40% vested on December&nbsp;31, 2002 and 40% vested on June&nbsp;30, 2003.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD><FONT SIZE=2>Based
on options to purchase a total of 944,901 shares of Common Stock granted during the fiscal year ended December&nbsp;31, 2002.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD><FONT SIZE=2>Options
were granted at an exercise price equal to the fair market value of Aerogen Common Stock on the date of the grant. Potential realizable value assumes appreciation from the
value at the time of grant. Value at the time of grant is equal to the exercise price per share times the number of shares covered by the option. </FONT></DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=31,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=174459,FOLIO='29',FILE='DISK032:[03PAL2.03PAL1722]DQ1722A.;9',USER='ATOBAK',CD='24-SEP-2003;15:16' -->
<A NAME="page_dq1722_1_30"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="dq1722_aggregated_option_exercises_in__agg02545"> </A>
<A NAME="toc_dq1722_2"> </A>
<BR></FONT><FONT SIZE=2><B>AGGREGATED OPTION EXERCISES IN 2002 AND<BR>  FISCAL YEAR END OPTION VALUES    <BR>    </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth, with respect to the Named Executive Officers, certain information relating to options held by such officers during the fiscal year
ended December&nbsp;31, 2002. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="33%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH WIDTH="9%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH WIDTH="8%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%" ROWSPAN=3><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=3 ROWSPAN=3 ALIGN="CENTER"><FONT SIZE=1><B>Number of Securities<BR>
Underlying Unexercised<BR>
Options at Year End(l)</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%" ROWSPAN=3><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=3 ROWSPAN=3 ALIGN="CENTER"><FONT SIZE=1><B>Value of Unexercised<BR>
In-the-Money<BR>
Options at Year End(2)</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH WIDTH="33%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%" ROWSPAN=3><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="9%" ROWSPAN=3 ALIGN="CENTER"><FONT SIZE=1><B>Shares<BR>
Acquired<BR>
on<BR>
Exercise</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="8%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH WIDTH="33%" ROWSPAN=2 ALIGN="LEFT"><FONT SIZE=1><B>Executives<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%" ROWSPAN=2><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="8%" ROWSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Value<BR>
Realized</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1><B>Exercisable</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="12%" ALIGN="CENTER"><FONT SIZE=1><B>Unexercisable</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1><B>Exercisable</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="12%" ALIGN="CENTER"><FONT SIZE=1><B>Unexercisable</B></FONT><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="33%"><FONT SIZE=2>Jane E. Shaw, Ph.D.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>233,333</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>125,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="33%"><FONT SIZE=2>John E. Ross</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>61,250</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>141,250</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="33%"><FONT SIZE=2>Robert S. Fishman, M.D.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>67,749</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>89,250</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="33%"><FONT SIZE=2>Yehuda Ivri</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>5,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>47,500</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="33%"><FONT SIZE=2>Robert S. Breuil</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>22,500</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>160,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE ALIGN="LEFT" WIDTH="120">
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD><FONT SIZE=2>Certain
of the options granted before 2001 may be exercised under the Company's early exercise program; however, any shares purchased early are subject to repurchase by the Company at
the exercise price if the employee's service with the Company terminates. The repurchase right lapses over time.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD><FONT SIZE=2>Market
value of the Company's Common Stock at fiscal year end based on the closing sales price as reported on the Nasdaq Stock Market on December&nbsp;31, 2002 ($0.37) minus the
exercise price of "in-the-money" options. </FONT></DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="dq1722_employment,_severance_a__dq102185"> </A>
<A NAME="toc_dq1722_3"> </A>
<BR></FONT><FONT SIZE=2><B>EMPLOYMENT, SEVERANCE AND CHANGE OF CONTROL AGREEMENTS    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company does not have employment contracts with any of its executives. The Company has an Executive Severance Benefit Plan which provides severance benefits
to eligible executive employees selected by the Board. Benefits are paid only upon involuntary termination of employment without cause, or voluntary termination of employment for good reason, within
one month prior to or within 13&nbsp;months following a change in control of the beneficial ownership of the Company. Upon execution of a release of claims, each eligible executive would receive
12&nbsp;months of salary continuation payable in monthly installments, continued health benefits for 12&nbsp;months and option vesting acceleration. The vesting of 100% of the executive's unvested
options would accelerate immediately prior to the date of termination such that the options would vest n 12&nbsp;monthly installments beginning on the date of termination. Dr.&nbsp;Jane E. Shaw,
Robert S. Breuil, Robert S. Fishman, Nancy Isaac, Yehuda Ivri, John S. Power and John E. Ross are the current participant in the Executive Severance Benefit Plan. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=32,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=917342,FOLIO='30',FILE='DISK032:[03PAL2.03PAL1722]DQ1722A.;9',USER='ATOBAK',CD='24-SEP-2003;15:16' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_ds1722_1_31"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ds1722_compensation_committee___ds102369"> </A>
<A NAME="toc_ds1722_1"> </A>
<BR></FONT><FONT SIZE=2><B>COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION<SUP>1</SUP>    <BR>    </B></FONT></P>

<HR NOSHADE ALIGN="LEFT" WIDTH="120">
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><SUP>1</SUP></FONT></DT><DD><FONT SIZE=2>The
material in this report is not "soliciting material," is not deemed "filed" with the Securities and Exchange Commission and is not to be incorporated by reference into
any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language
contained in such filing. </FONT></DD></DL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee is comprised of three non-employee directors, none of whom has any interlocking or other type of relationship that would call into question his or
her independence as a committee member. The members of the Company's Compensation Committee are Jean Jacques Bienaim&eacute;, Phyllis I. Gardner and Philip M. Young. In determining
compensation, the Compensation Committee has access, for comparison purposes, to compensation surveys for regional technology-based companies, with which the Company competes in the recruitment of its
personnel, and national pharmaceutical and biotechnology compensation information, as well as other executive compensation data and surveys. On issues related to executive compensation, the
Compensation Committee consults with the Chief Executive Officer and the Company's director of human resources. The following report of the Committee describes the Company's compensation policies
during the fiscal year ended December&nbsp;31, 2002 as they affected the Company's Chief Executive Officer and other executive officers. </FONT></P>

<P><FONT SIZE=2><B>Compensation Policies Affecting Executive Officers  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's compensation policies for executive officers are designed to provide target salaries competitive with those of other regional technology-based
companies, in order to recruit and retain qualified executives. To date, the Company has not paid regular Special bonuses to its executives. The Company believes that, historically, its compensation
has been at or below the 50th percentile of base salaries paid by regional pharmaceutical and biotechnology companies to officers in general, and to the Chief Executive Officer in particular. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's compensation policies take into account the Company's performance against objectives during the prior year, and the individual contribution of each officer, against agreed
upon objectives, to the Company's performance. In addition, the Company's policies recognize the importance of stock ownership through a stock option program to provide long-term
incentives that mirror the equity interests of the Company's stockholders. In determining the salaries of Aerogen's executive officers, the Board and the Compensation Committee have adopted policies
intended to (i)&nbsp;attract and retain executives whose skills and abilities are critical to the Company's long term success; (ii)&nbsp;reward executives for long-term strategic
management and the enhancement of stockholder value; and (iii)&nbsp;recognize performance compared to performance of executives at similar levels of responsibility in comparable companies. As a
result, compensation consists of salary, to provide current levels of competitive compensation, and stock options, to provide longer-term incentives and align the executives' interests
with those of the Company's stockholders. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation
to be paid to any individual executive has not been based on any particular mathematical formula. Rather, the Board reviewed the objectives, accomplishments, performance and
compensation as a whole for each executive, as well as the recommendations of the Chief Executive Officer, and then made appropriate compensation determinations in the exercise of its business
judgment. </FONT></P>

<P><FONT SIZE=2><B>Relationship of Corporate Performance to Compensation  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During fiscal year 2002, the Company concentrated on expanding its business, operating as a public company, hiring key employees and executives and moving forward
the development of its technology and products, as well as launching its first commercial product. During this time, the Company had </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=33,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=249289,FOLIO='31',FILE='DISK032:[03PAL2.03PAL1722]DS1722A.;6',USER='ATOBAK',CD='24-SEP-2003;15:17' -->
<A NAME="page_ds1722_1_32"> </A>
<BR>

<P><FONT SIZE=2>objectives
against which the performance of the Company as a whole, and the executive officers individually, were measured. In determining compensation, including any stock option grants, the Board
and the Compensation Committee consider the performance of the Company as a whole, and the executives individually, in achieving their objectives. </FONT></P>

<P><FONT SIZE=2><B>Other Compensation Plans  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has adopted certain broad-based employee benefit plans in which the executive officers may participate on the same basis as other employees who meet
eligibility criteria, subject to legal limitations on the benefits that may be made available to highly compensated individuals such as executive officers. During fiscal year 2002, these plans
included (i)&nbsp;an Employee Stock Purchase Plan qualified under Section&nbsp;423 of the Internal Revenue Code, under which an individual could elect to purchase Common Stock of the Company at a
price equal to 85% of its fair market value on the
enrollment date or the purchase date, whichever is lower; and (ii)&nbsp;direct contributions by the employee under the Company's Tax Deferral Investment Plan, with a small matching contribution by
the Company. </FONT></P>

<P><FONT SIZE=2><B>Chief Executive Officer's Compensation  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The compensation for Dr.&nbsp;Jane E. Shaw, the Company's Chief Executive Officer, was determined in accordance with the criteria described above.
Dr.&nbsp;Shaw's salary was not increased for fiscal year 2002. She had received an increase of 25% in fiscal year 2001. In December&nbsp;2001, the Board granted Dr.&nbsp;Shaw an option to
purchase 125,000 shares of Common Stock, exercisable over a 24&nbsp;month period beginning on January&nbsp;31, 2004. In setting Dr.&nbsp;Shaw's compensation, the Compensation Committee took into
account Dr.&nbsp;Shaw's experience, the scope of her responsibilities and the Board's confidence in Dr.&nbsp;Shaw to lead the Company's continued development. The Compensation Committee believes
that Dr.&nbsp;Shaw's compensation for fiscal year 2002 was at the low end of salaries for chief executive officers of technology companies in the San Francisco Bay area. During fiscal year 2002,
Dr.&nbsp;Shaw led the Company's efforts in launching its first commercial product in the United States and significantly progressing the Company's technology and product development activities. </FONT></P>


<P><FONT SIZE=2><B>Policy on Deductibility of Executive Officer Compensation  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;162(m) of the Internal Revenue Code generally places a $1.0&nbsp;million per person limit on the deduction a publicly held corporation may take
for compensation paid to its chief executive officer and its four other highest paid executive officers unless, in general, the compensation is exempt as "performance based." For stock compensation to
be "performance based," Section&nbsp;162(m) requires a limit to be set on the number of options that may be granted to employees subject to the deduction cap. The Board has approved a limit of
1,000,000 as the maximum number of shares as to which options may be granted to any employee, consultant or director under the Company's stock plans in any one year period. These limitations allow
gains realized upon exercise of options to qualify as "performance based" and, therefore, to be excluded from compensation subject to the $1.0&nbsp;million deductibility limit. The Company believes
that all of its compensation paid to date meets the requirements for deductibility. The Compensation Committee considers the deductibility limits of Section&nbsp;162(m) in determining executive
compensation. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>COMPENSATION COMMITTEE</B></FONT><FONT SIZE=2><BR>
Jean Jacques Bienaim&eacute;<BR>
Phyllis I. Gardner<BR>
Philip M. Young </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=34,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=960613,FOLIO='32',FILE='DISK032:[03PAL2.03PAL1722]DS1722A.;6',USER='ATOBAK',CD='24-SEP-2003;15:17' -->
<A NAME="page_ds1722_1_33"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ds1722_compensation_committee___ds102504"> </A>
<A NAME="toc_ds1722_2"> </A>
<BR></FONT><FONT SIZE=2><B>COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of Aerogen's executive officers serves as a member of the board of directors or compensation committee of any entity that has one or more executive officers
serving as a member of Aerogen's Board of Directors or Compensation Committee. There are no family relationship among any directors or executive officers of the Company. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=35,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=49695,FOLIO='33',FILE='DISK032:[03PAL2.03PAL1722]DS1722A.;6',USER='ATOBAK',CD='24-SEP-2003;15:17' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_du1722_1_34"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="du1722_performance_graph1"> </A>
<A NAME="toc_du1722_1"> </A>
<BR></FONT><FONT SIZE=2><B>PERFORMANCE GRAPH<SUP>1</SUP>    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The graph below compares total stockholder returns on the Aerogen Common Stock with the cumulative total stockholder return of the Nasdaq Composite Index and the
Nasdaq Pharmaceutical Index. The Nasdaq Composite Index tracks the aggregate price performance of equity securities of companies traded on the Nasdaq Stock Market. The Nasdaq Pharmaceutical Index
tracks approximately 280 domestic stocks in the pharmaceutical sector. All values assume reinvestment of the full amount of all dividends. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
graph below shows the cumulative total stockholder return assuming the investment of $100 on November&nbsp;10, 2000 (the date of the Company's initial public offering) and the
reinvestment of dividends, although dividends have not been declared on the Company's Common Stock, and is based on the returns of the component companies weighted according to their market
capitalizations as of the end of each period for which returns are indicated. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
stockholder return shown on the graph below is not necessarily indicative of future performance and the Company will not make or endorse any predictions as to future stockholder
returns. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>
<IMG SRC="g884964.jpg" ALT="GRAPH" WIDTH="529" HEIGHT="468">
  </B></FONT></P>

<HR NOSHADE ALIGN="LEFT" WIDTH="120">
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><SUP>1</SUP></FONT></DT><DD><FONT SIZE=2>The
material in this section is not "soliciting material" and is not deemed "filed" with the Securities and Exchange Commission and is not to be incorporated by reference
into any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation
language contained in such filing. </FONT></DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=36,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=461532,FOLIO='34',FILE='DISK032:[03PAL2.03PAL1722]DU1722A.;12',USER='ATOBAK',CD='24-SEP-2003;15:19' -->
<A NAME="page_du1722_1_35"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="du1722_certain_transactions"> </A>
<A NAME="toc_du1722_2"> </A>
<BR></FONT><FONT SIZE=2><B>CERTAIN TRANSACTIONS    <BR>    </B></FONT></P>

<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Registration Rights Agreement.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company entered into an agreement with the holders of its preferred stock, excluding John
S. Power, Aerogen's Senior Vice President, Sales, pursuant to which they have registration rights with respect to the shares of Common Stock into which the preferred stock has converted. </FONT></P>


<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification Agreements.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company has indemnification agreements with its directors and officers for the
indemnification of and advancement of expenses to these persons to the full extent permitted by Delaware law and the Company's by-laws. The Company intends to execute such agreements with
its future directors and officers. </FONT></P>

<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transactions with Officers and Directors.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Yehuda Ivri, Aerogen's Founder and Chief Technical Officer, has executed three
notes payable to the Company, only two of which remain outstanding. On May&nbsp;6, 1994, the Company received a promissory note for the principal amount of $69,009. The note bore annual interest of
6.43%, with principal and interest due the earlier of May&nbsp;5, 2003 or 90&nbsp;days after the date of termination of Mr.&nbsp;Ivri's service with the Company. This note was repaid in full in
June&nbsp;2003. On August&nbsp;15, 1996, the Company received a promissory note from Mr.&nbsp;Ivri for the principal amount of $200,000. The note originally bore no interest and the entire
principal balance was due on the earliest of (i)&nbsp;August&nbsp;14, 2001, (ii)&nbsp;90&nbsp;days after Mr.&nbsp;Ivri's Common Stock was no longer subject to a lock-up agreement
with the underwriters of the Company's initial public offering, or (iii)&nbsp;the date Mr.&nbsp;Ivri's service with the Company terminates pursuant to Mr.&nbsp;Ivri's resignation or is
terminated by the Company for cause. This note was amended effective December&nbsp;31, 2001 to provide that (i)&nbsp;interest will accrue on the outstanding principal at a rate of 4.38% per annum
beginning January&nbsp;1, 2002, (ii)&nbsp;principal and interest will be due on the earlier of termination of Mr.&nbsp;Ivri's service with the Company or December&nbsp;31, 2006, and
(iii)&nbsp;Mr.&nbsp;Ivri will pay the Company a portion of the proceeds of certain of his sales of Company Common Stock until his notes to the Company have been paid in full. On July&nbsp;21,
2000, the Company received a promissory note from Mr.&nbsp;Ivri for the principal amount of $50,000. The note bears interest at the rate of 6.62%, and the principal and interest are due on the
earlier of (i)&nbsp;July&nbsp;21, 2005 or (ii)&nbsp;the date at which Mr.&nbsp;Ivri's service with the Company terminates. These latter two notes are secured by 166,666 shares of
Mr.&nbsp;Ivri's Common Stock. On August&nbsp;31, 2003, the principal and accrued interest outstanding on the loans to Mr.&nbsp;Ivri totaled $275,165. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
1998, Aerogen received a recourse note from Dr.&nbsp;Jane E. Shaw, the Company's Chairman and Chief Executive Officer, in the aggregate principal amount of $140,000, in connection
with her purchase of 466,666 shares of Common Stock. The note bore annual interest of 5.93%, with original principal and interest due January&nbsp;28, 2002. The note was repaid in full in
January&nbsp;2002. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="du1722_householding_of_proxy_materials"> </A>
<A NAME="toc_du1722_3"> </A>
<BR></FONT><FONT SIZE=2><B>HOUSEHOLDING OF PROXY MATERIALS    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC has </FONT><FONT SIZE=2><I>adopted</I></FONT><FONT SIZE=2> rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery
requirements for proxy statements and annual reports with respect to two or more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders. This
process, which is commonly referred to as "householding," potentially means extra convenience for stockholders and cost savings for companies. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
year, a number of brokers with account holders who are Aerogen,&nbsp;Inc. stockholders will be "householding" our proxy materials. A single proxy statement will be delivered to
multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be "householding"
communications to your address, "householding" will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in "householding" and
would prefer to receive a separate proxy statement and annual report, please notify your broker, direct your written request to </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=37,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=448591,FOLIO='35',FILE='DISK032:[03PAL2.03PAL1722]DU1722A.;12',USER='ATOBAK',CD='24-SEP-2003;15:19' -->
<A NAME="page_du1722_1_36"> </A>
<BR>

<P><FONT SIZE=2>Aerogen,&nbsp;Inc.,
Robert S. Breuil, Secretary, 2071 Stierlin Court, Mountain View, CA 94043. Stockholders who currently receive multiple copies of the proxy statement at their address and would
like to request "householding" of their communications should contact their broker. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="du1722_other_matters"> </A>
<A NAME="toc_du1722_4"> </A>
<BR></FONT><FONT SIZE=2><B>OTHER MATTERS    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board knows of no other matters that will be presented at the Special Meeting. If, however, any other matter is properly presented at the Special Meeting, the
proxy solicited hereby will be voted in accordance with the judgment of the proxyholders. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="49%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%"><FONT SIZE=2>By Order of the Board of Directors,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="49%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="49%"><FONT SIZE=2><BR>
Robert S. Breuil<BR></FONT> <FONT SIZE=2><I>Secretary</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>Mountain
View, California<BR>
October&nbsp;9, 2003 </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>A copy of the Company's Annual Report to the Securities and Exchange Commission on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2002
is available without charge upon written request to: Secretary, Aerogen,&nbsp;Inc., 2071 Stierlin Court, Mountain View, CA 94043. Such Annual Report includes our audited financial statements for the
2002 fiscal year and certain financial information, which is incorporated by reference herein.</B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>You are cordially invited to attend the Special Meeting in person. Whether or not you plan to attend the meeting, you are requested to sign and return the
accompanying proxy card as soon as possible in the accompanying postpaid envelope. Your doing so may save Aerogen the expense of a second mailing.</B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=38,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=949631,FOLIO='36',FILE='DISK032:[03PAL2.03PAL1722]DU1722A.;12',USER='ATOBAK',CD='24-SEP-2003;15:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_dv1722_1_1"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="dv1722_appendix_a_certificate_of_amen__app04029"> </A>
<A NAME="toc_dv1722_1"> </A>
<BR></FONT><FONT SIZE=2><B>APPENDIX&nbsp;A<BR>  <BR>    CERTIFICATE OF AMENDMENT TO<BR>  AMENDED AND RESTATED<BR>  CERTIFICATE OF INCORPORATION OF<BR>  AEROGEN,&nbsp;INC.    <BR>    </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aerogen,&nbsp;Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the "Corporation"), does hereby certify: </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FIRST:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The name under which the Corporation was originally incorporated in Delaware was AeroGen (Delaware),&nbsp;Inc. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECOND:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The date on which the Certificate of Incorporation of the Corporation was originally filed with the Secretary of
State of the State of Delaware is March&nbsp;12, 1998. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIRD:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors of the Corporation, acting in accordance with the provision of Sections 141 and 242 of the
General Corporation Law of the State of Delaware adopted resolutions to amend the Section&nbsp;A of Article&nbsp;IV of the Amended and Restated Certificate of Incorporation of the Corporation to
read in its entirety as follows: </FONT></P>

<UL>

<P><FONT SIZE=2><B>"A.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Classes of Stock. This corporation is authorized to issue two classes of stock to be designated, respectively, "Common Stock" and
"Preferred Stock." The total number of shares which the corporation is authorized to issue One Hundred Million (100,000,000), of which Ninety Five Million (95,000,000) shares shall be Common Stock,
par value $0.001 per share, and Five Million (5,000,000) shares shall be Preferred Stock, par value $0.001 per share. Effective as of 5:00&nbsp;p.m., Eastern time, on the date this Certificate of
Amendment of Amended and Restated Certificate of Incorporation is filed with the Secretary of State of the State of Delaware, each [*] shares of the Corporation's Common Stock,
par value $.0001 per share, issued and outstanding shall, automatically and without any action on the part of the respective holders thereof, be combined and converted into one (1)&nbsp;share of
Common Stock, par value $.0001 per share, of the Corporation. No fractional shares shall be issued and, in lieu thereof, any holder of less than one share of Common Stock entitled to receive cash for
such holder's fractional share based upon the closing sales price of the Corporation's Common Stock as reported on The Nasdaq SmallCap Market as of the date this Certificate of Amendment is filed with
the Secretary of State of the State of Delaware." </FONT></P>

</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FOURTH:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Certificate of Amendment to Amended and Restated Certificate of Incorporation was submitted to the stockholders
of the Corporation and was duly approved by the required vote of the stockholders of the Corporation in accordance with Sections 222 and 242 of the Delaware General Corporation Law. The total number
of outstanding shares entitled to vote or consent to this Amendment was [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares of Common Stock. A majority of the outstanding shares of Common Stock, voting
together as a single class, voted in favor of this Certificate of Amendment to Amended and Restated Certificate of Incorporation. The vote required was a majority of the outstanding shares of Common
Stock, voting together as a single class. </FONT></P>

<HR NOSHADE ALIGN="LEFT" WIDTH="120">
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD><FONT SIZE=2>By
approving these amendments, stockholders will approve the combination of any whole number of shares of Common Stock between and including four (4) and eight (8) into one (1) share of
Common Stock. The Certificate of Amendment filed with the Secretary of State of the State of Delaware will include only that number determined by the Board of Directors to be in the best interests of
the Corporation and its stockholders. In accordance with these resolutions, the Board of Directors will not implement any amendment providing for a different split ratio. </FONT></DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2>A-1</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=39,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=712506,FOLIO='A-1',FILE='DISK032:[03PAL2.03PAL1722]DV1722A.;7',USER='ATOBAK',CD='24-SEP-2003;15:19' -->
<A NAME="page_dv1722_1_2"> </A>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>IN WITNESS WHEREOF,</B></FONT><FONT SIZE=2> Aerogen,&nbsp;Inc. has caused this Certificate of Amendment to be signed by its Chief Executive Officer as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2003. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="53%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><B>AEROGEN,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="53%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="53%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
Jane E. Shaw<BR>
Chief Executive Officer</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>A-2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=40,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=399220,FOLIO='A-2',FILE='DISK032:[03PAL2.03PAL1722]DV1722A.;7',USER='ATOBAK',CD='24-SEP-2003;15:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><B>PRELIMINARY COPY  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ma1723_aerogen,_inc._proxy_solicited___aer04526"> </A>
<A NAME="toc_ma1723_1"> </A>
<BR></FONT><FONT SIZE=2><B>AEROGEN, INC. <BR>  PROXY SOLICITED BY THE BOARD OF DIRECTORS<BR>  FOR THE SPECIAL MEETING OF STOCKHOLDERS<BR>  TO BE HELD ON OCTOBER 30, 2003    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby appoints Jane&nbsp;E. Shaw, and Robert&nbsp;S. Breuil, and each of them, as attorneys and proxies of the undersigned, with full power
of substitution, to vote all of the shares of Common Stock of Aerogen,&nbsp;Inc. (the "Company") which the undersigned may be entitled to vote at the Special Meeting of Stockholders of the Company
to be held at the Company's offices at 2071&nbsp;Stierlin Court, Mountain View, CA&nbsp;94043 on Thursday, October&nbsp;30, 2003 at 2:00&nbsp;p.m. (local time), and at any and all
postponements, continuations and adjournments thereof, with all powers that the undersigned would possess if personally present, upon and in respect of the following matters and in accordance with the
following instructions, with discretionary authority as to any and all other matters that may properly come before the meeting. </FONT></P>

<P><FONT SIZE=2>Unless
a contrary direction is indicated, this Proxy will be voted </FONT><FONT SIZE=2><B>FOR </B></FONT><FONT SIZE=2>Proposals&nbsp;1, 2 and 4, as more specifically described in the Proxy
Statement </FONT><FONT SIZE=2><B>FOR </B></FONT><FONT SIZE=2>all nominees listed in Proposal&nbsp;3. If specific instructions are indicated, this Proxy will be voted in accordance therewith. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>(Continued, and to be marked, dated and signed, on the other side)  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>^&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Detach here from proxy voting card.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;^ </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=41,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=53209,FOLIO='blank',FILE='DISK033:[03PAL3.03PAL1723]MA1723A.;33',USER='DNICHOL',CD='24-SEP-2003;15:47' -->

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="110%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="83%" ALIGN="CENTER"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="10%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="5%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="83%" ALIGN="CENTER"><FONT SIZE=1><B>THIS PROXY WILL BE VOTED AS DIRECTED, OR IF NO DIRECTION IS INDICATED, WILL BE VOTED "FOR" THE PROPOSALS THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS</B></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>Please mark your votes as indicated in this example</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="CENTER"><FONT SIZE=4><B>X</B></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=7><FONT SIZE=1><B>MANAGEMENT RECOMMENDS A VOTE FOR FOR PROPOSALS 1, 2 and 4</B></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=1><B><BR>
PROPOSAL&nbsp;1</B></FONT><FONT SIZE=1>.&nbsp;To approve the issuance of a convertible debenture and warrant to purchase Common Stock pursuant to a convertible debt financing with SF Capital Partners, Ltd.</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=1><BR>
FOR<BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><BR>
AGAINST<BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><BR>
ABSTAIN<BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="10%"><BR><FONT SIZE=1><B>PROPOSAL&nbsp;2</B></FONT><FONT SIZE=1>.&nbsp;To amend the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock pursuant to which any whole number of
outstanding shares between and including four and eight would be combined into one share of our common stock and to authorize our Board of Directors to select and file one such amendment.</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=1><BR>
FOR<BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><BR>
AGAINST<BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><BR>
ABSTAIN<BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="15%"><BR><FONT SIZE=1><B>PROPOSAL 3</B></FONT><FONT SIZE=1>.&nbsp;To elect three directors to hold office until the 2006 Annual Meeting of Stockholders.<BR>
<BR>
Nominees:<BR>
01&nbsp;&nbsp;Jean-Jacques Bienaim<BR>
02&nbsp;&nbsp;Yehuda Ivri<BR>
03&nbsp;&nbsp;Bernard Collins<BR></FONT>
</TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=1><BR>
FOR<BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="CENTER"><FONT SIZE=1><BR>
WITHHELD<BR>
FOR ALL<BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=5><FONT SIZE=1>To withhold authority to vote for any nominee(s), write such nominee(s)' name below:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="10%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="15%"><BR><FONT SIZE=1><B>PROPOSAL 4</B></FONT><FONT SIZE=1>. To ratify selection of PricewaterhouseCoopers LLP as independent auditors of the Company for its fiscal year ending December&nbsp;31, 2003.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=1><BR>
FOR<BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="CENTER"><FONT SIZE=1><BR>
AGAINST<BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><BR>
ABSTAIN<BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="10%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD COLSPAN=5><FONT SIZE=1><BR>
Please date and sign exactly as name(s) appear(s) hereon. If shares are held jointly, each holder should sign. Please give full title and capacity in which signing, if not signing as an individual stockholder.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="8%" ALIGN="CENTER"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="24%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="9%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="24%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="5%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="24%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="8%"><FONT SIZE=1><B>Signature</B></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="24%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1><B>Signature</B></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="24%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1><B>Date</B></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="24%"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="8%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="24%"><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="24%"><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="24%"><HR NOSHADE></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=11><FONT SIZE=1><BR>
NOTE: Please sign as name appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, trustee or guardian, please give full title as such.</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=1>^&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=1><B>Detach here from proxy voting card.</B></FONT><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;^ </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=42,EFW="2119226",CP="AEROGEN, INC.",DN="1",CHK=150235,FOLIO='blank',FILE='DISK033:[03PAL3.03PAL1723]MA1723A.;33',USER='DNICHOL',CD='24-SEP-2003;15:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="03PAL1722_1">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_be1722_1">NOTICE OF SPECIAL MEETING OF STOCKHOLDERS TO BE HELD OCTOBER 30, 2003 AT 2:00 P.M.</A></FONT><BR>

<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_de1722_1">PROXY STATEMENT FOR A SPECIAL MEETING OF STOCKHOLDERS October 30, 2003</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_de1722_2">QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING</A></FONT><BR>

<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_dg1722_1">PROPOSAL 1 APPROVAL OF THE SECOND CLOSING OF A CONVERTIBLE DEBT TRANSACTION WITH SF CAPITAL PARTNERS, LTD.</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_di1722_1">PROPOSAL 2 APPROVAL OF AMENDMENT TO OUR CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF OUR COMMON STOCK</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_dk1722_1">PROPOSAL 3 ELECTION OF DIRECTORS</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_dk1722_2">AUDIT COMMITTEE REPORT<SUP>1</SUP></A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_dk1722_3">PROPOSAL 4 RATIFICATION OF SELECTION OF INDEPENDENT ACCOUNTANTS</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_dm1722_1">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_dm1722_2">SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_do1722_1">EXECUTIVE COMPENSATION</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_dq1722_1">FISCAL YEAR 2002 OPTION GRANTS</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_dq1722_2">AGGREGATED OPTION EXERCISES IN 2002 AND FISCAL YEAR END OPTION VALUES</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_dq1722_3">EMPLOYMENT, SEVERANCE AND CHANGE OF CONTROL AGREEMENTS</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_ds1722_1">COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION<SUP>1</SUP></A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ds1722_2">COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION</A></FONT><BR>

<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_du1722_1">PERFORMANCE GRAPH<SUP>1</SUP></A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_du1722_2">CERTAIN TRANSACTIONS</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_du1722_3">HOUSEHOLDING OF PROXY MATERIALS</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_du1722_4">OTHER MATTERS</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_dv1722_1">APPENDIX A CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AEROGEN, INC.</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_ma1723_1">AEROGEN, INC. PROXY SOLICITED BY THE BOARD OF DIRECTORS FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON OCTOBER 30, 2003</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=ATOBAK,SEQ=,EFW="2119226",CP="AEROGEN, INC.",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g884964.jpg
<DESCRIPTION>G884964.JPG
<TEXT>
begin 644 g884964.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@`K1$E32S`S,CI;,#-004PR+C`S4$%,
M,3<R,BY/5510551=05)4,2Y%4%/_VP!#``<%!@8&!0<&!@8("`<)"Q(,"PH*
M"Q<0$0T2&Q<<'!H7&AD=(2HD'1\H(!D:)3(E*"PM+S`O'2,T.#0N-RHN+R[_
MP``+"`'3`A$!`1$`_\0`'0`!``("`P$!``````````````4&`P0!`@<("?_$
M`%L0``$#`P,!`P<&"0D#"P($!P$"`P0`!1$&$B$Q!Q-!%!46(E%AE2,R5'&!
MTS9"559UD;/2XP@D-%)B<G2APS."L1<E-4-3<X22LL'1)J)C@Y2C-SA$D\+A
M\?_:``@!`0``/P#Z1K2O-T@V6URKK<Y"6(<5LN.N*\`/=XGP`\37E[7;5!##
M-TF:3U!$T\\X$(NKC`+6"<!1`\,^PG[:M&L^T.S:83;F$M2;I<KF`J%"@([Q
MQ])Z*]@2?;X^`.#6II;M+@WC4`TU=+/<K#>EH[QF-<&PGOTXSZI\3@'CW'K7
M.G.TZT7[6]PT@S!F,S(:WT=\[M[MQ32@E03@Y\<].E+1VFVBZZZFZ.CP9@DQ
M2\E4A6WNE%OA6.<]<CIX5`1.VN'+MCUXCZ,U*]:V%*#TMIA"VV]N-V2%>`(-
M6?4':1IZS:)B:QW/2K?,4A,=#0`6XI6>,*(P1A6?9@U)VC5MNNVB1J^(VZ81
MBN22V<;QL!W)ZXR"DCK5)C=LK,BS^?&]$:G7:0DK5,1'0IL)2<*.=W08/ZJL
M#_:58DNZ1$5N3*9U,X417FP`&R"D'>"<C!5CC/0UI73M.2W?+G:+%I:\7U5K
M.R:]#2D(:7_5&3ZQX/'NJ5C]HVF'=#^FJY2V;6,I4EQ'RJ7`<=WM'XV?#[<X
MYJL-=LL-GR27>M)WZTV:8H)9N4E@=USRDG'0$<\9^VK!JCM)L6FM46;3]P0]
M_P`Z(2MN6@I+*`I12"HYSC(ZCCFI2;JV'$UO;='KC/JESXJY*'AM[M*4[L@\
MYSZI\*WM3Z@M>E[+(O-XD=S#8`R0,J43P$I'B2:\]:[98;/DDN]:3OUILTQ0
M2S<I+`[KGE)..@(YXS]M36L^TJ%IB^6^R(LMTNTN='\H83;D)<*DY/09R>$D
M\>%2&C=8OZEE26'=*WVSAEL+#ERC=TES)QA)\3735W:!:-,W.-:%P[E<[J^V
M7DPK9'[YU+8SZY&1@<']583VFZ8.CO2UER4_![],9333.7DND@;"@D<\CQ^K
M-;NE-:P]337XD>S7R"IIOO"NX02P@\@8!)Y//2M#M)[1[9H`VX7&!-E^7!TH
M\F"?5"-N<[B/ZW^5<:^[2K/HN!:YLN+*F(N*5+93&VD[`E)*CDCCUD_KKMJO
MM'M&G8UJ28DR==+JVER';8B-[S@4!R?`#G'OYP#@U@TMVEP;QJ`::NEGN5AO
M2T=XS&N#83WZ<9]4^)P#Q[CUK8TMVCV74>K+SI9AF1'N%M<6@A[;M>V+*5%&
M#X'!Y\#]=:CG:;'4Q>%V_3=ZN+MKN9MKK,-E+BU*`42X`#\SU<9/M%1-G[9&
M;O/<A0M$ZG<<9?2Q(*8R5".HG&%X/JXP>OL-7'2FL8.IKIJ&VQ(TAIRRRS$>
M4[MVN*RH93@]/5/6N-&:R@ZL?O3,.+(8-JF*B.E[;ZZAGE.">./&M;7>OK9I
M!V#!<BR[C=YYQ%M\-&YUSG&?<,\>T^`X-:NDNT>#?;T_I^?:+C9+VTUWR8<]
ML)+K?M2?'ZOU9P<2&A]:P-8:<?OT*))889=<:+;VW<2@`D\$CQJM.]L5E;T-
M$UCYJN*HDF<82&$A'>;P"<_.QCU?;4M>NTJSVK0MLUDN+*>B7`MAEAO:7,J!
M.#SC(VJSSX5C3VFVI2-'*\WS?_JA13&^9\E@I'K\_P!H=,U+:@UG!L>J-/Z=
MD19#DB]*6EEQO;L;VXSNR<^/A32.LH.J+G?[?$BR&7+-+\E>4[MPXK*AE.#T
M]4]:G+S<HUGM,VZS5;8T1E;SA_LI&3CW\52-,]J5LU+I:[7ZTV>Z/N6U:4.0
M&VTKD.;L8*4I)SU/_E-0J.VIE=S=M2-":J5<6F^]<BIBI+J4<>L49R!R.?>*
MGD]I<)5ROEM%EN7E=GMB+B^T0@**2A"R@`GYP"^0?$&M\:^LY[._3P-O^;NX
M[WNO5[S.[9LZXW;N.M0=X[68EL=L<8:9O4N9>(*9K$:,VA;@0<\%.>N!GCPJ
M<T=K1_4LY^([I._V@--=X';C&[M"^0-H/B><_94%J_M89TK,F-7#2.H3$C.A
MKRY,<!APGIM62`<_^U9VNU:V,6*?>[]8KW8XL8MI;$^-L7*4L*(2T,^L<)R?
M``Y-:47M@B-3(+>HM+WNPPIZ@B--FL@-*)Z;C^+P??\`JYIJ;M?8TW,D,7'1
MVHT,-R51FY1CI2T^H$@;%$C.<9'M%3D/M`95IB\ZBNNG[S9X]L3N4U<&`TX]
MQP$`GG)(3]9K=[/=;6S75E<NML9?82T^6'&7]N]*@`?`D8((KMH;64'6+-S>
M@Q9#`@3%1%A[;ZRD@'(P3QS5IKRJ'VO(N#DX6K1.I+@W#?6PZ[%90M(6GJ.%
M?;]M;<GM?TVWH=O6$>/-D13+$-R,E*4O-.D$X4"<=!X'Q%9+/VE2;E=(<!6@
M=5Q$R74MF1(A;6V@?QE'/`'MJ)N7;.S;)3$6=H?5+#LETLQPY%2@OJ!QA`)]
M8\CI[14O_P`I\5H6$7#3=ZM[UXN!@LLRVDMK0H%`WJ!/S3O'3V&IS4^LH.G;
M]IVRR8LAUZ]OJ896WMVMD%(RK)SCUATJMO=JS:K]=[+;-(:@NCUK?+$A<)I"
MT@Y(!^=D`X.,^RMF)VK6&7I&]:C;B3T*LRPW-@.H"'VE%02!C..N?'P-;C?:
M/97NSMW7<=F0[!91EQA.WO4*WA)2><9!(\>E<7+M-TM;#9DSYJ(Z[DVV\4.+
M2#';6V5I6OGIZNWC/)%6CSU;/IC7ZZD:\O\`Y1,>7([++GY*%*#;C+CP3_V8
M6,_J.#]E;MPU;HB%V:Q+E<U19=C7%90F($H=+G"0&PV3R01R#TVGV52E2K?;
M.WFPW">PFWVV984-6P/(#26%$8#>.B2!N3CPW`>-;?:E+B73M3[.;=:'6W[I
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MN<\A/VU2]37N5?\`LKCRYMJ@1V+1J9+5Q\VLA+$A(2<N`#@Y*L$^.1[<5ZIV
MT:@TX]V37-29\20W/90F&EM85WJBI)24@>S&?=BJ!+TR+YJO0.F;\@A;^DE-
M.%0RII80O:?[R2!^JLFB[M<YO;+IBU7Q"A>;)`DVZ6H]'2@+*'`?'<@I/^?C
M5O\`Y2;3ATA:)2VRY;XMV9<F)`S\GA0Y]V3C[16YVT:@TX]V37-29\20W/90
MF&EM85WJBI)24@>S&?=BO.YULU$O7'9?;85S\U7M.G4I$EQD.]R0AS(*#P3M
M!3[J]ST9:]56QN6-3ZF1>UN*26%(B)8[H`'(]7KGC]55?7^H[3IC4T<62R-7
M+75TC]RPG=MVM`\*<43@(!3G'CM/('-4^9HN/:=%6ZV7;64.!>+IJ!%P>F)8
M+K2I..&T`<#!(.58!Y\*LFB;GJ*U]J=TT1<;^[?H*8`FID/-I#D=>Y(V**?;
MGI]6,<UI]M4!JZZX[/K8^/DI;DQA7U*;0G_WKRB\3W=2Z'DR7BH^C6G8\!Q*
MARB0N6E!^WNVA5_B/Q[3VW::FWM:&8TO3K3,%YTX0'-F"`3P#\X?[P]M27:E
M+B73M3[.;=:'6W[I&FE]_N2%%IC<@G=CIPE9Q[/KJGVZS35S]<ZNL30-]T]J
M1Z4T!U?9RKO6C[BG)^P^VKK_`"?+BQ=Y&M[K&2I+$V\&0VE74)6"H`_KK+V(
M_A?VG?IH_P#K=JL=GUCO]WUGVB*LNK9-C2U>5AQ+,5M[O25N8)W=,8/ZZG_Y
M.S3K#NMV7Y"I#S=Y4A;RDA)<4-P*B!P,GG%+L\S;/Y2%OE7A:&H\NT%J"ZZ<
M)#G((!/`/SA_O#VU=9&H-(RNT&)8VX34W4:(BW$2VF$.>2MX5E)<SE&<]!_6
M'MKS[L$N5O@]F%\8F36&'8LN2I]#BPE38V)P2#]1_4:H=O;*>Q#1Y=0=B]5(
M4,CYR<K'_L:W)),F-)T3E1;TH+[)<0H?B)00P?UNG%;+KK<2V=ADZ4XEF*T\
MKO'EG"4>NWU/ATJY]HDF/,[:.S>/$?;?>96\XXAM044).""<>Y*OU5U[&Y\&
M%J_M+$R9'CE5Z.T.NI1GUW>F36Q_*#U`'-'P;!9UF7(OLH,I3$^56MM!!6$A
M/4[MHQ[S59T%>&;+VR(8CV2[66T7^$B,VS=(ICJ4\R@`*`R0<[<?6NK/8_\`
M^974GZ$;_P!&NNF$(=_E#ZZ;<2%(7;&4J21P04LY%>>)COC=V*[EY.I@KH?Z
M#M[S/_\`E5J[4XLESMHTA%MMZ1871;'$MSBVE08`[WC:H@<CU?MKT?042ZP9
M4M%U[0&=2EU">Z:2RVV6<$[CZBCG.1^JJY_*6_\`X82/\6Q_Q-1/;B$L1.S^
MYS6RJS1+FRJ;D92`0@@D>S"5U(?R@[S9)'9D_%;EQI4J>\SY"AI86IQ6\*W)
M`/3;GGWCVU%]N;,F/V8:0CS,^5-SX:'L_P!<,J"O\\UL_P`HNZK>AV+1T5B3
M)=NLH.R&(C9<>4PV<D)2.I)Y']RHOLPO:;?VO7NV)M%RLULU`T),2+<8W<+#
MK8YPG)X/RG0^`J1_D_W&WPX6K$2YT:.M5\>(2ZZE!(P.>37M3#[,EE+T=U#K
M2N4K;4%)//@17SEV2L:]=CZK.D9MD8C^>'@L3VG%++F."DIX`QCKXU491CN=
M@3[B6G$7`ZE`FNK6%=X]L)W#`&!@CCV@U[=IFW7^'>8,FX=KD>Z1$J]>"8S*
M.^R"`G<%9')!^RHWMN_"_LQ_30_];5=.W=QN+J+LYG2%AJ*Q>0775<)0-S9R
M3X<`G[*Z=JLJ--[4>S&-$D-OO-SENK0VH**4;F^3CP]57ZC4#HUG63O:1VD>
MB4NSL8N0\H\XM+7N]9S;MV]/QLY]U0,(N*[-NUSSH@JU"F>E-PD)4"VX>^XV
M``8`(7^L?4.FM([VB]&/LL-*\P:MM,982@>K'G(2VI7'@%I!/U_57M-OT;9M
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M$2)P'E4\/[@X`<#UBHI`X`XQTK#,L.D'[P;W*8B><+E&,/OR^4F0TH`%`&["
MLC'09Z5RU"T?9K2C1P7`B0GVUM(M[DD!3B%D[@`I6XYW']=8V=(:.:=LT)JW
MQP]9"7X#7?**H^Y62H#=D@J'CD5%ZFT+V;WUQS4-[M\%15_M9J9192O''K*2
MH`GC&3SQ5@LUGTOZ-IM-HAV]VQ.(*0RR$N,N`]<]0K/B3FJ[![,NS6SWB/+9
ML4%J<I>YA#SRE@J'.4H6HC(]PXJ?N472S>HXM[N+D)J\Q62TRZ[("%(;5G(V
ME0!!R><5KOP=%IU%'U4\JW(NY9VM3#)"2IO!3QZV%#!(SBIFY.6>5:'E7-R&
M[:G6\.JD*265(/M)X(JFV'LV[,FI+=]L]EM[^U6]MY+ZGVDD<Y`*BGC_`"J>
M9AZ2OFH(^H([D&==K<A3+<AB3O+"3G((2K'XRNH\:E&KU9WG4,M76$MU9VI0
MF0@J4?8!FJUJ#1N@-2RG+Y>H$*8ZD!E<E<E02-IP$Y"@`<G'VUG:[.M%,V&3
M8&[#'3:Y#H><8*ED=X!@*!)RDX'4$5VT?IS1>F`4::C0XZIV3N0_WBW@GKA2
ME$D#G@<"I"YVW3MRFQ+S<$1G9%F<6II]3V!&5@;LX.!P!G=43;](:#N%JNK%
MN@PI5NNSP<F^3R"M#RTJW#*DJXP3G`(J0U/IK2MVLK<'4,"([;HP`;+ZMG<\
M`#:O(*?`=>:B-)V#LYTLZ\]IY%JC/J02MT2@XX$=3ZRE$A/M\*GK3:M/V25*
M7;FF(TB[/*DNX=),AS&2H`GGKGCBM#3$+15@7(C:>7;8RYKV]QIF2%%Q?N!4
M?U"M^UV;3U@N$QVWL,1)EW>+[_RIW2'!DD@$_P!HGCVUQ9+-IZT2[O+M###,
MB6^79ZT.E14[R<JR3M/K$XXZUQIVT:<M+<Z;8F8[34YY4B0ZTZ5I<7SE622/
M;TXK3O=OT7KBUK:N1MMVA1E%2G$/I5W!QR=Z#E/'7D5BT3IS0^GS(1I.-`;<
M<`[Y;+_?.$9X!45$XSX=*T+MV;=G-_O<F7-LL-^Y;@N0&GU())\5H0H<GVD<
MU)W&U:)FMV_2\Q%M_F3B'HEO#X;4VI(.TI0E0/`)K+(TGI1B5>;Q(MT=MZYQ
MU,W"0MQ20ZT0`H*).`,`<C%:;MIT#<=(,6=8M4G3K!#;0\I"FVU#.`ES=D*Y
M/CFM?1VE.SO3DQZ7IJ-;FY?=G>ZB5WRTH\>5*.T=,]*U$]G_`&7:CES+FU:[
M;<7WGE.2'F)2G,N*.3G:O`).:W[3I?L_B76`Q;(UO%QLX<\F81**UQMQ)4=F
MXXR5'DBI.]VS2MZ,&ZW9,1\6M\N1Y*G]H8<!&?6"@,Y2.#[*RKM.G+=?']5.
MM1XURDM)CN3''2G>CC">3M_%'AGBC%ITY"U1)NS34=J_7!H(=7WI[QY"<8]4
MGIZHY`\*Z)L6F%:N5?4Q8IU$AG8IT.?*AO&.4Y]G&<5%ZHT[V?ZFN;2]0LVZ
M9/93W"$N2MJTC.=NT*'.3[,UDTYHG0^F[J]+L5KBP[@VUL=*'E*4A"L'D%1P
M#CKCPK<U*SI'4%I1!OS\"3;WR'$(<E!*5E)Z@A0S@^PUFN$C2L^V&VW"5:Y$
M!YO;W+SR%(6D''0GG!'7VBH#3/9SV<V^:B\6*S0G'VU^H\'U/I;4/%.Y1`(_
M6*G;U;M+ZLCQH%S$2X-(>+[+8?\`QVR4DC:H$[22#[#UK(FRZ>G:@;U,F.Q(
MNT5"HJ)272HMCD%&`<`^L?#/-:TN#I"^ZCAR7EP9=[M)*F0W)^5CG/.4I5GK
M[14&_P!EW9F_<'&WK!#5.="GU(,AS>H%7*MN_.,GKTJV6N+9=/0(UE@=Q#C,
M-J4U'+OS4`DJ/K'.`2<FM;3]JTU8&%^96XT9JY2"_E#VX/NJ')223DD#H/94
M&WI'LYDV][3C46WNQ7I1E+AHEDY>`P58"\YQX"M!&@>R>U7!MT6VU19D5Q+B
M=\Q25-J!"@<%?U'FK5=[9IF^2HDNY)BR7[.X)+2R]CR97"@HX/'S0>>.*VKQ
M:;+J>T&%<XL>X6]["PE7K)/L4DCH?>#4/I?L[T;I6:J?8[(U&EE)1WREK<4D
M'J`5DXS[JE[5IZS6BX7*XVZ"AB7<G`[+<"E$NJ&<$Y.!\X],=:T%:(TLIB]1
MS:6^YO3G>7!`<6`^K<59/K<'))XQ6W==,6&[V)NP7*VM2+8V$)0PHJPD(&$X
M(.>![ZE(<9B%$8AQFPVPPVEMM`/S4I&`/U"LU*4I2E*H/;/>7[3H28Q!"UW&
MZ*3;HC;8RM:W3@[1U)V[O\J\=\J;M?9QV@Z,,.XPX\8,SH+-Q:[I[R=QQL*R
MG/0+!_\`-6%L/2+UI2W22HC25XB6H[O%:YCF/_VF6_UU8+>WH]_2_:!(UGY$
MK429TP/KF;?*6\#Y$-;O6`Z;=O%:5M]((VH+7JH^4NWBSZ9@R)D90]>5'*W`
MZA0/X^S"AX[D^VL6DUVV3#[,FM1*;.FW57-U*9(`CN2>_<[L.9X^:>`?$_77
MH?9%-MSFHM90+?;84(1WF%NIMTTOQ5+4E62A.U(0?5`5CC/U5Y_VG769<=;W
M;4%O@724-)J8;AO16"N.AU"PY)[U0^;ZIV^/3PJ5U0_"O/:0JX-)T@[&DV&(
M^R=2#+>U2UD%O^U@\^ZL]SMR+AK^P1K9I[2U[0C3)5Y*I21!21(`4IKU%=%$
M@<=">:K6FDV\HT-&U`4MZ=7=KGY5%?(\D:E`_)-<D@H'.W/4E59=9F/%EZ[9
MTBHMZ9+$$7/S=CN6UET!W9MX![OYV/?FKA$DZ5@]J6FH6G;79DLRHCS<>5:Y
MH"E-!DJ/?-)3A0)'JDJSD$^%5WL8CP?(=-OR&M`9[PX6Z!YUW[U;>OX^[&/=
MBJQ,\OLN@;D<NOVC4-S6DC'$66S-!!_NK;01]:/?7U,S/@RU3&(LQA]V*HMO
MH;<"BTK&=J@.AQX&OF335MN-PLG9NJS/%J[PX5UEP\=%NMR<A"O<H92?[U9F
M[E#O-G\XW)MV/INX:Z6Y<FW?5"$%ILI0[[$A60<\<?57J>FY?9S8]17^=89S
M,..U&8\X*CK2FW-J*L(P4^J'#G'!_P`\U>W_`#'?V9MKD"!<FF5AN5%7L>2A
M0PH)6DYP>AP:\!9LEF8[.NU6:S:8+<J+=YT>.\B.@+9:!0`A*@,I3@G@<<U.
M,HU*GM`[+S?I%J=9,69Y*(3+C:DI\E&=^]1R?F],>-178NQ!\ATX_);[/P=Y
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MZ[)0O6DB0^'));W36IZ5J4G<H>NCH`/"O5NTIH2>S&WLW^Y-P)"UP^^=DLJ=
M84\"DE+P3T;*@03T%0>@8-GN.J[[8[SIK3KKQBL27O-2P_;ED*4E![I0PV[@
MGWD$_;2(EKMT;LAL]R%OCL1W[_Y/>);+(2XJ#Y0H*0M8&=F0CC..!5IU,F!#
MUS$3V:IB-RE6.>9J+2$]WM#1,<J".-V_&#UZ5AT:SV9>C^@WVG4#4RY+!"[>
M4F8N3_U@>QE7=YSNW<8^NJWI52V)]JE:L9;=T4+W-:9"5?)-3"YE#D@'A2>H
M3G@8)/O]/[?8`N^EK-:LX$V]Q8^?[^](_P"->>:/N3E][1]':HF**2D+MI*^
M-I8@;WCSX=XXK]5:]AO\AO7\+M#D0;HW%NUT=B.RG(Y3&,-82VP`O/5*D9--
M16Y]ZT]IMP3IBRS6&;S)2NYR%#RN-_L\]V-O.,Y'KCDG[>NIF[NK4>IE6]4F
M78F;?:G+PE"]DN3$#0W`$9ZC)5ST'7K5BU>+'+U7I-5E;TFJSJL;QBIO21Y&
M$=XG&!X+'Z_G>-9^TJS6!78M,N;5KTNJXQ@TV)-F9066B9*=R6U8R!ZQR/:3
M[:]'U,U&TGV>7Y_3D"-;U1X+S[:(K*6TI<[OY^$@#/`.?=5!MHMFG]:]FZ7)
M#$:#Z.NH0\ZH(0M92E1.X\9.2?MJ3[);K;6-/WCOIZ&_.=]N*X6U7KR$CDEL
M=58`)XJBZ2%NM4S1BT-:?N\5=P2S"N-K<5&N14LJ!,AHY*TC\89X'^?I6L;K
M"?O6@K]9)C$I2[RJW%QA6]*VG$+#J<CJ`4)/N(%0O:@3Z>,'Q]%KG_Z#5-TT
MJ=:7>S+3LOO7H<B7&NMND*Y"4.1U=ZR?[KBLCW+'LK6DM:6'9;,=C(MPUH;N
MZ(*HX1Y<7?*SLQCU\;?;QBIF5'9>U_K$RFM!K6);&XZD&7`?)T9[O^SU^VL?
M:\JUIU4VJS&28!M['I/YNQL\A[Q'=]/QMOLYV8\*^@K;Y'YNB^;NZ\A[I'D_
M=?,[O`V[<>&,8K9I2E*4I2E*4K!(AQ)3C#LF*R\Y'7WC*G&PHMJZ;DD]#[Q6
M&7:;7,<6[+ML20XMON5*=82LJ;SG:21RG(SCIFN#:+47%NFVPRXMY,A2BPG*
MG4_-63CE0\#U%89NGK#/GM7&=9;?)FM8[N0]&0MQ&.F%$9%;HB11*7+$9D27
M$!M;VP;U(&2$E74CD\>^M5ZQV5ZV>:7K3!<MV<^2*CH+77/S,8Z\]*RV^UVV
MVH#=NM\6(@(2V$L,I;&U.<)X'09.![S79FWP&67V&84=MF0I2WFT-)"7%*^<
M5`#DGQ)ZUHOZ9TY(#0D6"UNAIL-MAR&VK8@=$C(X`R>!6M<I.E-),19DWS;:
MF_Z(PYW:6\!1*N[3@<`D$XZ>-+DG2414;3UQCVQL79Q9:A.LIV25C!4=N,$\
MCD\UJ&]Z'TW:I;*9%LMMNB2?)'VVV@VVV\I.=A2!C)%8M*2.SV3$DS]+(L?<
MQ5%UY<)E""TK:05$``@[=PSXC-0MNU)V/.7&*+>]ISRY;R`P6HB`OO"1MP=F
M0<XP:L*[GHHZ9,]:[8;#Y04E19'<]]WF/FXQNW^..O-1)U7V>:9OEZ1)U!#C
MW.5("YB'#@A24!(&`G'`'O)SR35AG/Z6TY`BW.4FW6^(S\DP_P!TE"6^\.<)
M('JA1Y..OC60)TVN9*TZ&("GY+7EDB'W2<.H4K:7%)QA62,9/LK2L*=$SHUR
ML5CC6AR-#>V3(<=A'=H<S^,G&,Y3U]WNJ.TQJ+0CFI;I$L]\BR+O<7^]>2#@
M.*0D)P@X"58`\"3U))KF-J[LWERY%A:NEE4[,?4EZ*I*0'W2<$*!&%*)&.>3
M4W.N&F8E]M5LFNP6[LXE7D#2TCO`G&%;./5X&.,9Q5?OD[LPTI<8Z;HQ88$\
MX>:Q#07$8/"_522D9'SCCI5K6_9WXC-_4N(\PPRIYJ;@+"&RG*E)5X`@<XZX
MJM6?4W9Q>)JTVR=99$MM2IQV-IWA8'K.C(R58ZD<XJ4<NNDWF+?>W7H"V[KM
MA192FP3("R<-`D9(.#P>*P,,Z&L=U3IN-#LT"?=&BKR-J.ALR4`'.0!A0X5U
M]AJ,N-[[,-,39=IFN6*VR7&PF0QY,E&]"AD!0"<$$>!J8?N^CG'+-:'I-L=\
ML2EZVL%*5I<"1ZJF^,<>!'V5J(BZ`U)>[JP(%EN%VB@LSBJ,A;J,Y3M4HC/@
M1UJ2MMUTQJ*RRO(94"=:F=T=\<*:2$@92H'C`&/=BH?1>H>SIZ5(L^CY5G:>
M&7%QX+0:"\=5#``7CVC-=+5K;LXE+:L-LN]I5Y4X6D0V482XI9Y&W;@Y)^W-
M;EIG:%LMGD76T"U6^VF1W#ST5A+2"Z%;-IV@9.XXJ%1K#LEMEXDS6[A88MUW
M*0^^A@)>)SA0*@G)Y%3;]UT*W9+H'W;0BT1'RB:A;:0TETX40I)&"HD@]"2?
M?6U8+YI35\-+UGE0;DQ#=0H)",EA8^8=JAE)]AP/=6"US-$W"%,F6WS2]%MS
MCW?K:93M844GO2>."4YR1U'MJ3@Q[#=;%$3$BPI-G=;0Y';#*2R4=4D)(P!X
MCBH^YW71]N3>(5P=MS*&VQ*N++C0VE+A"0MP8PK)P,G)Z5G3-TO"D,AM<!EZ
M?#+J%(;`+T=M(YR!RE*5#`]AXJO6J[]E6H9,:T6]>G9KR$J\GC>3M\`G<H(2
MI/UD@?77+&K>R_C3;$^R!#KX:\@0R`A3I6!C9MVYW8^VIN7JC2;]IFN2;I$7
M!1(-ODA1.`Z?5+13C.3G&,4MVD;2UIJ!IZZQV+Q$@IV,>7L(<P@$[!@C&4IP
MG/CBI=JU6QI,-+5NB(3"SY*$LI`8R,'9QZO'LQ6O%T[8(ER7=8EDMS%P7DKE
M-1D)=5GKE8&>:TUZ5MRKY:KDVA#+%L2\J/#9:2AL/.<*=('56,@?WB>M2\BW
M0)+XD2(4=UX-J:#CC25*"%?.3DCH?$=#7!MMN(B`P(Q$/'DP+2?D.,>IQZO'
M'&.*UHVGK#%F";&LEN9E@E7?MQ4)7D]3N`S729IK3LZ0Y)FV&V27W.5NO1&U
MJ5QCDD9-;+5HM3*)"&;;#;3)2$/A#"0'4@;0%8'K`#C!\*V8T=B)';C16&V&
M&T[4-MI"4I'L`'`%9:4I2E*4I2E*4I2E*4I7AO:U"NFLM8^CMMLKESBVJVN*
M=2)"6$MR7TE+:LJX44I`4![ZB)3,W7S'9NR^MZ)=&XEQ94_@A4>8PEO8L_[Z
M`?>":CT7&6Y:I=YOD)R`\UKF&_-;V*4&MC:>\(`!)3E)(]V*]%TA)8U#VKW?
M5%B;<-B%I;AN22RIM,F1WF[("@"=J>"<5N65M0[:]2K*"$&TQ`#CCYQKR)5G
MOG_(P9OGR7Y#YUQYJ\E;VY\KQNW[=_7UNM6-%[%FUEK%#^N#I]"[N7?)U6CR
MKOD]VCUMV#CIC'NS5Y[9&(UXTA:V%(4_#EW6"%A((W-J<&?>.#5%MEQN^D-7
M:D7=VGGW-/Z:\EB25`J\L0'\QU'^T0M*3[TFM?L\@WW1VI[0B[V!^*Q?K<Y%
MD+\I0Z94H;G@LX^8H[B@!7M^NL6E+@VU<])66U7$7J/'N"4HL=QMG=S;0G)W
MN%U&!ZG4[N#G]6)RYP+CV7S=#PVGI6IY-U>$:*B.O+:C+*@X5[<)`3SG-8]6
MHU)>;UJ#6=MLCTYNQ2F&H,\R$H[H1>7L-GUEA:E*Y'^=6&%JZTZ5U#K*^7R&
M^Z;VB-+MBE-Y\NCEL#N4*(QN3G!2:E^SIIP=A=S*>&W6+BIA@*W%E!+F&S["
M.>/#-16E-*W^XZ6TO?[M.@)AV>S/&#'BQEI>5WC!3AU2E'.!_5`R?"H&!9[X
MUHWLMF/WR5*A+O4'9;E16THC^LOUMZ4[SCGYQ\?JK#J=>H;G?[YVB6^Q/28U
MJN;1AS1(2G8Q&)2XD-GUE)65*)(_^:M;Z-07+66O[AIJ;#CQGK9!</ED-3W?
M),=92$^L`#C.<A74<52G8_<6[0MXM\-X&RV'SBELDK45-RVRZ,X'4%SCPSBM
MVS2KAIVV:PN;;+OG>[VJ&XV`D[C(ENO$`>](<_\`MK69L>I+%;M2Z-18G[>J
M]6-#D5E,A+_?/QPE+N"C@%Q&X[?;@>->A:;U'HN_W'2EOLMC=E7&VLDEQ#2V
M?-`#>%;R0`<G*=O.3S58['+^W"M^G+9+UR62%EKS(JSG(4I:@E'?[<]5`Y^R
MHJ1/9]!+CH(I?]*'=1DHM_<J[Q2?*`O?TQMV@G=G%>I7IM1[:M-+""4>:)>3
MCCYPKS>YLK8GW:[38+TFSV[72Y4]M+16`UW8`<*<>LE)_P"-6FZ:SL"X>K=5
M:3M+[LD06X;=W;0M")<A9VMMI00-Q22"58XQC/2JKIN!>-&/76Q7"PN6Z/>M
M..H3B0E\/2V&5;EY3PDJ"E<'GIUKT#L@UIIV5IW3FEV9CQN[4!"%L*BNI"5(
M1ZPWE(3QCVU3.U5EY=Y[1MC2U;K'`"<))W?+IXKMYNN5DUU'TRZRZY;;=9[D
MJVR3DE4=U`*6R?:A04GZMM8[9<X.HM.=F>G+&AZ1?+;,AORE)86D0VFT_*E2
MRD#GIC/-<]GNH&K8\W#E:Y,!L7:1NLZK.7"L*?5A/?;<C=D<^&:Q71V*>U)>
MN$VIU>DHES;ARG`5;5S$H4GRL-XP4H)"=WMYZFOHD$$`@Y%<TI2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E<;1G.!FN:5P0#U%$I2@;4I"1DG`&.O)KFE*4I2
MN`D#)`'-<UQM&<X&?;7-,5P``,`8%<TI2E*8I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I4#K+43>EK!*O3
MMOES6V$E2FXR02``3DDGA/')J)OVN?,\V,VY8;@[`68R7IPVI;;4^K:A*0H@
MN$'YP3G`KC3NO8M[O;-O3:Y<:-,1(7;YCJD%$M+*]CA"0=R>3D;AR.:E+GJZ
MSVRYBURDW$RR"I*&;;(="P`"2E2$$*QN&<'C/-8O3.T_1+Y\%E_=T],[3]$O
MGP67]W3TSM/T2^?!9?W=/3.T_1+Y\%E_=T],[3]$OGP67]W3TSM/T2^?!9?W
M=/3.T_1+Y\%E_=T],[3]$OGP67]W3TSM/T2^?!9?W=/3.T_1+Y\%E_=T],[3
M]$OGP67]W3TSM/T2^?!9?W=/3.T_1+Y\%E_=T],[3]$OGP67]W3TSM/T2^?!
M9?W=/3.T_1+Y\%E_=T],[3]$OGP67]W3TSM/T2^?!9?W=/3.T_1+Y\%E_=T]
M,[3]$OGP67]W3TSM/T2^?!9?W=/3.T_1+Y\%E_=T],[3]$OGP67]W3TSM/T2
M^?!9?W=/3.T_1+Y\%E_=T],[3]$OGP67]W3TSM/T2^?!9?W=/3.T_1+Y\%E_
M=T],[3]$OGP67]W3TSM/T2^?!9?W=/3.T_1+Y\%E_=T],[3]$OGP67]W3TSM
M/T2^?!9?W=/3.T_1+Y\%E_=T],[3]$OGP67]W3TSM/T2^?!9?W=/3.T_1+Y\
M%E_=T],[3]$OGP67]W3TSM/T2^?!9?W=/3.T_1+Y\%E_=T],[3]$OGP67]W3
MTSM/T2^?!9?W=/3.T_1+Y\%E_=T],[3]$OGP67]W3TSM/T2^?!9?W=/3.T_1
M+Y\%E_=T],[3]$OGP67]W3TSM/T2^?!9?W=/3.T_1+Y\%E_=T],[3]$OGP67
M]W3TSM/T2^?!9?W=/3.T_1+Y\%E_=T],[3]$OGP67]W3TSM/T2^?!9?W=/3.
MT_1+Y\%E_=UDC:PLS\V+#VW)EV4YW3)DVR0RE2]I5MW+0!G"3X^%6*E*4I2H
MG5-G3J#3ESLBGRPF='6P70G<4;AC.,C-5J^:)N5RU%;;PSJ)#3=O:0B-%?@!
M]MM8^<Z`5@!9Z;L9`Z5SIC0#=BO$>8J[O2HD!$ANVQ%-)3Y*E]86L%8Y7T`&
M<8'MJ1O'X>Z:_P`)._T*M-*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E5?67].TI^F4?L'JM`Z"E*4I2E*55KQ^'NFO\`"3O]"K32E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I57UE_3M*?IE'[!ZK0.@I2E*4
MI2E5:\?A[IK_``D[_0JTTI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*55]9?T[2GZ91^P>JT#H*4I2E*4I56O'X>Z:_P`)._T*M-*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E5?67].TI^F4?L'JM`Z"E*4I2H
M;56HK=I:SO7>Z>4&,T#D,,J=4>">@''3J<#VD5%7C7MCM-P:A2$3%DH9<?>:
M8W-1$NJVMEU6?5W*X&,UWL>N;+>[T;3$3,2M275QY#K.UF6&E['"TK/K;5'!
MX'M&17%U>:7V@:=;0ZA2T1)VY(4"4_[#J/"K.9#`?$<O-AY0R&RH;B/JZT<D
M,-NH:<>;0XOYJ5*`*OJ'C1^0Q'"2^\VV%'`WJ"<G[:Y??9CMEQ]U#:!^,M02
M/UFO!-:=O<K3>J;G8VM.,26X;Q;2\993O&`<XVGVUZ3V5ZU<USI=R^/P402B
M2MDMI=WC"0DYR0/ZU7)A]F0CO&'4.HSC<A04,_97#,AA\K#+S;A0<*V*!VGW
MXHB0PXZME#S:G4?.0%`E/UCPIY0QWXC]\WWQ&>[W#=CZNM')##;J&G'FT.+^
M:E2@"KZAXT?D,1PDOO-MA1P-Z@G)^VN7GF6$=X^ZAM&<;EJ"1^LURIYI+7?*
M<0&L;MY4`,>W-$.M.-!Y#B%-D9WI4",?77##[,A'>,.H=1G&Y"@H9^RN&9##
MY6&7FW"@X5L4#M/OQ1$AAQU;*'FU.H^<@*!*?K'A3RACOQ'[YOOB,]WN&['U
M=:.2&&W4-./-H<7\U*E`%7U#QH_(8CA)?>;;"C@;U!.3]M<O/,L([Q]U#:,X
MW+4$C]9KE3S26N^4X@-8W;RH`8]N:(=:<:#R'$*;(SO2H$8^NN&'V9".\8=0
MZC.-R%!0S]E<,R&'RL,O-N%!PK8H':??BB)##CJV4/-J=1\Y`4"4_6/"GE#'
M?B/WS??$9[O<-V/JZT<D,-NH:<>;0XOYJ5*`*OJ'C1^0Q'"2^\VV%'`WJ"<G
M[:Y>>981WC[J&T9QN6H)'ZS7*GFDM=\IQ`:QNWE0`Q[<T0ZTXT'D.(4V1G>E
M0(Q]=<,/LR$=XPZAU&<;D*"AG[*X8D,2`HL/-NA)P=B@K!^RC<AAQU;3;S:W
M$?.2E0)3]8\*>4,%_P`G[YOOL9[O<-V/JZT7(8;=0RMYM+J_FH*@%*^H>-'I
M##!0'GFVRLX3O4!D^[-<OOLQT=X^ZAI&<;EJ"1G[:Y6\TVT7G'$);`SO4H`8
M^NB7FE,]\EQ!:QNWA0*<>W-<,O,OH[QEU#B,XW(4%#]8KAB0Q("BP\VZ$G!V
M*"L'[*-R&''5M-O-K<1\Y*5`E/UCPIY0P7_)^^;[[&>[W#=CZNM%R&&W4,K>
M;2ZOYJ"H!2OJ'C1Z0PP4!YYMLK.$[U`9/NS7+[[,='>/NH:1G&Y:@D9^VN5O
M--M%YQQ"6P,[U*`&/KHEYI3/?)<06L;MX4"G'MS7#+S+Z.\9=0XC.-R%!0_6
M*X8D,2`HL/-NA)P=B@K!^RC<AAQU;3;S:W$?.2E0)3]8\*>4,%_R?OF^^QGN
M]PW8^KK59UDXWYSTHUWB>\-X0H(SSCN'N<5:QT%*4I2E0NL;0[?]+7>RLO(9
M=FQ7&$N+!(25#&3BJAJ+L_N-SN<E46Z1F;;<X\-BY-N,J4[B.O<DM*!P-P]4
MY!QUK+I+0EPLUY@/S+G&D6^T(EMVUMIE27=LAP+5WJB2#M`P,`9ZFI*XP84?
MM&L4MB'':DR(DWOGD-A*W<=QC<H#)Q[ZLR[9;5W%%S7;XJI[:=J))9274CG@
M+QD#D^/B:2;7;9<MB;*M\5^5'Y9><92I;7.?541D?92X6NVW-+2;C;XLP-*W
M-B0RES8KVC<#@UVN%O@W*,8MQA1Y<<D$M2&DN))'0X((KYCUIV(:YO.I;M=H
MYLW<OO*6TVV\IO"/Q4A)3@<`#KBICL9N>HM-::EV7T?:NR6)KOG&W-.;)T,$
M)&XM+X=2H#@)_P`\\>WZ8GZ6=MZ!IU=O9C+=*>XCH2R4NXY2IO`*5X'((!XJ
M3@6NVVY3RK?;XL0OJWNEAE+?>*]JL`9/)Z^VD>UVV--?GQ[?%:F/\.R&V4I<
M<_O*`R>@ZT-KMIN(NAM\4W`)V"5W*>]"<8QOQG&/?23:[;+EL395OBORH_++
MSC*5+:YSZJB,C[*7"UVVYI:3<;?%F!I6YL2&4N;%>T;@<&N]P@0;E',6XPH\
MN.2%%J0TEQ)(Z'!!%<NP83T(P'HC#D,H#9CK;!;*1T3M(QCW4CP84:&(,:(P
MS$2DI##;82@`]1M`QCDUUMUNM]LC^36V#&AL;BKNH[26TY]N$@#/%=8%KMMN
M4\JWV^+$+ZMSI892WWBO:K`&3R>OMI'M=MC37Y\>WQ6IC_#LAME*7'/[R@,G
MH.M#:[:;B+H;?%-P"=@E=RGO0G&,;\9QCWTDVNVRY;$V5;XK\J/RR\XRE2VN
M<^JHC(^REPM=MN:6DW&WQ9@:5N;$AE+FQ7M&X'!KO<($&Y1S%N,*/+CDA1:D
M-)<22.AP017+L&$]",!Z(PY#*`V8ZVP6RD=$[2,8]U(\&%&AB#&B,,Q$I*0P
MVV$H`/4;0,8Y-=;=;K?;(_DUM@QH;&XJ[J.TEM.?;A(`SQ76!:[;;E/*M]OB
MQ"^K<Z6&4M]XKVJP!D\GK[:1[7;8TU^?'M\5J8_P[(;92EQS^\H#)Z#K0VNV
MFXBZ&WQ3<`G8)7<I[T)QC&_&<8]])-KMLN6Q-E6^*_*C\LO.,I4MKG/JJ(R/
MLI<+7;;FEI-QM\68&E;FQ(92YL5[1N!P:[W"!!N4<Q;C"CRXY(46I#27$DCH
M<$$5R[!A/0C`>B,.0R@-F.ML%LI'1.TC&/=2/!A1H8@QHC#,1*2D,-MA*`#U
M&T#&.372WVZWVR/Y-;8,:&QN*N[CM);3GVX2`,\5Q;[7;;8'4VZWQ88=5N<$
M=E+>]7M.T#)I&M=MB2Y$V+;XK$J0<O/-LI2MWG/K*`R>?;06NVBXFZ"WQ1<"
MG:97<I[TIQC&_&<8]])%KMLF:Q/D6^*[,8X:D.,I4XW_`'5$9'4]*3[7;;BI
ME5PM\666%;FB^RESNU>U.0<'@=/97:XVZWW./Y-<H,:8QN"NZD-)<3GVX4",
M\UVD084J&8,F(P]$4D)+#C84V0.@VD8QP*-083,(0&8C#<,(+8CH;`;"3U3M
MQC'NKB!`@VV,(MNA1XD<$J#4=I+:03U.``*Z6^UVVV!U-NM\6&'5;G!'92WO
M5[3M`R:1K7;8DN1-BV^*Q*D'+SS;*4K=YSZR@,GGVT%KMHN)N@M\47`IVF5W
M*>]*<8QOQG&/?21:[;)FL3Y%OBNS&.&I#C*5.-_W5$9'4]*3[7;;BIE5PM\6
M66%;FB^RESNU>U.0<'@=/97:XVZWW./Y-<H,:8QN"NZD-)<3GVX4",\UVD08
M4J&8,F(P]$4D)+#C84V0.@VD8QP*-083,(0&8C#<,(+8CH;`;"3U3MQC'NKB
M!`@VV,(MNA1XD<$J#4=I+:03U.``*Z6^UVVV!U-NM\6&'5;G!'92WO5[3M`R
M:1K7;8DN1-BV^*Q*D'+SS;*4K=YSZR@,GGVT%KMHN)N@M\47`IVF5W*>]*<8
MQOQG&/?5<UG$B&]:3G&*R9:;LAI+Y;'>!!9>)2%=<9\*MXZ"E*4I2E*55KQ^
M'NFO\)._T*M-*4I42[IZS.:@9U&J`WYV994PF2DE*BV>J3@X5[LYQX5YR_`T
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MK\<IZ$?7UP:B=0:`MD]+[ML3'ANO*[QZ,['2_#DJ]KC!XW?VT;5^\U\O=O=P
MO4O7KD:],LQWH49IE#,=XN-`;=VY&0"`HG.",C@'.,UZM_)/ER';'J"&XZI4
M=B2TMM!/"2I*MV/KVBOH&E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E5?6
M7].TI^F4?L'JM`Z"E*4KRW54V%`[9]-2+A+CQ6!:90+C[@0G)4,#)XK!V</1
MKAVI:]NED<;<LJQ%:4ZR06GI`3ZY21P<<Y(]OOKUFE*JUX_#W37^$G?Z%6FE
M*4I2H#6&EK9JNV"'/2MMYI7>19;)VO17!T6A74'('UUBAW-C3D:Q634E_;D7
M>8"RU(<;[KRIQ(R>!D`X(ZGD^\UXSVM]D&J]7:YFWRU.6Y,1YMI*>_?4E64H
M"3D!)\16U_)^T!J"QO.WR1>1&84ZMA^WM'O$O;"M"DK!QL6E:001GC(\:]^2
MM*L[5`X.#@]#7:E*4I2H75.IK+I2UJNE]FIBQ@H(22"I2U'HE*1R3Q4=HK7N
MF=:H?\Q3BXZQ@NL.H+;B0>AP>H]XS5KI2E*4I2E*4I2E*4I2E*4I2E*4I2E5
M?67].TI^F4?L'JM`Z"E*4J)O&GM/WEQMV\V6W3UMI*4*EQD.E`ZD`J!P*W+;
M`@6V(B);8<>)%1\UJ.V$('U`<5M5!775FGK1=8]IN-T9CS9`24-J"C@*5M25
M$#"03P-Q&37-KU7IZZW>59K?=&7Y\8*+C*<_BG:K!(PK!X."<'@UI7C\/=-?
MX2=_H5::4I2E*5%:EL%JU+:'[1>(J7XKHZ'A2%>"DGP4/`BO*]1:RO/918FX
M%^G1[X\Y+2W;%DD2%Q$XWJ>Z#<!ZH(/)()Z&KEI>=%1J:4(3@<M6H(R+O"6.
MA7A*'@/?CNE8]JE5+0;)9M,RK[?6G7(S4Y7E<Q*W3W*%)2=S@3T22.5'QQ4S
M!F1;A#8G0I#<B*^@.-.MJW)6D]"#6Q2E*4KY^_E!VG4>LIC%MT_I^Y2&[(E3
MLA_:$MO%P)PEH'EP@#G'3D5%_P`G;0&J+-JF3?KS;I%MBMQEL)0^G:MY2BG\
M7KM&,Y]N,>-?23;C;J`MM:5H/123D&N]*4I2E*9I2E*4I2E*4I2E*4I2E*4J
MKZR_IVE/TRC]@]5H'04I2E>0ZOB(UAVMP]'WIY\6&-:#/5$;>4VF4Z7-OK%)
M!(`]_@?::[Z#B^BO:E>M%VN1(783;6Y[4=UTN"(X5A)2DG)`(.<?57K=>3Z\
MT9J6\ZO,^WADQ7D0TH>\J[M+!9>+BBZSM(D`_B@G@^SK671.CK_;+Y:!<F8K
M<"Q-3FF)#3^]<T2'0M)*,#9M`YR3D]*G9ELAP^TFRS6$NA^7%G%TK?6M)([C
MHE1(3_N@5939X!O";P4/>6I1L"O*'-F,8_V>[9X]<9I-L\";<(MPD)>,B*<M
M%$AQ"1SGE*5!*OM!I=K/`NZ64SD/*#*]Z.ZD.-<^_8H9^H\5DNULB7:&8<U+
MJF2H*(:>6T<CIZR"#_G7+]NBOVTVQQ+ABEL-$!Y:5;0,?/!W9XZYS2);HL.W
M)MS"7!&2@H`4\M:L'.?742KQZYKK:+5"L\3R2"EU+.XKPZ^MTY/]I:B?#IFN
MEJL\"U*DJA(>29"][G>2''<GGIO4=O4\#%(MG@1+E)N;"7A*DC#A5(<6D].B
M"HI3T\`*\NU_V+G6NI)%[G:KDM;TI0TP(J5)90!PD'</')^LFH5C2-]T.8R9
M"'KI:M/*%Q@7%MQ39;9WCRF.ML*P<I4I:2,_-QT)`]HNEIME^CQ_+$N/,I/>
M-]U(6V%9'CL4-P(\#D57]3(TEI72\.WSH;\2Q&4AD"$7&T1U+42%+4A0*4;C
MR<XY%6A^W19%L-L<2X8I;#6$O+2K:!CYX.[/'7.:1+=%AVY-N82X(R4%`"GE
MK5@YSZZB5>/7-=;1:H5GB>204NI9W%>'7UNG)_M+43X=,UTM5G@6I4E4)#R3
M(7O<[R0X[D\]-ZCMZG@8KHS;+9;[D_<TEQN5+(0LN2G%)42>`E"E;0>/Q0*A
MY>G;F_KZ!J%FY)8ML>.I+L9)<*I#A!2`H%6P)`(((&<CG/A-S;-`FSXMPD(>
M,B*<M%$AQ"1SGE*5!*OM!I=K-`NZ&43D/*#*]Z.ZD.-<^_8H9^HY%0:=(Z>L
MNG[E#C0II@+=7-5$BR'0H+QDI:"5`C)'"0<$FMRPS;+JS2C+D`R%6Q]ON=JU
M.-.HV^J4DY"@H$8)SU'4U*Q+=%AVY-N82X(R4%`"GEK5@YSZZB5>/7-=;1:H
M5GB>204NI9W%>'7UNG)_M+43X=,UTM5G@6I4E4)#R3(7O<[R0X[D\]-ZCMZG
M@8I$L\")<I-S82\)4D8<*I#BDGIT05%*>G@!0V>`;PF\%#WEJ4;`KRAS9C&/
M]GNV>/7&:3;/`FW"+<)"7C(BG+11(<0D<YY2E02K[0:IO;7=H%CT5(NKX"YS
M"D^1-&2XUN=40G)"%)*P`22.1Q7SMI/M.U1=M3VZVZEN<BYVN=,;:>8WEDIW
M*"0I"FMJDXSG&<'Q%?8$NWQ9EN5;GPX8RDA!"7EH5@8QZZ2%>'7-&+=%8MHM
MC:7!%#9:`4\M2MI_MD[L\]<YKBU6R):88APDNI9"BH!UY;IR>OK+)/\`G6.T
M6>!:$O)@H>2'E[U][(<=Y]V]1Q]0XI"L\"%/E7".AX2)1RZ5R'%I/.>$J44I
M^P"@L\`7A5X"7O+5(V%7E#FS&,?[/=L\.N,TEV>!+N<:YOH>,J,,-E,AQ"1U
MZH"@E77Q!I=;/`NJHRIJ7E&.O>WW<AQK!XZ[%#=T'!S7>[VJ%>(GDDY+JF=P
M7AI];1R/[2"#X],UVEVZ+,MRK<^EPQE(""$O+0K`QCUTD*\.N:,6Z*Q;1;&T
MN"*&RT`IY:E;3_;)W9YZYS7%JMD2TPQ#A)=2R%%0#KRW3D]?662?\ZQVBSP+
M0EY,%#R0\O>OO9#CO/NWJ./J'%(5G@0I\JX1T/"1*.72N0XM)YSPE2BE/V`4
M%G@"\*O`2]Y:I&PJ\H<V8QC_`&>[9X=<9I+L\"7<XUS?0\9488;*9#B$CKU0
M%!*NOB#2ZV>!=51E34O*,=>]ONY#C6#QUV*&[H.#FN]WM4*\1/))R75,[@O#
M3ZVCD?VD$'QZ9KM+MT69;E6Y]+AC*0$$)>6A6!C'KI(5X=<T8MT5BVBV-I<$
M4-EH!3RU*VG^V3NSSUSFN+5;(EIAB'"2ZED**@'7ENG)Z^LLD_YUCM%G@6A+
MR8*'DAY>]?>R''>?=O4<?4.*0K/`A3Y5PCH>$B4<NE<AQ:3SGA*E%*?L`H+/
M`%X5>`E[RU2-A5Y0YLQC'^SW;/#KC-5[6<&.;_I*XD.>4INB60>]5MVEEX_,
MSM)]^,^^KD.@I2E*J>L=$6[4\J'<3-GVR[0@4QY]O>[MU"3U23@@I/L]Y]IK
MMHW15MTJN;*:E3;A<YR@94^>[WCSN.@SC@#V#_XJU4I56O'X>Z:_PD[_`$*M
M-*4I2E*4K%)9;DQW8[R=S;J"A0]H(P17D>@]1772MY>T3J,./VUF=Y!:[CRI
M2,@*99=QTW(4-JO<1X<>ON-MNH*'4)6@]4J&0:A)%ZF,:LB61=EE+A2HZG47
M)OUFT.)/+:QCU.,8)/).*G:5!ZJU)`TS!9E36I;ZI#Z8[#$1DNN/.*SA*0/<
M">2.E=KQIJT7NY6NY7*,I]ZV++L9*EGNTK./6*.A(QP3TJ:I75M:'$!;:DJ2
M>A2<@UVJ,OR;NFRRQI[R--T",QQ*22T59SA6W!YYY]IK/:G9SUMBNW.*W%G+
M:27V&W.\2VO'("O'!\:W*4K5F7&!!7';FS8\=<AP-,I>=2@NK/1*<GDGV"HV
M]+U-YTM;5E8MWF]3FZ>_*6K>E`(]5M*>JB,\DX&.E=[]IBP:A"?/=IBSBAI;
M2%/-@J0E8PK:>H/`Y'(\*I^E>QO16F;TU>8;$M^4R=S(E/!:6E?U@`!R/#.<
M=>O-6W4=HN-S5!<MNH)=I<C.[U=RVAQ#Z>,I6E0YXSCV$YYKG4]]58(K$KS-
M<[DVMT-N"WLAU;0/XY3D$CZLU-9'&>,US2E*4I2E*4I2E*4I2E5?67].TI^F
M4?L'JM`Z"E*4JB=H.H+I9K[HN';WTMLW.ZIC2DEM*M[9'3)''UBKV.E*4JK7
MC\/=-?X2=_H5::4I2E*4I2JC<@FT:ZMMPQB->6O('SP`'V]SC"OK*>]3_P"6
MHMS5MTTUJ]RU:N#(LMR?_P":;HVC8VV3_P#T[OL5[%'K_P`/0J\VO':&=$JG
MIUV&$!<I7FLV\%:Y+'7)03ZI3D`DD`GI6[;==-ZRTM.G:`+$JZ-%+8CSR6NY
M4HXW+`SD8R1@\X(SFKI!1*3"C)GN-.RTMI[Y;22E"EX]8I!)(&<UL5T=<;9:
M6ZZM+;:`5*6HX"0.I)\*\0[4>VVU6ZU2K?I53LV<^A32+@T,1V5="4K/SU#/
MAQR.?"HW^3'K?RJ$_HRX/9?C!3\)2E<J;)RM'V$[A[B?97T)2H755@8U':_(
M'IDV&I#J'FI,-XMN-.).0H'H?J((_P`JQ:BU38-*-0_/]T3$3(W):<>22%E"
M<G)`P#CZLG@5"Z9[4]#ZEG^;[9>VQ+5@(:D(4R7"3@!.X#<?<.:GKR]J5-TM
M;-FAV]<!;FZ?(E.J"FVP1ZJ$`<J()P2<#'-;$^Q6>XW"'<I]LBR9D+/D[SK8
M4IK."2G/0\#GPJ3I2E*AM3Z;M>I[>B!=6W5-MNAYI3+RFEMN`$!25)(.1DUH
MZ[NEUTYI*7=K+$CRW(#?>N-27%#+21E6",DJP/'WU\JV[MOU^Q?&I\JZB5%[
MW<Y"+*$MJ03RD8&1QT.<_77V<TL.-(<`("@#@C!&:[TI2E*4I2E*4I2E*J^L
MOZ=I3],H_8/5:!T%*4I5![3M,:@O[^G)VG';<B9:)WE8$]2PA6!P/4!)Y^JI
MG2'IM_._3#S'^)Y-YK[WW[M^_P#W<8]]66E*JUX_#W37^$G?Z%6FE*4I2E*4
MJ#UE:WKMIV7&B';/;"9$-?\`5?;4%MG_`,R0#[B:Z,)M&M=*1USH3<FWW!A#
MBX[HS@GDI/L*3D>T$5H7+5C&G]30;'=+>85JF-I;A7+>.Y4]S\BK^H<8VYX/
M->8_RB>SS4.IY]MOE@BJG%A@QWHR%`+2`HJ"@">?G$$#G@5N_P`G;0%^THU=
M+I?F3$=FI0TU%*@5!*225*P2!U&!UZU[?52U=JV39YK-GL]@G7F]2&N]:9:3
ML90G.-SCI]5(R/>>GMK-IFWZD>M\].M)5OF*G<>0QF,,QVRG"F]QY<!SR3[_
M``J<CVZ!&AM08\*.U$:&U#*&DA"1[`G&!5;UMHJ)J&"RN"[YLO,)??0)\=(2
MMASWXZI/0CQJ?MC\A$6'$NTF(J[F.%O(8.$J4,!:D)/.W)_S%2%*\\[;],W/
M5>@I-OLZ.\FM/-R$,[@.]"<Y2"?'!R/>*\$[&^S75BM>6RXW.RR[?`MSX?==
MELE&XIZ)2%?.)..1TZ^ROKX=*4I5(T;VB675>I+]8H"AWEL6`VYNR)*!PI:?
M<%\?40?&KO2E='V6I#+C#[:7&G$E"T*&0I)&""/$8KR4]@6A!/<F-^<V@H[D
M,HE80T<Y&T[=W'O)KT>7J"S0+W!L,N>AFXS4*7&9<R.]">#A73/NSDU+4I2E
M*4I2E*4I2E*J^LOZ=I3],H_8/5:!T%*4I59U7JI&GKGIV`J$J0;S.$,+#FWN
MB1G=C!S]7%6:E1UPO=GMLJ-#N%UA1),H[6&7WTH6Z<XPD$Y/)`XKM$O%IF3Y
M-NB7.&_-B_[>.T^E3C7]Y(.4_;4+>/P]TU_A)W^A5II2E*4I2E*&JEI8^:M0
M7W3B_59[SSE"!/'=/$]XD?W70O[%IJ=OMGMM^M4FU7:*B3#D)VN-K\?80?`C
MJ".0:J=\U%:.S#2<)BZS;A.#;3C<=Y])<6^M*2I*%K`P">$@GV>XU+:8U=;M
M4:=%UL;C,N3Y,EU<-+R=[;A22&UG\4Y!&2/#-5QC3FL=5/MS-8795HMZ5AQN
MRVAX@G!R`\^.5'W)P*])XI2E5#7>DE7]$6YVJ7YNU';B5P9R1T/BVO\`K-JZ
M$?\`^P972=SN=ULC$J\6AVU7#*D/QW""`I)P5).>4GJ,^'ZS-4IQ2E<$@#)(
M`%>7ZGU1<M7F=I/L_`>606)U[*L1H8/SDH4/GN8X]7IG/U>?6'L$U39+HS<+
M?K%F&Z@X4Y%2XA>P_.`/O'MR*]RTQ9KO9FY;=QU-+O2'"GN/*VD)4R!G(W(`
MW9R.OLJNF1VMP22Y;]+79H=`P^]&</\`Y@I-6*XWV?:].QKI,T[/DS%A`?@6
MS;(<:41D\DI"@#QD?JJ)M':/8KC<HUK=AWFW3I*]C3,^VNM%2L$XS@I'0]35
M9LW:]`N7:O)TD@M^;"CR>-)_[22DDJY_JGE(]Z1_6KU.3"A2WHSTF(P\[&7W
MC"W&PHM*QC<DGH<'&147$ODEW54VPR++-CLM,)?CSR-S$A/`4,CYJ@3C:>3@
MFIVE*4I2E*4I2E*4JKZR_IVE/TRC]@]5H'04I2E>6=LB)S5RT5=(EHN-R:MU
MU\H?;@1R\L("?8/_`'Q5NTAJKTE\K'H]?+3Y/L_Z4B=QWF[/S.3G&.?K%66O
M']<Z8U,]KE^[6F-(D^5-0D1U@LJCM%ITEP2$N>MMP=PV?C>\"N=`Z7OL#45H
M\MM*X:;.S<&I,Y2T$7`O/A393M45'@%1W`8-6F9!<C=I-EDJN,R0F1%G%+#R
MDEMG_8?,PD$?:35E-M=-X3<O.L\-A&WR(*1W!XQG&W=GQ^=2;;795PBRT76=
M&0P<JCLJ0&GN<^N"DD_812[VUVXI92U=9\`MKW$Q%(!<]RMR5<?5BLEV@N7"
M&8S=PEP5%0/?1%)"QCP]9*AC[*Y?AK=MA@B?*:66PCRIM2>]!`^=DI(S]F/=
M2)#7'MR82ITI]804^4O*273G/)(2!D9]GA72T0'+=$\G=N4R>K<5=]+4DK^K
MU4I&./9XUUM5M=@*DJ<NL^=WR]P$I2"&NO"=J4\<^.>@I$MKL>YR9RKK.?0\
M,"*ZI!::Z?-`2#X>)/6AMKIO";EYUGAL(V^1!2.X/&,XV[L^/SJ3;:[*N$66
MBZSHR&#E4=E2`T]SGUP4DG["*7>VNW%+*6KK/@%M>XF(I`+GN5N2KCZL55^T
M>&MI5HO[,^5`\CD"/+D15)2L1GB$J.5)(PE?=J/'1)JVO0W';88(GRFEEL-^
M5-J3WH(_&R4D9^S'NKRSM5[-M3ZRA6VUPM1M>;X0*R)P)<?=)/KK4A('"3@8
M'B:VNQ?0&H-`(N4.Y3;;*ARREQ)CA?>)<'')*1E)'ZB/>:]$M5M=@*DJ<NL^
M=WR]P$I2"&NO"=J4\<^.>@I$MKL>YR9RKK.?0\,"*ZI!::Z?-`2#X>)/6AMK
MIO";EYUGAL(V^1!2.X/&,XV[L^/SJHG:OK>WZ(N%CEW!Z]%#Y<*8\!30:<V%
M)/>!8R?G#H141IGM2M':-?HMAMAO]H?2E;_>MJ9`6$CE*LA7'U8KU:[07+A#
M,9NX2X*BH'OHBDA8QX>LE0Q]E5[7-BO]QT^RWIN_RH%VA$.,N%0"9)"<%+O&
M"#GKC`/.*Q]GFH&M1:=<C*=GLW6$3&GLS"GRF.[SU(2`?[*L8('M!JQVB`Y;
MHGD[MRF3U;BKOI:DE?U>JE(QQ[/&NMJMKL!4E3EUGSN^7N`E*00UUX3M2GCG
MQST%(EM=CW.3.5=9SZ'A@175(+373YH"0?#Q)ZU&7Z5;].NOZEO.HI46`A&T
MQG%H[C..-J=N\J..@)Y\*@M.O7_6-Q=O%PBR[3IHM!$2"ZI(<FI.=RWFRD[4
MJ!&!D'CQS5D]&XK$.#`M$J39X<,Y2Q;]B$K''"@I)R./#!Y/-;]W@.7&)Y.U
M<ID!6X*[Z(I*5_5ZR5#'V5VF0UR;<J&F=*CK*0GREE20Z,8Y!*2,G'L\:,0U
MM6P03/E.K#91Y4XI/>DG\;(2!G[,>ZN+5!<M\,1G;A+G*"B>^EJ25G/AZJ4C
M`^JH\6%[S5<;>Y?[LZ9J5)$A;C?>L`C![LA``Z^(->6(_D[::8E(E0K_`'MA
MUI06TH*;)0H<@YVCH1FKK";NND[;+O\`K;5DB:U$RE7D\<)9+7JI2M3:4E6_
M.2=IQ4]%,2_NP;[:=0R'((3ZK<1UM3#_`%^=ZI.><8!'2M"!:]42R^W?;RIC
MR>8I<5ZV;6_*63@A+J%)5C'S>#S[?&IZ[P'+C$\G:N4R`K<%=]$4E*_J]9*A
MC[*[3(:Y-N5#3.E1UE(3Y2RI(=&,<@E)&3CV>-&(:VK8()GRG5ALH\J<4GO2
M3^-D)`S]F/=7%J@N6^&(SEPESE!1/?2U)*SGP]5*1C[*QVBVNVY+R7;K/G]X
MO<#+4@EOW)VI3Q]>:0K:[%GRY:[K/DH?.4QWE(+3/.?4`2"/M)HFVNB\*N7G
M6>6RC;Y$5([@<8SC;NSX_.I+MKLBYQIR;K/80R,&*TI`:=Z_.!23X^!'2EUM
MKL]493=UGP>Y7N(BJ0`[TX5N2KCCPQU-=[O`<N,3R=JY3("MP5WT124K^KUD
MJ&/LKM,AKDVY4-,Z5'64A/E+*DAT8QR"4D9./9XT8AK:M@@F?*=6&RCRIQ2>
M])/XV0D#/V8]U<6J"Y;X8C.7"7.4%$]]+4DK.?#U4I&/LK':+:[;DO)=NL^?
MWB]P,M2"6_<G:E/'UYI"MKL6?+EKNL^2A\Y3'>4@M,\Y]0!((^TFB;:Z+PJY
M>=9Y;*-OD14CN!QC.-N[/C\ZJ]K.*LW_`$E-\LD!";HEOR8%/=*/<O'>1C.[
MPZX]U7(=!2E*5'WR\6VPVM^ZW>6B+!8QWCJP2$Y(`X&2>2!66UW"'=;?'N-O
MD(D1)"`XTZCHI)Z&MNE*JUX_#W37^$G?Z%6FE*4I2E*4I6I=8$>Z6R9;9:=T
M:4RMEP>U*@0?^-1&AI\B;IYEJ<O=<8*UP9ASR76CM*O]X`+'N4*L5*4I7S]_
M*%LMUUK=;5:M+P7+E+M*'%3DM%(#'>["A)4H@;B$D[>N,'H154[)=%:\T9K!
MJ^S](RW8C3#B74MO-;]I'.P;O65[$\9]N:^G++>+=?("9ULDI?8)*3@$*0H=
M4*2>4J'BD@$5(5#:D%WC6>;*TU%AN7?U5I1(!"7MI&4DC!R4@@$]#CPK7T9J
MJWZLM/ET-+C#[2RS*B/##L5T?.0L>T>WQJPU3]7ZWB6.4W9K=$=O&HY"<Q[9
M%.58_KN*Z-H]YJ2B6DW:W6F1JRVVYZ[Q"'L-)*VV7<8RC=ST_P`_L-3U*4I2
ME*X4`H$$`@\$&J?&T%:K;J1N^V"1)LZEK*ID.(H"-+&/QFSP#[TX\?;FL%\U
MC8T7>9I+4*9UH3*068\U[+3,H*3SW;P/JJ&2.<&IJU"/I?3T")=K^9`;*8Z)
MLY:4*=*CA"2>A.,#VG&:GLTI2E*4I2M:1.A1G6V9$MAIUSYB''`DJ^H$\ULT
MI2JOK+^G:4_3*/V#U6@=!2E*5XYVVW,2KSI?2B;=.N;+DD7&?$@M!QUQAH\)
MVY&059\1\VMCL"N;B;3>-*2HTF*_99BNZCRT['41W25M[D^!^=[1R*];I2JM
M>/P]TU_A)W^A5II2E*4I2E*4JI-?\S]H#K72+?X_>IYX$ID!*OM4T4G_`/*-
M6VE*55M0WF=(N*=-:<4GSHM(5*EE(4BVM'HM0Z*<5^(CQ^<?5',O8K/"L=O1
M!A(5MW%;CCBM[CSAY4XM1Y4HGDD_\*DL#V56+UII:YRKYI^4FVWO`#BRG<S,
M`Z(?0,;O8%C"D^!QP<MAU*B?*5:;G%5;+ZTG<N$ZK<'$_P#:-+Z.(]XY'102
M:L54/6\C3V@V;MK]48)N;T=,7:E92)3F<MA21P59_&ZA(->7=B':7JO4%P;T
MR\F))>,ER8_,F/$*$<G*VVTCJK<K*?`#C&!D>_1+1:X<^9<8L".S-FD&2^A`
M"W2!@;CXUOTI2E*4I2E:=UMEOO$%V!=(3$N(Z,+:>0%)/V'Q]]5'46FFK;V?
MJT]9-.M7N&V<>;IDM0*VRHJ(0X<D*&?5Y&/;Q7R1,[1=:KO7G)N_SXCC2_DH
M[3JDM,I'1`;^;M``&"#G'.:^R;;JN$QH^QW[4TN-:U3X[*EF0L-H#JT;MN3T
MZ$\U9D+0XA+C:@I"@"E23D$'QKM2E*5C#[)>[@.H[[;N[O<-V/;CKBH<ZFMG
MI,G3*?*E7'N^]5MC+[M"<9&7,;1G!QSUXKXH[5%W=?:'?S>B[Y4)C@2'/!O<
M>[V_V=N,>ZOK_LA7=W.S>P+OI>,\Q_6+V=Y1N/=E6><[-M72E*J^LOZ=I3],
MH_8/5:!T%*4I6F+9;A<S=1!C^<"UW)E=T.]+><[=W7&?"C5MMS5Q>N;4&.B>
M^@(=DI:`<<2.@4KJ0,>-;E*55KQ^'NFO\)._T*M-*4I2E*4I2E5G7T5]RP^<
MH397/M+J;A'2GJLMYWH_WFRM/^]4_"E,38<>9%<#D=]M+K:Q^,E0R#^HUGI5
M7U)>YBI8T[IW8N]O("EO+3N:@-'CO7!XGKM1U41X`$B4T]98EBMXAQ=ZUJ47
M'Y#IW.R'3\YQ:O%1_P`N`,``5*4I47?K%;K[%3'GM*W-J[QA]I90['<\%MK'
M*5#VCZCD<5`,WNY:8<3#U:L/V\D)8OB$!*.>`F0D<-*_MCU#_9/%3M\L%BU'
M'::O-MBW!ELE3:7T!822,9'OQXU%6CL^T99K@Q<K7IZ'%F,$EMYH$*3D$'Q]
MA-6NE*4I2E*4I2NKJ2MM:$K*%$$!0`RD^WGBO#Y'\G73<B0[(>U!>ENNK*UK
M46B5$G)).WK5CG6K6]@8[@M1-;6`)2DPIC2&I;24@#U3C8YP,\@$FK9W,#66
MDVDR8MRM\:6D'N%E460T4JX!VG*3E/3QK?>MTMG3QMEHN*X\EN.&F)<E)D*2
M0,!2@H^N?K/-+8F\Q+&D71UBX75M"BHQD=RAY63M`"B=N1@<G&:^0-6]K>OI
M6IY;[-UE6E+#RD-P65C8SM.-JN,+.1R3U^KBOI_LKU%?-4Z3B7F]6^/%4^D%
MI3+I5WP'!64X]3)!P,GBIFRVJZ0;C<I=PU#)N+4IS+$=QE#:(J,DA*=HR>"!
MD]<"LD+3=C@WR;?XMM9;NLP;7Y0!*UCCCD\#U1T]E2]>>=H&J](6#4NG;??;
M?"DS)[VT//-(4J(WT#A)!(&_`\/QCX5Z&*4I57UE_3M*?IE'[!ZK0.@I2E*\
M0[76X,CM(T]'NEENMYAFVR%*AVPJ[U2@H85ZJT\#QYK>[#E@WG6,>")T"T,2
M641[/<%J5(B*V'<I043M"CT&3T_7[#7!('4XH""2`>157O'X>Z:_PD[_`$*M
M-*4I2E*4I2E",C%5+0F;>+II=>1YHDD1\^,5S*VOL&5-_P#Y=6VJUJ2^R&)C
M-@L;;<B_2F^\2ES);BM9P7W<?B@\!/59X&!DC=TW8HUAA+9:<<D27W"]*EO<
MN273U6K]0``X```X%3%*4I71UMMYI;3J$K;6DI4E0R%`]01XBO#NUZ??>R^S
M0Y.D+L8UME2NZ$!]E+R8YVJ5AHJR4H./F<@'YN!Q5/[+.UO7&H=?66S72Y,N
MPI+JDNH3%;02`VHCD#(Y`KZD'2E*4I2E*4I2E*5$:FT]:]36PVV[,K<8WI=0
M6W%-K;6GYJTJ20014#IVS:QL-V:ANW]J]:=*597/21-8P/5`6GAP9ZE6#4S`
MU5I^X7F98XMT85=(:RAZ*HE#@(&3@*`W#GJG(JGZH[+^SJ[:D9GW:*&KC<'3
MAI$E30E+`*E>J#R<`DXQ[:]%A18T&(Q#ALH9C,H#;3;8PE"0,``>RJ[J;7FE
M]-2TP+I<L3UI"D0V&EO/+!Z82D'KCQK/IG43VHHLN0U8KI;$MD!A5S8[GOL@
M\A.20`1XXZU7!ISM%O&#?-:Q[4RKA<:Q1<''N>=RH'ZA7G&J>PO56I;T_=KA
MJN(ZZL)0DN-K44H2,)!/B<#D^))/C7N&C8%WM>FX-MODQF9-BM]T9#0(#J1P
MDD'G=C&?>,^-3E*55]9?T[2GZ91^P>JT#H*4I2H.7IN%*U5!U,XZ^)D.,Y&;
M;!'=E*R"21C.>/;6.S:7@VC4=]O\9^0J1>5-*D-N%)0DMIVC;@9'!YR35@KR
M+M3C:FE:GL+[-DDR[5!N4%V,IA](!=+ORBEIZ_-`2"?52"HGKQ']FUNN#6KX
M#RK?/8N;3-P3J"2^RM"9"U/@L'>H;7.,D;<X3[*N\QBXM]I-E<ESVGXKD6=Y
M.RB/L4R/D,Y5N.[]0JRF/=?/"9(N3(MH1@Q/)?7*L=>\W>WPVTFQ[J[<(KT.
MY,1X:#\NPN+WBG>?!>X;>/<:7>/=9"6!:[DS"4E>7"[%[[>GV#UDX^OFLEV8
MN,B&6[9.:A2=P(==C]\`/$;=R?\`C7+[,]=L+#,UIN=W82)*F-R0O'*MFX<=
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M<..O&?MKSW4E[@Z5U18I-XU);T7"3&7"FJ4`UEM14ME[NRHX2E:5)Z_CFMJ%
MK0282;98;W;=4:@D.$-F(WW;,='&7'@%*VH3]>5$A(YYJ>T=IR98$SUW"ZHN
MDR:Z'G99B]TXM7(]8[CD`8"0,!(&`*E8D>ZMW.2_)N3#T%8^1C)B[%-=.J]Q
MW>/@.M#'NOGA,D7)D6T(P8GDOKE6.O>;O;X;:38]U=N$5Z'<F(\-!^787%[Q
M3O/@O<-O'N-+O'NLA+`M=R9A*2O+A=B]]O3[!ZR<?7S62[,7&1#+=LG-0I.X
M$.NQ^^`'B-NY/_&N7V9Z[86&9K3<[NPD25,;DA>.5;-PXZ\9^VC#,]%L##TU
MMR=W929*6-J2OP5LW'CW9^VJ5K;L]>UOIZ':;_?5%Z-),CRB+%#85ZI2$[2I
M7MZYJG:;[`V-/7>/>(.KIJ)T916PXB(WA)VD<A1((YY]WLZU<X%_OU@N;S6O
M)$5J"ZH)BSHL8HB9SQO65DMJ/L6`G/11Z5;4,715V,H71A5K4CU8HB^OG'SN
M]W<CQQMKF7'NKESC/QKDRS!0/EHRHN]3O7HO<-OAX'I2ZQ[J^J,;9<F(:4+R
M\'8O?=XGC@>LG;X\\]:[W=BY2(G=VJX-0I&X'O78_?C;XC;N3[N<UVF,SW+<
MIF+-;8FE``D+8WI"N,G9N'7GC/C1AF>BV!A^:TY.[LI,E+&U)7X*V;CQ[L_;
M7%I8N,>&&[G.:FR=Q)=:C]R"/`;=RO\`C6.T1[K'2\+I<F)JE+RV6HO<;$^P
M^LK/U\4A1[JU<);TRY,R(:S\@PB+W:FN?%>X[N/<*"/=?/"I!N3!MI1@1/)?
M7"L=>\W>WPVTEQ[JY<XS\:Y,LP4#Y:,J+O4[UZ+W#;X>!Z4NL>ZOJC&V7)B&
ME"\O!V+WW>)XX'K)V^///6N]W8N4B)W=JN#4*1N![UV/WXV^(V[D^[G-=IC,
M]RW*9BS6V)I0`)"V-Z0KC)V;AUYXSXT89GHM@8?FM.3N[*3)2QM25^"MFX\>
M[/VUQ:6+C'AANYSFILG<276H_<@CP&W<K_C6.T1[K'2\+I<F)JE+RV6HO<;$
M^P^LK/U\57[YHB)J.5(<U(J+-9!S"4S&+$B)SD$/A94?U`>ZOF76\K7$S4\)
MZTQM3R8MC46[;,E17%O+PK/>J.SDDXZCYH2#XU[;HS1DB\NZ?UE/U'?9+[82
M\["NV\%IX9"@E*5("`#QRD@CGQKTFZ0)[TB/(MDV+"<2</K<AAY3J/!(.Y)3
MX^WK6:[Q[E(B=W:I[,*1N![UV/WXV^(V[D^[G-=YC,]RW*9BS6V)I0`)"V-Z
M0KC)V;AUYXSXT89GHM@8?FM.3N[*3)2QM25^"MFX\>[/VUQ:6+C'AANYSFIL
MG<276H_<@CP&W<K_`(UCM$>ZQTO"Z7)B:I2\MEJ+W&Q/L/K*S]?%(4>ZM7"6
M],N3,B&L_(,(B]VIKGQ7N.[CW"@CW7SPJ0;DP;:48$3R7UPK'7O-WM\-M5[6
M;4SS_I)X2VQ"%T2E4?N?6*^Y>PK?G@8XQC[:N0Z"E*4KR[M6U7<K)>;%:V[X
MC3MLG)=4_=U0Q(VK3C:V`?5&<]3_`.QJ=[-+G>+C;IOG.\VV]L,R-D2YP5(_
MG#>,^NA/"%CQ'O\`M-TI2JM>/P]TU_A)W^A5II2E*4I2E*4I7R7_`"ITJ.O[
M?M23_P`UM]!_^*Y4C_)12H:AO^X$?S-OK_WE?4=*4I2E*4KHZVV\VMIU"5MK
M!2I*AD*!Z@CQ%5%>G+E8%%_1TAM$4'*[++4?)E?]TKDL'W`%']D=:DK%J>#=
M)*[<\T];KPTG<[;I@"70/ZR<$AQ']I!(^H\5/TI2E*4I2E*4I2F*4I2E*4I5
M7UE_3M*?IE'[!ZK0.@I2E*J&MK=JJ3(@S-.2+>^RT%HEVNY)^0DI/16X))"D
M_J/_`!T.S32$[3LJ_76XM6Z)(N[S:_(+8"(\9*$D#;D#*CDD\5?J4JK7C\/=
M-?X2=_H5::4I2E*4I2E*5P4)4<E()]XHE*4_-2!]0KFE*4I2E*4I49?+%:[[
M&3'N44.=VK>TXE10XRO^LVM.%(5[P15%U=J/4O9O8GKC+:1J2U-*0A#[CHCR
M6MRL`.824N#^TD`^T'E54BR_RBO.EXM]M&DNZ\KDML=YY?G9O4$YQW?.,U]"
M4I2E*4I2E*4I2E*4I2E*J^LOZ=I3],H_8/5:!T%*4I2E*4JK7C\/=-?X2=_H
M5::4I2E*4I2E*4I2E*4I2E*4I2J-VPZ<N>J]"3;+:$-JF/.-*2'%[$X2L$\_
M4*^?K)V'=H=OO-OGI8MJ3&DMNA2Y(4D;5`Y(')''05]*V;4R7IPLM[BFUWO!
M*6%JW-R0.JV'.`XGW<*'BD59:4I2E*4I2E*4I2E*4I2JOK+^G:4_3*/V#U6@
M=!2E*4I2E*JUX_#W37^$G?Z%6FE*4I2E*4I2E*4I2E*4I2E*4I2H^\VBW7N$
MJ%<XJ'V"0H`Y"D*'125#E*AX*!!%5KRR^:1&VZJD7JP)Z3T(WRXB?_QD)'RJ
M0/\`K$C</QDGE56Z#,B3XC4R#):DQGD[FWFEA2%CV@C@UGI2E*4I2E*4I2E*
M4I2JOK+^G:4_3*/V#U6@=!2E*4I2O'.T>ZPF]>6ZWMZED0;EF,\5O3C'BPF0
MYE>$`@/..CU=J@>.<@5J]F]SN$O6$`*N,Z1<G&;AZ017GEJ1&<2^`P-A.UOC
M(2$@9%7>8JZ'M)LHFLPT0Q%G>3*9<4IQ0^0SO!2`/L)JRE5Z\\)2&(/FG9RX
M75]_NQ_5V[<9Q^-2:J]"X11!8@K@D_SE;SJTN)&?Q$A)!X]I%+NJ])2QYG8@
MNJ*_E?*W5M@)_L[4JR?KQ62[*NB89-H:B.R]PPF6XI",>/*4J.?LKE]5R%L*
MH[44W'NQA#CB@UOQR-P!..O.,^ZD15R-N2J8U%3<-AW(9<4IK=SC"B`<=/"N
MEH5=E1,WEF&U*W'U8CJG$;>,<J2DYZ^%=;4J]*5)\[,06TA?R'DKJUE2>?G;
MDC!Z=,^-(BKT;G)3+8@IMP'\W6TZM3JCQ\Y)2`/'H30JO7GA*0Q!\T[.7"ZO
MO]V/ZNW;C./QJ357H7"*(+$%<$G^<K>=6EQ(S^(D)(/'M(I=U7I*6/,[$%U1
M7\KY6ZML!/\`9VI5D_7BLEV5=$PR;0U$=E[AA,MQ2$8\>4I4<_97+ZKD+851
MVHIN/=C"''%!K?CD;@"<=><9]U(BKD;<E4QJ*FX;#N0RXI36[G&%$`XZ>%=+
M0J[*B9O+,-J5N/JQ'5.(V\8Y4E)SU\*ZVI5Z4J3YV8@MI"_D/)75K*D\_.W)
M&#TZ9\:1%7HW.2F6Q!3;@/YNMIU:G5'CYR2D`>/0FA5>O/"4AB#YIV<N%U??
M[L?U=NW&<?C5S+5>!<8J8;,)4`_TA;KJTNI_N)"2#]I%<755Z2J-YI8@N)*_
ME_*G5H*4\?-VI.3UZX\*[7=5V3$S9F8;LK</5ENJ;1M\>4I4<]/"N\Q5R%N4
MJ&U%5/V#:AYQ26MW&<J`)QU\*,*N1M@5(:BIN/=G*&W%%K?X#<0#CISC/NKB
MTJNBH8-W:B-R]QRF(XI:,>'*DI.?LK':%7I27O/#$%I07\EY(ZMP%/\`:W)3
M@_5FD)5Y-PEB<Q!1!!_FRV75J<4,_CI*0!Q[":)5>O/"DEB#YIV<.!U??[L?
MU=NW&<_C4EJO(N<9,1B"JW$?SA;KJTNI//S4A)!\.I%+JJ])5&\TL07$E?R_
ME3JT%*>/F[4G)Z]<>%=KNJ[)B9LS,-V5N'JRW5-HV^/*4J.>GA7>8JY"W*5#
M:BJG[!M0\XI+6[C.5`$XZ^%&#<3;`J0U%%Q[LDH0XHM;_`;B`<=.<9]U5&/I
MR_0.\N]H5;[=<W7%+DVUIQ:X$O\`M'*06W#_`%TCK\X*K<T=J>9=GYEOOL2-
M:[Q'.XV_O5*<#?3?DI`6G/12,I]I!XJ;A/78SY8G(MR((/\`-ELOJ4XH9_'2
M4@#CV$UV2N]>>"DL0?-.SAP.K[_=C^KMVXSG\:DM5Y%SC)B,056XC^<+==6E
MU)Y^:D)(/AU(I=57I*HWFEB"XDK^7\J=6@I3Q\W:DY/7KCPKM=U79,3-F9AN
MRMP]66ZIM&WQY2E1ST\*[S%7(6Y2H;454_8-J'G%):W<9RH`G'7PHPJY&V!4
MAJ*FX]V<H;<46M_@-Q`..G.,^ZN+2JZ*A@W=J(W+W'*8CBEHQX<J2DY^RL=H
M5>E)>\\,06E!?R7DCJW`4_VMR4X/U9I"5>3<)8G,0400?YLMEU:G%#/XZ2D`
M<>PFB57KSPI)8@^:=G#@=7W^[']7;MQG/XU):KR+G&3$8@JMQ'\X6ZZM+J3S
M\U(20?#J12ZJO251O-+$%Q)7\OY4ZM!2GCYNU)R>O7'A7:[JNR8F;,S#=E;A
MZLMU3:-OCRE*CGIX5WF*N0MRE0VHJI^P;4/.*2UNXSE0!..OA1A5R-L"I#45
M-Q[LY0VXHM;_``&X@''3G&?=7%I5=%0P;NU$;E[CE,1Q2T8\.5)2<_972T*O
M"FW?/#,)IS?\F(CJU@H]IW)3@^X5Q;U7E4R6+BQ!1$"OYLIAU:EJ&3\\%(`.
M,="?&C:KSYW=2XQ!%JV_)N)=67RK`ZIV[0,Y_&]E5[6)G^?]*I+<?S?YT0=^
M]7>]YW+_`!MQC;CQSG/A5R'04I2E*4K@H23DI!/U4``)(')JKWC\/=-?X2=_
MH5::4I2E*4I2E*4I2E*4I2E*4I2E*4I5$[9+7;Y_9[?9$N*AQ^'"=>CN]%M*
M">J5#D9Z$=".#FOAHK<R?65^LU^@NEKW:;S:V%VNX,2N[;0EQ+:\J;.!PI/5
M)]Q`J;I2E*4I2E*4I2E*55]9?T[2GZ91^P>JT#H*4I2E*4I56O'X>Z:_PD[_
M`$*M-*4I2E*4I2E*4I2E*4I2E*4I2E*4K6N,&)<H,B!.80_%D(+;K2^BTGJ#
M51_Y*^SW\U+?_P"4_P#S4U=]*6*ZK;?D0@W,:2$M3(RU,R&P!P$N((5CW9Q[
MJCC&UE9>8<MC4,,?]3,Q'E)'N=2-B_\`>2GWJK9M^L;1(E(M\_O[1<E\)AW)
M'<K6?["L['/]Q1JRTI2E*4I2E*4I2JOK+^G:4_3*/V#U6@=!2E*4I2E*JUX_
M#W37^$G?Z%6FE*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E:UP@0;E%7#N$1B5&<
M^>T^V%H5]8/%5.9I>99XC[NEK[)@-(;4?(9694;YIX2%$+;]VU0`_JFOC;TZ
MUKQ_]77S_P#7N_O5]9Z!UW9VM$V#SW<Y3<M4)HNOS8[R0XK;RKO5)VJS[<G-
M72!J73UQ(3`OMMDJ/XK,I"C^H&I8$'I7.1[:JCO:'H9EU;+NJ[2AQ"BE2524
M@@@X(-6&VW"%=8+,^W2FI41X$MO-*W)6,XX/U@UM4I2E*4JKZR_IVE/TRC]@
M]5H'04I2E*4I2JM>/P]TU_A)W^A5II2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2NCS:7FEM+SM6DI./81BO)_^0+L^^CW#_P#5G_XKTRR6N)9;1"M,$+$6&REE
MH+5N.U(P,GQK'/L-DN1)N%G@2R?^WC(7_P`143Z!:60LN1;<N"OVP9+L;'V-
MJ`K@:4DL'=`U;J"/[$N2$24__NH4?\Z^%[\E:+[<4K<+BA*=!6<#<=YYP*^L
MNQQ>L4=FUA-N8LC\/N5]VE]YUIS'>*ZD)4/;X5=UW7631PYI.$][XUV!_P`E
MMIKGTDO#8_G.B;TGGJR[&='^3H/^5<(UC'!`DV+44;)QE=J=6!__`&PJOF>_
M=M^OH]]N4>%=&D16Y3J&4N04!24!9"00I.0<8Z\^VOHWLBOMRU+V?6F]7=Y+
MLZ1WO>+2@(!VNJ2.!QT`JZ4I57UE_3M*?IE'[!ZK0.@I2E*4I0UY!H'5%]N6
MHK,N9=E2T7ABX.28&Q`3;U,/!*`G`W#@X.XG)YJR:BNBH^M[2^+1>'V(,>2V
M\['M[KJ,N!HIVE(PKYISCICFI/TRB_D34?P=_P#=IZ91?R)J/X._^[3TRB_D
M34?P=_\`=IZ91?R)J/X._P#NUH736<@>1^;;#?59E-B3WEH?X9YWD<=>G_Q6
M]Z91?R)J/X._^[7/IE%_(FH_@[_[M/3*+^1-1_!W_P!VGIE%_(FH_@[_`.[6
MA>=9R$P%&TV&_+F=XWA+MH?V[>\3O\!SLW8]^*W_`$RB_D34?P=_]VGIE%_(
MFH_@[_[M/3*+^1-1_!W_`-VGIE%_(FH_@[_[M:5XUFZFTS56JPW]=Q#"S&2[
M:']I<P=H/`XSBMQ.LHVT;K'J+..?^9W_`-VN?3*+^1-1_!W_`-VGIE%_(FH_
M@[_[M/3*+^1-1_!W_P!VL<C637<.]Q8]0E[8=@59W\%6./Q?;6"UZS6;9#-R
ML-_3.+"#(2W:']H<VC<!QTSFMOTRB_D34?P=_P#=IZ91?R)J/X._^[3TRB_D
M34?P=_\`=IZ91?R)J/X._P#NUH6;6<A4!)NU@OR)G>.92U:']NSO%;/`\[-N
M??FM_P!,HOY$U'\'?_=IZ91?R)J/X._^[3TRB_D34?P=_P#=KCTRB_D34?P=
M_P#=K1M>LY!\L\Y6&^IQ*<$?N[0_RSQL)XZ]?_BM_P!,HOY$U'\'?_=IZ91?
MR)J/X._^[3TRB_D34?P=_P#=IZ91?R)J/X._^[6A"UG(,^XB98;\(8<1Y&46
MA_<I'=IW;N.N_</#BM_TRB_D34?P=_\`=IZ91?R)J/X._P#NT],HOY$U'\'?
M_=IZ91?R)J/X._\`NUHM:S?\[RDNV&_"VAAHL*%H?WEW<OO`>.F.[QQXFM[T
MRB_D34?P=_\`=IZ91?R)J/X._P#NT],HOY$U'\'?_=IZ91?R)J/X._\`NU$/
M:D8-YC=WI6[FW%ATOK-C=WAW<C9CU>A'>9X\!4HWJZ$T@(;L.H4('1*;,^`/
M_MKOZ91?R)J/X._^[7'IC$_(>H_@[_[M/3&)^0]1?!W_`-VOGO4'99$N.H%S
MVG=3]S.EO/2"=/NCN`K<H8'XWK$)^W->Q:"F0='Z5@Z>;M^I9:(N_#RK(^@J
MW+4KI@X^=CK5C],HOY$U'\'?_=IZ91?R)J/X._\`NT],HOY$U'\'?_=J+N=V
M5?;KIQF)9[TWY/<TONN2;<ZRA"`RZ"2I0`ZJ`^VKX.E*4I2E*5H0K-:(,V3/
MA6N''F2CE]]EA*%NG.?64!D_;6_2E*<4XIQ3BE.*<4XIQ2E.*<4XI2G%.*<4
MI3BG%.*4IQ3BG%*4XIQ3BG%*<4XIQ[J4IQ3BG'NI2G%.*<4XI2E*4I2E*4I2
ME*50+:BY*[1-4VQ=^N*F5VZ*ZQN4@^2E:W@>[3MV\;1RH$G')-487G4+_9U9
MH$&X39-X4_<IJGUK*W7&HCCI2#[=SG<IQTP2,8XJ*BZAD!#3,;5MRD::DOVH
M7&Y+FJ4J,MU#I>0'LY:!4EK<`1MSCU<UZWV53)D[1<5^9*>E@/R$,27R5+?8
M2\L-+)/SLI`Y\1S5RJ.O[+TBS3&H\Z1"=+2BF1'V[T8&>-P(\,=/_FO$;W?'
M/0+18>U7.CWJ?:QY,DW#R5OOL)S)D/$@E*>?5.=Q.,$UENEY?FWF/<+CJ>5#
MTS.F.0%7"-*+#:Q&C$I6EQ)PD./J=/'SMB1R.*BK)J74<J3:W+I>[@SJ!#MH
M1#M_>J0F7'=`[Y:FNCF1N*E'YNT=*^CQ2O'^U^ZB!/0J%J:;%N[*([C-O;E*
M8"D%["EMMA.V2XK&W8HX`YX\:Q?[Y-><EW:=J*X6NW72-<IUL+,I3&]YDH:C
M-@@\Y0DK[L<**^A-7VPR;T>T2SHN5RFJ$S3)E/07"$M,/A;(5M2`.<E7*LGD
M@$#BO2J5X9JW4ERMO:=)7<+@^W`A2H28\-JX+8<<84G+CB60"EY(5NWE70)P
M-O6H&[7F^QX[TN5?KC"NDJ`U=[1#;D*2E^0_*5\EMS\KM;[I&SD`$G'4UZO8
M%SVNTW4D.1=9DJ-YOB/M,O+&Q@K6Z"E"4@`#U1R<DXY)J]4KP.^ZINVG]?S)
M+EV=F"//>6]':N&Y"(0CE0:,4_,4%!/RO0E0`)S@:L:=?K5>HUMGZ@N'G^)+
MM2(T#RA6V4V_Z\HEO/R@"E.@J.=H0G&VO2]".3T:KUO`F769<&XLV.&52E@E
M"51TK*0$@)`R?`#WY/-7NE>6W"5*@:GURW-U5<(T%NSL24OKVJ\B"EO;N[0`
M!G"0!P5'CD\53K3?+G<+=Y#8[W(E>42W+E&BKN(F2HT:.QN2EY042"Z]W?R9
M)P%$>T5GT]<KC/L.H3:]6760PG3;$]^6)/>KCS]KA<:"E@]WD`90,%/&-M>Q
MZ.>=D:1L4A]Q3CSMOCK6M:B2I1;2223U.:F:KNNY$2-IF4[/O$JTQ=S:7)<8
ME*T`K`QN`)0#G!5^*#G(ZUXDWJ'44G3]QC6NZRGWK*;C<`^W)5*06TX;82AX
M\O(&]U04H<EKIP*R3[_&C1KK'8UA=Y5F$QENU+1="A4M]<8%:52U*!2VVLA2
MN<`G!!Z5[EH];[FEK0J3=&+G(\E;#LUA86A]83A2DJ'!!.>?&IFJ'VMW:ZVN
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M5K#33+C#<I:%2I*U<*2IM(2$C!)&1G)Q]!#I2J1VG2;O`MULFVRZN0T)N45I
M]M#:27T./H21N/*1@GIUS58FZAEP.T*4M&JG94&WJ>=ND=7=MQHS`9*FV$)/
MK./9&XJ2>!UQTJLVS4>JF9[1N&HY+=S9GVU+=K44E,AN60XZ"DC<K:%E((.$
MANKAV<72Y3]77%*=4.WFTH86AQU_NT)=EAWDQVAZR6DI]4DY!.,$]:]4I2E*
M4I2E*4I2E*ZA"`LN!"=Y`!5CDBNJ&6D$%#:$D`@$)`QDY/\`G7`CQPTIH,-A
MM1RI.T8/UBLB4A*0E(`2!@`>%<T(R,'I6!<.(XE"5QF5!`PD%L'`]@XKMY-'
M[D,=PWW0Z(V#;^KI78M-%Q+I;07$C"5%(R!]==Z5T6RTXM"UMH4M'S5%()3]
M7LKJ8[!0A!9;*$$%*2D83CICV5WV(WAS:G>!C=CG'LS7:E8ULLN*"G&D*4`0
M"I()P>HHIEI1;*FD$M_,)2/5^KV5V"$!9<"$A9`!5CDBNU*Q+886I2ELMJ4H
M;22D$D>RNQ::4XETMI+B1@*(&0/KKE*$)4I24I"E<J(')^NNU*QK997OWM(5
MO&U64@Y'L-=68L9A16S':;41@E"`#C[*[(890E:$-(2E9)4`D`*SUS[:[I2$
MI"4@!(&`!X5S7"TI6DH6D*21@@C(-=&V66^&VD(]7;ZJ0./9]7-8U0XBFTMJ
MBLE"22$EL8&>O&*S-H0V@(;0E"$\!*1@"NU89<6--C.19D=J1'<&%M/("T*'
ML(/!K`W:K8W'=C-VZ(AAU`;<;2RD)6D#`21C!`'&/96J]IG3C[#,=^P6MUEA
M)0TVN&VI+:2<D)!&`,\X%2C+3;#2&66TMM(2$H0@8"0.``!T%=ZU;A;X%RC^
M37&%'EL;@KNY#27$Y'0X4",UT=M=L>C/Q'K?%<CR%;WFELI*'%<<J!&">!R?
M8*U9.FM.RBV95AMCY:0EMOO8C:MB1T2,C@#P%2X&!@4K#)C1Y38;DL-/("DK
M"7$!0"DG(.#X@@$'PJ.?TSIR1)7+?L%K=DK45*=7#;4M1/4DD9)-;;ELMSLY
MJX.0(JYC2=K<A3*2XA/L"L9`Y/2L$"P6*W23*M]FM\204E)=8C(;60>HR`#C
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M2`\\XK`3D>[)^RJK=.TEQ&D-+7Z$FVQS>'NX>5<'E-LQ5A"RL*4D9X4@IK#<
M.T.YQ86GUIFZ44;J[)29RIKB8;8:`(&\C.XDD8]M9+1K^_:@$"V6:W6SSJ^J
M4I<IQY:X988<#9>;(`4X%*5@=.AYKN=?WI7<6%NTPDZK<NCEM*%.K,5)0T'5
M/9`W%.Q22$\')]U8[CVA7BV:?ER9;=@<EQ[DQ",J/.WQ%)<."XH`E;>WD*2H
M>!(S6&9VE7*!9;?<PU9KTA^YJC.^9GUNA#*&2ZX1N`RL!).WV8JZZ4U(-03+
MXAI+)BP92&H[S:LAYM3+;@5_]]5[6NNKG8I=YB6^U,S'H;,!3#:EE)>7(>4W
MM]V-HQ[S6K.[46VX=SN$&WB5'9M\.1&;W[7%O/NK:[I?@G:I.#[,&K+IB=K)
M5Q?@:IM-O0V&0\S-MKJE,DYP6E)7ZP4.N1P1[*M5*4I2E*4I2M2Z7"+:K=)N
M4YPMQ8S9==6$%92D#).`"3]E4D=K^@"<"[R<_HV3]W4[K#6>G]'Q&95]EN,(
M?"NZVLK<WE(!QZH(!Y'7'6J5V/\`:O%UJJ1;+B!'O(>=<990VHI5'SD'<!@%
M(.TY/.`?&K+>NTO1MDNDBUW*Y/M3(Z@EQ"8+[@!(!^<E!!X(Z&ME.LK9=='W
MG4&GI!D(@L/D*=CN-_*(;WX*5A)(Z54](]H5VN]RTI:9S$9B?*#_`)R;2GP#
M"7F7&^>$J2H'QZ$>%<:6[1;M>-07F+Y)%>B/QI$BP);.U<D,.*;4E9R>5$`C
MIQ4?8=?7\HN`N-SB+GMVE^8Y;95M=@OQ7T(W!*`HD/(Z@G.>,^-3%FU=J&!<
M=+)U',MTJ!J&`[*2Y'C*87$4VR'E!65J"D[21GCD5"V3M8NIL.I+C=H,426(
MK=QM;#9QWD=U9;;WG)Y"MN[IPJK7$NFJ+)JJQVB_W&!<V+T'D!4>*8ZHKS;?
M>8'K*WH(!&3@YQ[:@]<:SU%9=3365RV+1;HX9,)<RW..QIY4`5A<A.0S@Y3T
MXZGK4K/N&LDZS@6>/?[2F'/C/S4*\V%9:;;4@!&>]`7D.?.XZ=.:B6]8:K]%
MF.T)4FWFRO/H/F@1CWB8ZG@V%=]NY<Y!(VX\*W(5]UW?9%UO%C=M*;=`N;D%
MNV/M'?)0VL)6M3V[U%'D@;2.!FM&#VA7J[:SDZ,AF'%F-W62V9;[1V",UMPA
M`S\H\023R`!S@U-]IVL+KI6XZ<3`;CKBRGG%3>\05*#*-FXI.1@@*)\>E1=E
M[1YCCFOIUR1'\UV1'>P"VDA3S>YY`R<\[E-#'3K6BQVBZA;[.[[/N(@,:DM,
MR.R^$-%QI+;RV]J]H5D^JM7&>J:Q/=I5XB6K4LEN?!NC-I$%?EB+>Y%VEU\(
M6VIE:BHG9E04#C)QS6\O7M_DZ"U%K>*J"Q&9=[F!"6T5NL[74H47_6^><YV#
M&!CDYJ1AW?4T^RW69`U/$==A#O"9&FWXH*0A9V[7'`3D@<CICIS4SI&\78Z'
M;U1J*;%D)?@(N`1%BEGN4%K>I'*U;C[^/JJ'TAJR_P!PU!9K;<Q%")^G57A8
M0V04+4\`A`.>@0H#VDC-<6W5VI;CV01-4Q(*)-YD(RI$=A2PA/?%"EI:!RO:
MD;MH/.*WNS34LF^F[1Y-YAW/R-;>QQ$5<20G<#E+K"OFX(X4"01]5;ECO,NY
M6K4T&X[3-M4J1$6M*=H=1LWMKQX$H6G/O!J4T/\`@7I[]&QOV2:G:4I2E*4J
MJ:?_``VU9_X/]D:M=*\/O_\`)^M%YOEQN[NH)S3DV2Y(4A+*"$E:BK`_77I'
M9[I&/HG3J+'%F.RFTNK=[QU(2?6.<8%6BJOJO1\'5-PM+UT?>5"MZW'?)$**
M$NN*3M2HJ20H%/.,'QJ";[,VX,1B+9KY)@HB75RY0CW*7O)RMLH4V-^=R?6)
MR>>:EV-(/NW"RW&]7IRYR;6Y(4@KBMMI6'4!.TI2,>KC(/OJ-1V=^0N)F62]
MNV^XLRI3S+PCH<0EI]86MA39X*`0",$$45V<-""PZQ?)2-0M3UW+SNII"EJ?
M6G8O+?S=A2`G8,8`'-:B>RX!F>LZ@?\`.$V;%GKDHB-)2AY@DIVM@;0GD<'/
M3DG)J<9TG/>DVN3>=1/7%VW33+9)B-LCEI3900C&1Z^<]>,5IV'0RM+*4SIV
M>ZS%DW@3GVE!.U+/=E)9&024\)QC!&!S@<[E\T3'N]UEW%R<\VN3Y#E*4`A/
MDSQ=3_YBK!J-F=EUCE2=4NE^2TU?PTIQMH@>3NH65AQ!\"5G=CIG/MJ8TOIJ
MY6N?(N=ZU--O4UQI+""XVEAIIL'/#:/5W$]5=?JJTTI2E*4I2E*4JK:]T9"U
MO:FK3<KA/C0TNAU:(BTI[T@<!6Y)R!UQ[?JJLZ,['-/Z.OS%\M%UO'E#:5(4
MAUULH<0H8*5`(&1T/7J!7I]:MS@LW*VS+=(*@Q*96PX4'!VJ24G!]N#59>[/
M["Y-MD])DLS+=;EVUE]IP!9:+90-QQRH`D@^!-8(W9CI"(+285M1%=MR%-AY
MA*4.24*;+:DO*`RO*2<]#GD8KK$[.+6UM3,NMWN+3,-V%$;EOI4(C3B=JPC"
M02=OJY5N.!6)OLPLODCD:3=+S+_F*K>PY(E!2HK"@`I+7J@)*D@))P3CBMEW
MLTT>I]+C%H9BMF&Y">9BH2TB2TL#/>8&5$%((5D$$9K'9.SFVVK4L?4BKO=I
M]P8:+"%S74+^3V[0DX0"2!^-G=[216Q?]!V^\SI\E5UNT-JY-I;N$6*^E+4M
M*1M`4"DE.4^J2DIR*FC8(`O-ONZ`XAZ!%<B,(2?4#:R@GC'4;$XY]M5YOLXL
MR'FV_+[H;.W)\K19C('DB7-V\83MW;=WK;-VW/A76;V:6.7<Y,I<RYH@2Y0F
M2K4W)Q$D/9!*U(QGD@$@$`D#BMN9H"QRHTADKEMNNW15V1):="76)!(R4*QP
M.,8YXK?U)I2UZC<C.7(ODL,2&$A"PD%+S?=KSQUQT]AJ$1V8Z;3;EVW,PQ'6
MX;3K9<3AU$8J*$J]7D$J)5[?=6:1V;:76[/5$BFWLSD1TOQX(0RTHLNAU"MH
M3PK(P3XC/UUO7O1=IO,NX2I;DD+GM1FGDMK`&&'>];(XX.[K[16K=.SZQW!=
M^)=FQV[XEORQF.Z$H+B%!0=2"#A?`R?'V>-;]LTSY''GQY%]O-R:F-%I0G2$
MK[L$$$IPD8)S[^@K=BV*#&TRUII(<7;VX0A`+5E1:"-G)]N*J4/L^6[:;(F=
M=YD&\VN$JW"?:W0E3T?.$I5O21R`D],A6<'QK?/9Y9!:46=F3<V+>U#;BM,-
M2RE+10YWB7DCP=W<[O$<8Q7>%H>-&<DR7+[>Y%PDO,./35R4I=6ADDH:]1(2
M&^3E('.3DUS9K')M%HU'*GNMN3[I)D3'N[)*4`IVMH!(&<(2D9QUS4EH?\"]
M/?HV-^R34[2E*4I2E533_P"&VK/_``?[(U:Z4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*T[M_P!%S?\`N'/_`$FH[0_X%Z>_1L;]DFIVE*4I
M2E*JFG_PVU9_X/\`9&K72O/-8=KNC=)W@V>XR9+TU`'>HBL[PSGD!1R.<'.!
MDU=++=K??+7&NUKDHDPI*-[3J.A'U=00>"#R"*WZ@K_JFSZ?N%H@71]3+MU>
M+$96WU=XQPH^'4#[:UY&L['&LUZO+SSJ8EHDN19)[LY[Q!2"$CQR5`#VYK!)
MUU96[19KE%;FW`W@;H,:&QO>>`3N5ZN0!M'7)&*UE=HUB,*V2&(UTDNW!QYI
MN(Q#4M]#C7^T0M'5)3XUEE=H>F8NDUZI=DO"`A_R9:"RH/(>W8+9;."%`]1[
M.:V+MK6U0#;VH\>==)4^/Y4Q&MS'?.%GCY0C("4\@9)Y/`S6_:M1VNZV%=\A
MNK5$;2X7$K;*7&U(SO0I!Y"@000:@(7:7IZ5&=D+9N<1M-O<N31E0E-B1'0G
M<I39/"\`@X!\15A:U!;W;E;;<A3GE%PB*F,91P6T[,Y/@?73Q499M=Z=O,*^
M38$EQQFS*6)1[LCA()*D_P!8':K!\<5HQ>TFP/-%U^-=82%0G)S*ID);0D--
MHWK+9/"B$D''L-9FNT733S6G'$//GS^ZIJ&GN3G<E6T[Q^+A1Q4@WJ^QKU@[
MI!,A7G9MCOU(*/5VX!QN_K8(./945;NTK3L^Z1H3+=Q3&ER#%B7)R(I,22\,
MC8AWQ)(('&#@XK8M&N[==Y`;A6N]*CE;J/+%0%"."V5!7RG3&4D?7Q60:ZLB
M[99+BTF8ZW>DK,-MM@J<64H4LC;[<).!XFM!GM*LSB+DXNV7QANVMK7,6];U
M(2QM1O*5$]%%)!`\<BLEZ[1[!:9S\1R/=)*8B$.3I$2&IUJ$E0W`NJ'S>#GC
M/%25XUII^T7*R6Z7+^7O*@(A;3N2H$@!1/@"5``^.:DH-YA3;O<[0P5^56WN
MO*`I.`.\3N3@^/`J2I2E*4I2E*4I2E*4I2E*4I2E*5IW;_HN;_W#G_I-1VA_
MP+T]^C8W[)-3M*4I2E*55-/_`(;:L_\`!_LC4B_IZ*]J2/J!4RX)D,M]VEA,
MI084,*&2W\TGUCS[A[*7C3T6[7*W7!Z9<&7(*][:(\I33;AR#A:1PL<=#[Z^
M8^U?LGUF_KJZ7&TVMVY0KC(5(;=:4G*"HY*5`D8P>,],8KVW0&@'[9V91=+7
MJ9)9D+67WC"DJ;4THKW;$K3[.,XX/-7=RT,+L)LAD2PQY/Y/WP?4'MNW&[O.
MN[W]<U5-7:*\_7'345Q)>M,.-+CRE.NY=PXRE"%`GDJ!&<]01FJC$T#K5VSQ
MK+-G1$J=U"[=)L\@.=XE"4EHEKC=N6D$ISQB@T'?X=A;LLVSPK]#@71Y^,6Y
M)AR.Y<3N!96E0#2DK*LI)((/'2MJWZ;UQ;3IBZ.1?.DBVR9R_))5R!<88>0$
MMMEXI/>%.#DX]U:[?9WJF;)B>52H,)M^XS+W,^3$E#<AT!MMH(.W>$HW$JXY
M-=K!I;76E$QID2'&NLJ-;G+,E!D);5W2'5.1WQNX(`64J02#P,$U9]%6"_1-
M&WV->F66[U=),R2ZEI8+6]T8&T^">G7GK47![-E1=".1UO2I6HCI]RW-"5,4
MXS&6MD)4EL'U4)*@!D#H!6!S0-PLC\:X:6AH1-189$19=F+4/*E]T$$;R<`;
M5'C`X%:=I[.-2:>,F-#G19T.=I]VV/)#0C]VXE)[I1&3OY4L%77FN9?9M=F+
M?!;@K?DO*TW,MTE,R<IY++[C"$H[K>3L!4%`[<#&.,5K0>S;43&H8<I8C&#`
MN421$0'1EMLDN2OM[S&!XBLC'9_K!-QCZI=F1#<UWAR:_!2A.4LN#NE(#^>0
M&@G"<8S4UHNU:ZLD:S:4<MEK1:K8\>\NJG@X9+(4HI"&<`H<.0"22!@]:T=%
M:2O=EF-M2]/.$F1)*YZ+ZLMI0ZMPA7DOS#@+`Q[>>M-*Z4U6S(T7:[G;8T:%
MIA;RE3D2@X)>4*0C8@#*?G9.['2IJYZ5N\BS=HT1IMKO;XXI4(%P`*!CH1ZW
ML]9)K1%HUOI^ZWY%@M-NGQ[XXV^F5)DA"83G=I0L.-XRXGC(VFH[5_9[JK4U
MROMP\YQ8BT1&(MN`9"BYW1#NX*S\CET>&>*EX$?7-IU1=KPSIN%-3=VH1>W7
M(,]PMMK:L`;%;ADG!XZ>^O3:4I2E*4I2E*4I2E*4I2E*4I2E:=V_Z+F_]PY_
MZ34=H?\``O3WZ-C?LDU.TI2E*4I54T_^&VK/_!_LC5KI2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4K3NW_1<W_N'/_2:CM#_@7I[]&QOV2:G:
M4I2E*4JJRM/7I%]N%UM%^8AB<EH.-/0.^P4)*00>\3U!]E<^:]9?G9`^#_QJ
M>:]9?G9`^#_QJ>:]9?G9`^#_`,:GFO67YV0/@_\`&IYKUE^=D#X/_&IYKUE^
M=D#X/_&IYKUE^=D#X/\`QJ>:]9?G9`^#_P`:GFO67YV0/@_\:GFO67YV0/@_
M\:GFO67YV0/@_P#&IYKUE^=D#X/_`!J>:]9?G9`^#_QJ>:]9?G9`^#_QJ>:]
M9?G9`^#_`,:GFO67YV0/@_\`&IYKUE^=D#X/_&IYKUE^=D#X/_&IYKUE^=D#
MX/\`QJ>:]9?G9`^#_P`:GFO67YV0/@_\:GFO67YV0/@_\:GFO67YV0/@_P#&
MIYKUE^=D#X/_`!J>:]9?G9`^#_QJ>:]9?G9`^#_QJ>:]9?G9`^#_`,:GFO67
MYV0/@_\`&IYKUE^=D#X/_&IYKUE^=D#X/_&IYKUE^=D#X/\`QJ>:]9?G9`^#
M_P`:GFO67YV0/@_\:GFO67YV0/@_\:GFO67YV0/@_P#&IYKUE^=D#X/_`!J>
M:]9?G9`^#_QJ>:]9?G9`^#_QJ>:]9?G9`^#_`,:GFO67YV0/@_\`&IYKUE^=
MD#X/_&IYKUE^=D#X/_&IYKUE^=D#X/\`QJ>:]9?G9`^#_P`:GFO67YV0/@_\
M:GFO67YV0/@_\:GFO67YV0/@_P#&IYKUE^=D#X/_`!J>:]9?G9`^#_QJ>:]9
M?G9`^#_QJ>:]9?G9`^#_`,:GFO67YV0/@_\`&IYKUE^=D#X/_&IYKUE^=D#X
M/_&IYKUE^=D#X/\`QJZ/V;6#[#K*]60-KB"@XM'@1C_MJG[+`3:K/`MB7"XF
M)';8"R,%00D)SCPSBMVE*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2L3DF.T\TRX^VAUW(;0I0!7@9.!XUK.W:V,W-BU.W"
M,BX/H*VHRG4AQ:1U(3G)_P#^^RNTBZ6V,Q(D2+A%98C*V/N./)2EI7'"B3A)
MY'!]HKE5RMR9,>(J?&$F2DK8:+J=[J1R2D9RH>\5D1,B+F.0D2652FD)<<9"
MP5H2HD)44]0#@X/N-9Z5B\H8\H$7OF_*"CO`UN&[;G&['7&>,UR^\S'8<D2'
M4-,M)*UN+.$H2!DDD]`!7+3C;K2'6EI6VM(4E23D*!Y!!KO6)V0PRMI#SS;:
MG5;&PM0!6K!.!GJ<`G`]E8W)T)H22Y+80(J.\D;G`.Y3@G<K^J,`G)]E<><;
M>$.K,Z.$LM!YPEU.$-D$A2N>$D`\GC@UC\[VHL1Y`N40L20I3#@>3M="4E1*
M3G!`2"3CP!-=1>K.68CXNL$LS%;(S@D(VOJ]B#GUC[AFME<R(B8W"7)93+=0
MIQMDK`6M*2`I03U(!(R?>*SUB<D,-.--.O-H<>44MI4H`K(!)`'B<`GCP%9:
MP^5QC+,+RAKRH-ATL[AO""<;MO7&01FLU=77&VFUNNK2AM`*E*4<!('4DUTC
M2&)<=J5%>;>CO("VW6U!25I(R"".""/&N#*C)EHAJD-B2M"G$LE0WJ0"`5`=
M<`J`S[Q6;-*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2HJY:?M-SNEMNLV&E
MV;;E*5%=)(+9/7Z_MKSN]:>N[_:O&N,6QYBK<:<>DOJ;=CN-(2E)4`1O:>3G
M`VY"N#_6KI)T9-M[,L6_3C$B!'U,FXM6U"VTB1'\E2V=H4=N0LE6%8^;GV5&
M6K0>HX4NQ,/VMIY2$VM:IX?0?(!&6M3C0R=QR%!(VC!R<X%6O5MBU#<=4+=@
MF6W;7Q;6WEQY?<DMH?>4^,A04/44C..2.G2H%C2FMD.6:()4WR%]Q<>XJ<G%
M2V&&9BG65`[LJ*VL-G'.",]*BX.E^T=NS7YF8]=G)LA+8443D;7UA_<5M$NY
M`V<%/R60<<$9KE6C]=&'%E,1Y3%Z-CDPDR3<2HL.>4;T)45.$@J:W)&"K:HC
MGC<.D[2FN7M.(A+BWJ6PMJ<AN&;HAER.XXA`94M7>J"VQAP;2M6-W0C@7755
MGOSNGM-QHL29*CQ0D7"!!G"(\\`R4IPYN3PE>"1N&<>.,5"(TQKA;421-F7!
MVX0H]J#2FKB4MJ<2^KRK<D*"5GNBD$J'K>&35PU5IT3]2:7O46`VY+A3\OR.
M`M$?N7AC)ZC>I/`JM3]&SFY^IX-KM2(]KOC]O;=6RM"1W0*C)5C.<E/J^T[J
MZZ@T1*+^KC9K-'3'GM6YY#(4E"9;C+ZW'D'V%2=HRK@Y'AFH-[0NI+C;+HVN
MT-1$!$J3`@K>1M"Y$H.*9.TE(/=-!/\`5^6(YYK6N.A-1R6ICS6FV@FZ":W'
MBJ?:'FE3KS2D.GG;T0I1[O)!P.:OO:#:M1S7TO6#O@ZBS3V$N-/AHB0ON>ZP
M<C!]5>#X>T9KO;+'>[;;=86^,[/4V\LFU*=G%;HW1T!6UQ944GO=^,\`\]*I
M6G=):M0FP2+O;IKKEOO*G4][/W.-M+C%'>%)>6,!W:2D*.1N]7D@]H.G>T!N
MUSFU,71"U1HZ)C;EX"UW%Y+X4\MA6[Y$*:W)'*/G`8&,URYI;6(NMJN<>#/;
M@QV&T2H#UR2](?:$M:@SW^0?42I*\9((&S<KQG^T:S:MN%Z0]9$3G&C#2W#=
MC7'R9$*4'25/.HR.\24;1C"OFD8YS4WINR7**-3RIZI:I<Z;)\G2[*4XA+&3
MW00G<4H')/0'GGH,5&V:7UBVJT29#EQ0]!194);3<"&P$`";E`7M5QUR#G'%
M0+VD.T);TQ]EBX-W$0WV7ICES2L2RJ6VLAD;\M!322`/4'`''4R,G36N#:[`
MTRU>'/)W'53FU7%#;CD0O)*8V0XK*\94%;N$@IW\XKURSL79A$@76X1I:E.E
M3)8BECNV_!)!6K)]_'U5(TI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2H.\:BB
M6BYLQ9VQF.N&_+7)6X`&TM%&[(ZGYX.?"M%6OM()M:[JJ],^2(D&,5;%[N\"
M=Q3LV[OF^MG&,<]*S6S5]HN%Q?A-/)XDHCQG0K<F451DR,H(\-A)Y]E:,[M$
MTRP]:H\6<F7)N3D4,--@@E#[@0E9)&!U*L'!(!P*,=H>FD0H3UTN#%O?E[MK
M*UES`#JFLE21@#<G&3@`\5)1]8:;DW]6GF+JTY=4K6V6$I5G<A.Y0W8VD@=>
M>.G6L<W6VF(4J?%DW5M#\`I3(;[M9*%*QM3PGUE'<,)&2?`<&M=&NK"5O/+F
M,IMJ(C$E$WO,I6'7%MA.T#<#N01SX\>%98^N])R8ZI#%X:6VEMMPX;7G:MTM
M)XVYSW@VXQD'J!7(UUI,BXD7N/BWC,@X5@#?LRGCU_7]7U<^MQUK2:[1M,/7
M%,5N6LL&`Y.5++2DM-H0O8H*)&4J!!R"!C&.I`K9@Z_T?/F>1QK['4_APE*@
MI&.[!*\E0`&`"K!\!GIS7*-?:17;%7,7IGR5+P8)+:PKO"DK2D(V[CE()''(
MZ9KO8=9V6_7J3:K8XX\6HC,M,@-GNG$.9QM5CJ,>/MXZ*QJW+M$TK"CWA;=Q
M3*D6MEQUZ.PE14K8<*"3C"L*(!()"<\XK;7K"TP].6R^7IWS:B>A!;:=RI04
MI.[;@#)P`23C``R:T;#KZUW1<%#Z/(C/CQ78P<6%%Q3R7%!'`X(#2N3P<<5D
M;U_I\HERW9:&K8RS&>:EDD]^'E+2D)0!NZMG''/AQ72V=HNF)D.!(?GMQ53W
M741T+)5N2EY3062!A*5*'!5@<XZUNMZWTHY)G1DWJ-WL%IQZ0#N`0AL[5G)&
M#M/!`R14;%[2]*O,39CLWN83$I,9IY3:R7U%I+IVH"=PV@G.1Q@DU<XS[,J.
MU)CN)=9=0%MK2<A22,@@^PBLE*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*55]7:2CZE42_,=8S;Y4#U$@^J_W>5<^([L8^NM&ZZ%\KN4BZP;Y*M]Q7-\K
M;?::0ONB8R8ZD[5`@@I3G)Z&L;V@/E1*AW^;'FHFMRT2>[;6O*8HC*!!&T[D
M`G..">*TH?9BQ"<MJ8U^F(BQ3!6]'[ILIDN12.[421E/"0"$GPS67_DS@^02
M87G.1M?@JAE6Q.0#)4_N^O*\?4*T+5I#4#':,BY+PU8(LN9,90J0ES<N0GUM
MH"`H$J420HD#H,U-7SL_@W>'=&'9KJ')MT;NB'`VE7<NH;0@#:>%)PCD'VFL
M,/LX@Q41THGN#NA#SL8;;"E1Y*Y&=J0`-RED'`Z>TUV/9Q;57>W7-<R05PYT
MB8I```>[Q_OTH5[D.84/JJ,B]DELBQ+K$8N3@9EMJ::W1&%J90IT.%)4I)+@
MR`.?#WX(R-]EK"+9Y!Y^FJ2NWRH#REMI.Y#R]_J@_,"5#@#PXJ5N6@;=<GY:
MY<M\M2IK\MUM(`SWL3R920?#U?6!]M:NG>S>'94P2+BMYV).;EA8C--%P(96
MTE*M@&>'"<G)S[*D=):,;TS+0]&N3SS7D#<)QEQM("RVXM:%Y'(([Q0QT.:B
M_P#DTC%N9&<O4UR"J+-C0HRFV\0Q*SWI"@`I9YXW'@5.Z@TN;JW:5Q;I(M\V
MV+*F)+3:%G:ILMK24K!2<I/V'%0"^S""JR+M:;I*0H0X49F2A*0ME492RAQ/
M]H]XH&MN9V>0ED+@7&1`=8;@IAK;0E7DYB]X$'"N%9#J@0:BO^22VEVW/N75
M]UV.%ID*>C,N>4H5(4_T4DA"MRU#*1T/2I.5V<V^7!$)^?(+7<W!K*0`?YT\
METD>]*DC'M\:C[GV7FZ0934_4DE^9)F"8[)7$9Y6&4M<)`&W`2,%)!]N:NMB
MM<JU(6P[=Y,Z,EIEIA$A*=S00@))*P,K*B-Q)\>G%2U*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*5YSVD3-1#4-@M=A=N6)$:6ZZU;WV&7%["T$G<\E2<
M#>>.O/NJ$O6N;UI9%T80DW!]B>U'_G[Z2IM(A-NJ(2VD%7K*.=H.,D],"I!C
MM,<>G/NA-E;MC#0WAVX%$A:O)1(WH04>LW@@9QNX)QQBM6Q:]O5\EVEB0PU!
M=3>VHTA+!)2\TY#=>`(6-PP4I]A.!TZ5*WK7TZUZIE:>5:T.O-'RI!0597!#
M"W%N?WPM'=@=,J%5N-VM7J18Q)%GM[<UY:%1DF0M2%M*:4XKA()W)">2=J<'
M.>,5<='ZMNNI;LE"($-BW)ML.8ZHO*4Z%R&BL(2,8(&#DG'AQ598[5KDXC4$
MKS"SY+`:?7'!D;5DM/!HI<&.-V<Y`XZ'/6MBX]H-^B,NV]^#:(UT;GR8BWG)
MBD1@EJ.A[(64YWD.``$8RDGI6GIO6FHE0H;37=W"XSU6UALS7N[:;6[;R^M?
MJ(SC*#QSR?"NTCM6N7DEOE,VVV-!R%%DOM29:DN+4\^IG#*0/7"=A)SCJ/MG
M];3G_2RVVUS5;^GX"K;*DK>:6RC<XAQI*<EQ)&`%J.!BJKI?M5OTI^R0)MG0
M\5L1S,?*NZ<=[W?M=;0<#&$I5CQW$#&*VCVJW06)BX)@69YZ>Y&$5$:<7?)T
MO!9`D)P"E0",<<$G'&*VW^T>_*B0Y$2PP0HQ8;\E#\P\*D25QPE!0E0("DA6
M3X'IFHNY]HVHH,P3'46IOR2#-\KA.RBAMUR/+[I1944[E+4`=J3CKS6^KM3N
M*KCJ%#=C;3#MS$TM*<>VN]Y';W>NGV*Y'J\CC/6K+?KK=FM'PI4RZ1;+<Y3B
M0/)BAS>2%*2RVM["`M20!N4,`YXZ5!Z8U)J.>]H"3*NL=V)=F'T2VD10A2W6
MVE$J*\D$;D]$@#QR017IL25&F1T28<AJ0PX,H=:6%I5X<$<&LU*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I6);#"Y#<A3+:GFTJ2API!4D'&0#U`.!G
MZA6G-L]IG(<1-M<*2AQP.K2]'0L+6!@*.1R0.,^RN3:K69?EAML,R2UW)>[A
M._N\?,W8SM]W2ND*RV:%L\CM$"/L6%I[F.A&U0!`(P.H"B,^PGVU5K,TA_M8
MU'*>!6]%@1F&%*)^3;7ZRD@=!E0!-67T?L(CJCBQVT,*=[\M^2HVES^OC&-W
MOZUNPX,*'D1(<>/E"4'NFPCU4C"1P.@R<#PK7-FM!>EO&U02[*`$A9CHW/`=
M-YQZWVUVE6FURD+1)MD-Y*W0\I+K"5!3@``6<CE6`!GKQ79JV6UI3:FK?%06
MU)4@I92-I2G:DCCC"24CV#CI7E/:';H2^T'1UJ\G2F`^0E<=&4H`#FX;0/F\
M@9VXSCG->IW.SVBZ*;5<[5"FJ;SL,F.APHSUQN!QTKN[;+:[-CS7;?%7+CIV
MLOJ925M#V)5C('U5A38[+Y+)BBSP/)I*M[[7DR-CRO:H8PH^\UF%LMH2E`MT
M0)"&T`=RG`2A6Y`Z=$GD#P/(K$_9+*^M#C]H@.K0M3B%+C(44J*MQ4"1P2KG
M/MYKNNT6I<F3*7;(2I$ALM/NJ825NHQC:HXRH>X\5FFP84Z(8<V''DQ58!9>
M:2M!QT]4C%<B'#2(V(C`\G!#&&Q\D,8PG^KQQQX5VA18L*,W%AQF8\=L80TR
G@(0GG/`'`K/2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E?__9
`
end

</TEXT>
</DOCUMENT>
</SUBMISSION>
